EP3196200A1 - 2-aminothiazole derivative or salt thereof - Google Patents
2-aminothiazole derivative or salt thereof Download PDFInfo
- Publication number
- EP3196200A1 EP3196200A1 EP15836701.1A EP15836701A EP3196200A1 EP 3196200 A1 EP3196200 A1 EP 3196200A1 EP 15836701 A EP15836701 A EP 15836701A EP 3196200 A1 EP3196200 A1 EP 3196200A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- esi
- compound
- alkyl
- formula
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 104
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 253
- 230000008602 contraction Effects 0.000 claims abstract description 44
- 230000003551 muscarinic effect Effects 0.000 claims abstract description 44
- 208000026533 urinary bladder disease Diseases 0.000 claims abstract description 25
- 208000014001 urinary system disease Diseases 0.000 claims abstract description 25
- 208000012931 Urologic disease Diseases 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 81
- -1 R5 is H Chemical group 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 35
- 238000004519 manufacturing process Methods 0.000 claims description 31
- 229910052736 halogen Inorganic materials 0.000 claims description 27
- 150000002367 halogens Chemical class 0.000 claims description 27
- 229910052757 nitrogen Chemical group 0.000 claims description 26
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 22
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 22
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 18
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 13
- 125000003386 piperidinyl group Chemical group 0.000 claims description 12
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 11
- 125000004193 piperazinyl group Chemical group 0.000 claims description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 125000002393 azetidinyl group Chemical group 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- MFSXGLZLGLAACB-MJGOQNOKSA-N 3-[(2S)-4-[6-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]-2-(methoxymethyl)piperazin-1-yl]propanoic acid Chemical compound ClC1=C(C=C(C=C1)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=C(C(=NC=N1)N1C[C@H](N(CC1)CCC(=O)O)COC)F)C(F)(F)F MFSXGLZLGLAACB-MJGOQNOKSA-N 0.000 claims description 4
- VOADVSLNDGQWIA-UTKZUKDTSA-N 3-[(2S)-4-[5-fluoro-6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]-2-(methoxymethyl)piperazin-1-yl]propanoic acid Chemical compound FC=1C(=NC=NC=1NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C)N1C[C@H](N(CC1)CCC(=O)O)COC VOADVSLNDGQWIA-UTKZUKDTSA-N 0.000 claims description 3
- WSMINEUCGADSDE-OAHLLOKOSA-N 2-[1-[5-fluoro-6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]piperidin-4-yl]oxyacetic acid Chemical compound FC=1C(=NC=NC=1NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C)N1CCC(CC1)OCC(=O)O WSMINEUCGADSDE-OAHLLOKOSA-N 0.000 claims description 2
- CWFWPRZPGBEJBG-IAGOWNOFSA-N 3-[4-[6-[[5-[[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl]-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]amino]-5-fluoro-2-methylpyrimidin-4-yl]piperazin-1-yl]propanoic acid Chemical compound C[C@H]1N([C@@H](CC1)C)CC1=C(N=C(S1)NC1=C(C(=NC(=N1)C)N1CCN(CC1)CCC(=O)O)F)C1=CC(=CC(=C1)C(F)(F)F)F CWFWPRZPGBEJBG-IAGOWNOFSA-N 0.000 claims description 2
- CBDXLQAQJCNWLZ-IAGOWNOFSA-N 3-[4-[6-[[5-[[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl]-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]piperazin-1-yl]propanoic acid Chemical compound C[C@H]1N([C@@H](CC1)C)CC1=C(N=C(S1)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)O)F)C1=CC(=CC(=C1)C(F)(F)F)F CBDXLQAQJCNWLZ-IAGOWNOFSA-N 0.000 claims description 2
- YQBWTZVDEUIWLK-MRXNPFEDSA-N 3-[4-[6-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]piperazin-1-yl]propanoic acid Chemical compound ClC1=C(C=C(C=C1)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)O)F)C(F)(F)F YQBWTZVDEUIWLK-MRXNPFEDSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- 229940126027 positive allosteric modulator Drugs 0.000 abstract description 20
- 208000004168 Underactive Urinary Bladder Diseases 0.000 abstract description 14
- 238000003860 storage Methods 0.000 abstract description 11
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 2
- 206010013990 dysuria Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 126
- 239000011541 reaction mixture Substances 0.000 description 106
- 239000000203 mixture Substances 0.000 description 96
- 235000002639 sodium chloride Nutrition 0.000 description 93
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 81
- 210000003932 urinary bladder Anatomy 0.000 description 75
- 238000002360 preparation method Methods 0.000 description 65
- 239000007787 solid Substances 0.000 description 65
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 60
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
- 239000000243 solution Substances 0.000 description 53
- 239000012044 organic layer Substances 0.000 description 48
- 238000010898 silica gel chromatography Methods 0.000 description 46
- 108020003175 receptors Proteins 0.000 description 38
- 102000005962 receptors Human genes 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 36
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 34
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Substances [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 32
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 32
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 32
- 239000000126 substance Substances 0.000 description 31
- 239000003921 oil Substances 0.000 description 30
- 238000012360 testing method Methods 0.000 description 29
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 29
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 230000000638 stimulation Effects 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 21
- 230000004064 dysfunction Effects 0.000 description 20
- 238000001914 filtration Methods 0.000 description 19
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 18
- 230000036724 intravesical pressure Effects 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 17
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 125000006239 protecting group Chemical group 0.000 description 17
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 238000000605 extraction Methods 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 13
- 229960004484 carbachol Drugs 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 210000002700 urine Anatomy 0.000 description 13
- 0 **c1c(*)nc(NC(*)=O)[s]1 Chemical compound **c1c(*)nc(NC(*)=O)[s]1 0.000 description 12
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 12
- 239000012300 argon atmosphere Substances 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 235000011054 acetic acid Nutrition 0.000 description 11
- 230000009471 action Effects 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- WGXZDYPGLJYBJW-UHFFFAOYSA-N chloroform;propan-2-ol Chemical compound CC(C)O.ClC(Cl)Cl WGXZDYPGLJYBJW-UHFFFAOYSA-N 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 125000001153 fluoro group Chemical group F* 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 230000007383 nerve stimulation Effects 0.000 description 7
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 6
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 6
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 6
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000001309 chloro group Chemical group Cl* 0.000 description 6
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 6
- GAOSVGXZVALTIA-UHFFFAOYSA-N ethyl 3-piperazin-1-ylpropanoate;dihydrochloride Chemical compound [Cl-].[Cl-].CCOC(=O)CC[NH+]1CC[NH2+]CC1 GAOSVGXZVALTIA-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 210000002460 smooth muscle Anatomy 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 5
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 230000005684 electric field Effects 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000003708 urethra Anatomy 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- NNRHZBRRHGJCPM-SECBINFHSA-N 4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-amine Chemical compound C[C@@H]1CCCN1CC1=C(N=C(N)S1)C1=CC(F)=CC(=C1)C(F)(F)F NNRHZBRRHGJCPM-SECBINFHSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 206010020853 Hypertonic bladder Diseases 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 4
- 206010029279 Neurogenic bladder Diseases 0.000 description 4
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 206010046555 Urinary retention Diseases 0.000 description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000012295 chemical reaction liquid Substances 0.000 description 4
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000000752 ionisation method Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 208000020629 overactive bladder Diseases 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 210000005070 sphincter Anatomy 0.000 description 4
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 229940126585 therapeutic drug Drugs 0.000 description 4
- DGMIGAHDDPJOPN-UHFFFAOYSA-N 4,6-dichloro-5-fluoropyrimidine Chemical compound FC1=C(Cl)N=CN=C1Cl DGMIGAHDDPJOPN-UHFFFAOYSA-N 0.000 description 3
- UKJQCMKGJGFQFQ-UHFFFAOYSA-N 4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(C=C(F)C=2)C(F)(F)F)=C1 UKJQCMKGJGFQFQ-UHFFFAOYSA-N 0.000 description 3
- MBTRXVMIYWEMIP-SECBINFHSA-N C1(Cl)=C(C(F)(F)F)C=C(C2=C(CN3[C@@H](CCC3)C)SC(=N2)N)C=C1 Chemical compound C1(Cl)=C(C(F)(F)F)C=C(C2=C(CN3[C@@H](CCC3)C)SC(=N2)N)C=C1 MBTRXVMIYWEMIP-SECBINFHSA-N 0.000 description 3
- IOIMAUTWPUNAMX-NXEZZACHSA-N C[C@H]1N([C@@H](CC1)C)CC1=C(N=C(S1)N)C1=CC(=CC(=C1)C(F)(F)F)F Chemical compound C[C@H]1N([C@@H](CC1)C)CC1=C(N=C(S1)N)C1=CC(=CC(=C1)C(F)(F)F)F IOIMAUTWPUNAMX-NXEZZACHSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MMTFCYGVOJJQHJ-UHFFFAOYSA-N N,6-dimethoxy-N-methyl-5-(trifluoromethyl)pyridine-3-carboxamide Chemical compound CON(C(C1=CN=C(C(=C1)C(F)(F)F)OC)=O)C MMTFCYGVOJJQHJ-UHFFFAOYSA-N 0.000 description 3
- TXNXEUMZUOBERJ-UHFFFAOYSA-N N-[4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=C(C=C(C1)C(F)(F)F)C=1N=C(SC1)NC(C)=O TXNXEUMZUOBERJ-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 206010036018 Pollakiuria Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 230000001270 agonistic effect Effects 0.000 description 3
- 230000003281 allosteric effect Effects 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- XXRMYXBSBOVVBH-UHFFFAOYSA-N bethanechol chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(N)=O XXRMYXBSBOVVBH-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 229960001446 distigmine Drugs 0.000 description 3
- GJHSNEVFXQVOHR-UHFFFAOYSA-L distigmine bromide Chemical compound [Br-].[Br-].C=1C=C[N+](C)=CC=1OC(=O)N(C)CCCCCCN(C)C(=O)OC1=CC=C[N+](C)=C1 GJHSNEVFXQVOHR-UHFFFAOYSA-L 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- PRXNKYBFWAWBNZ-UHFFFAOYSA-N trimethylphenylammonium tribromide Chemical compound Br[Br-]Br.C[N+](C)(C)C1=CC=CC=C1 PRXNKYBFWAWBNZ-UHFFFAOYSA-N 0.000 description 3
- 208000022934 urinary frequency Diseases 0.000 description 3
- 230000036318 urination frequency Effects 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- UYNMUXTXDHJBEN-UHFFFAOYSA-N 1-[4-chloro-3-(trifluoromethyl)phenyl]ethanone Chemical compound CC(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 UYNMUXTXDHJBEN-UHFFFAOYSA-N 0.000 description 2
- WGSXKYXKAARAKD-UHFFFAOYSA-N 1-fluoro-3-isocyanato-5-(trifluoromethyl)benzene Chemical group FC1=CC(N=C=O)=CC(C(F)(F)F)=C1 WGSXKYXKAARAKD-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- WGLLSSPDPJPLOR-UHFFFAOYSA-N 2,3-dimethylbut-2-ene Chemical group CC(C)=C(C)C WGLLSSPDPJPLOR-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- RGHPCLZJAFCTIK-UHFFFAOYSA-N 2-methylpyrrolidine Chemical compound CC1CCCN1 RGHPCLZJAFCTIK-UHFFFAOYSA-N 0.000 description 2
- BQKZZBCKCUOHPJ-MRXNPFEDSA-N 3-[4-[5-fluoro-6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]piperazin-1-yl]propanoic acid Chemical compound FC=1C(=NC=NC=1NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C)N1CCN(CC1)CCC(=O)O BQKZZBCKCUOHPJ-MRXNPFEDSA-N 0.000 description 2
- ZLOQCWGVYZIUQW-MRXNPFEDSA-N 3-[4-[5-fluoro-6-[[4-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]piperazin-1-yl]propanoic acid Chemical compound FC=1C(=NC=NC=1NC=1SC(=C(N=1)C=1C=NC(=C(C=1)C(F)(F)F)OC)CN1[C@@H](CCC1)C)N1CCN(CC1)CCC(=O)O ZLOQCWGVYZIUQW-MRXNPFEDSA-N 0.000 description 2
- SKFDQIWSTJNSAU-UHFFFAOYSA-N 4-[4-chloro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=C(C(Cl)=CC=2)C(F)(F)F)=C1 SKFDQIWSTJNSAU-UHFFFAOYSA-N 0.000 description 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- DJNDUPFORUXVQJ-ZDUSSCGKSA-N C(C)OC(CCN1[C@@H](CN(CC1)C(=O)OC(C)(C)C)COC)=O Chemical compound C(C)OC(CCN1[C@@H](CN(CC1)C(=O)OC(C)(C)C)COC)=O DJNDUPFORUXVQJ-ZDUSSCGKSA-N 0.000 description 2
- LUQLMOCMNVUHHF-GHMZBOCLSA-N C[C@H]1N([C@@H](CC1)C)CC1=C(N=C(S1)NC(C)=O)C1=CC(=CC(=C1)C(F)(F)F)F Chemical compound C[C@H]1N([C@@H](CC1)C)CC1=C(N=C(S1)NC(C)=O)C1=CC(=CC(=C1)C(F)(F)F)F LUQLMOCMNVUHHF-GHMZBOCLSA-N 0.000 description 2
- 101100241173 Caenorhabditis elegans dat-1 gene Proteins 0.000 description 2
- BNINBHFOJFEZLF-OAHLLOKOSA-N ClC1=C(C=C(C=C1)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=NC=CC(=C1F)N1CCNCC1)C(F)(F)F Chemical compound ClC1=C(C=C(C=C1)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=NC=CC(=C1F)N1CCNCC1)C(F)(F)F BNINBHFOJFEZLF-OAHLLOKOSA-N 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- RTUDFIGPZVMUFT-GHMZBOCLSA-N N-(6-chloro-5-fluoro-2-methylpyrimidin-4-yl)-5-[[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl]-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound ClC1=C(C(=NC(=N1)C)NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CC[C@H]1C)C)F RTUDFIGPZVMUFT-GHMZBOCLSA-N 0.000 description 2
- RKGVBABCQPDOIN-GHMZBOCLSA-N N-(6-chloro-5-fluoropyrimidin-4-yl)-5-[[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl]-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine Chemical compound ClC1=C(C(=NC=N1)NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CC[C@H]1C)C)F RKGVBABCQPDOIN-GHMZBOCLSA-N 0.000 description 2
- ZKJUADODNYUUGU-SNVBAGLBSA-N N-[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound FC=1C=C(C=C(C1)C(F)(F)F)C=1N=C(SC1CN1[C@@H](CCC1)C)NC(C)=O ZKJUADODNYUUGU-SNVBAGLBSA-N 0.000 description 2
- DSOKTTHOZFOQMI-SNVBAGLBSA-N N-[4-[4-chloro-3-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound ClC1=C(C(F)(F)F)C=C(C2=C(CN3[C@@H](CCC3)C)SC(=N2)NC(=O)C)C=C1 DSOKTTHOZFOQMI-SNVBAGLBSA-N 0.000 description 2
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 208000028484 Urethral disease Diseases 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- BPUPIWUBEALZHE-UHFFFAOYSA-N benzyl 4-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]piperazine-1-carboxylate Chemical compound C(C)(C)(C)OC(CCN1CCN(CC1)C(=O)OCC1=CC=CC=C1)=O BPUPIWUBEALZHE-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229960002123 bethanechol chloride Drugs 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000013507 chronic prostatitis Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000009989 contractile response Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- SACNIGZYDTUHKB-UHFFFAOYSA-N ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C SACNIGZYDTUHKB-UHFFFAOYSA-N 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- MSXRAYVENVDBRN-XRIOVQLTSA-N ethyl 3-[(2S)-2-(methoxymethyl)piperazin-1-yl]propanoate dihydrochloride Chemical compound Cl.Cl.CCOC(=O)CCN1CCNC[C@H]1COC MSXRAYVENVDBRN-XRIOVQLTSA-N 0.000 description 2
- PKXQIACLJVDXJZ-NSHDSACASA-N ethyl 3-[(2S)-4-(6-chloro-5-fluoropyrimidin-4-yl)-2-(methoxymethyl)piperazin-1-yl]propanoate Chemical compound ClC1=C(C(=NC=N1)N1C[C@H](N(CC1)CCC(=O)OCC)COC)F PKXQIACLJVDXJZ-NSHDSACASA-N 0.000 description 2
- WZZOZKRCZSXXEP-CTNGQTDRSA-N ethyl 3-[(2S)-4-[6-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]-2-(methoxymethyl)piperazin-1-yl]propanoate Chemical compound ClC1=C(C=C(C=C1)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=C(C(=NC=N1)N1C[C@H](N(CC1)CCC(=O)OCC)COC)F)C(F)(F)F WZZOZKRCZSXXEP-CTNGQTDRSA-N 0.000 description 2
- FIIYFYSPHNLOEF-LJQANCHMSA-N ethyl 3-[4-[2-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-3-fluoropyridin-4-yl]piperazin-1-yl]propanoate Chemical compound ClC1=C(C=C(C=C1)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=NC=CC(=C1F)N1CCN(CC1)CCC(=O)OCC)C(F)(F)F FIIYFYSPHNLOEF-LJQANCHMSA-N 0.000 description 2
- PELXOJZECXJHCZ-GOSISDBHSA-N ethyl 3-[4-[5-fluoro-6-[[4-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound FC=1C(=NC=NC=1NC=1SC(=C(N=1)C=1C=NC(=C(C=1)C(F)(F)F)OC)CN1[C@@H](CCC1)C)N1CCN(CC1)CCC(=O)OCC PELXOJZECXJHCZ-GOSISDBHSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- XPKDIIULSIBZMT-UHFFFAOYSA-N methyl 2-[1-(6-chloro-5-fluoropyrimidin-4-yl)piperidin-4-yl]oxyacetate Chemical compound ClC1=C(C(=NC=N1)N1CCC(CC1)OCC(=O)OC)F XPKDIIULSIBZMT-UHFFFAOYSA-N 0.000 description 2
- KXIMBESKTCQLSZ-MRXNPFEDSA-N methyl 2-[1-[5-fluoro-6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]piperidin-4-yl]oxyacetate Chemical compound FC=1C(=NC=NC=1NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C)N1CCC(CC1)OCC(=O)OC KXIMBESKTCQLSZ-MRXNPFEDSA-N 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- YVQFGKAAMFWLMS-UHFFFAOYSA-N n-[4-[4-chloro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC(C=2C=C(C(Cl)=CC=2)C(F)(F)F)=C1 YVQFGKAAMFWLMS-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 239000004533 oil dispersion Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- LUCKNBKNQXBMPL-MXMFLMJRSA-N tert-butyl (3R)-3-[(E)-3-ethoxy-3-oxoprop-1-enoxy]pyrrolidine-1-carboxylate Chemical compound C(C)OC(/C=C/O[C@H]1CN(CC1)C(=O)OC(C)(C)C)=O LUCKNBKNQXBMPL-MXMFLMJRSA-N 0.000 description 2
- ZXQYPUAMXAINBY-GCJKJVERSA-N tert-butyl (3S)-4-[5-fluoro-6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]-3-(methoxymethyl)piperazine-1-carboxylate Chemical compound FC=1C(=NC=NC=1NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C)N1[C@@H](CN(CC1)C(=O)OC(C)(C)C)COC ZXQYPUAMXAINBY-GCJKJVERSA-N 0.000 description 2
- QBJWNCXOPXVECA-VIFPVBQESA-N tert-butyl (3s)-3-(methoxymethyl)piperazine-1-carboxylate Chemical compound COC[C@@H]1CN(C(=O)OC(C)(C)C)CCN1 QBJWNCXOPXVECA-VIFPVBQESA-N 0.000 description 2
- ZJRHRHJWVLTNAC-HXUWFJFHSA-N tert-butyl 3-[4-[3-fluoro-2-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyridin-4-yl]piperazin-1-yl]propanoate Chemical compound FC=1C(=NC=CC=1N1CCN(CC1)CCC(=O)OC(C)(C)C)NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C ZJRHRHJWVLTNAC-HXUWFJFHSA-N 0.000 description 2
- WRLIMUYTLLVFLP-UHFFFAOYSA-N tert-butyl 4-(2-chloropyridin-4-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=NC(Cl)=C1 WRLIMUYTLLVFLP-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- AFHNFHHYTYQLIO-KGZKBUQUSA-N (2r,5r)-2,5-dimethylpyrrolidine;hydrochloride Chemical compound Cl.C[C@@H]1CC[C@@H](C)N1 AFHNFHHYTYQLIO-KGZKBUQUSA-N 0.000 description 1
- SQMYKVUSWPIFEQ-JEDNCBNOSA-N (3s)-3-methoxypyrrolidine;hydrochloride Chemical compound Cl.CO[C@H]1CCNC1 SQMYKVUSWPIFEQ-JEDNCBNOSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- RGHPCLZJAFCTIK-RXMQYKEDSA-N (R)-2-methylpyrrolidine Chemical compound C[C@@H]1CCCN1 RGHPCLZJAFCTIK-RXMQYKEDSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- 125000005960 1,4-diazepanyl group Chemical group 0.000 description 1
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 description 1
- ACJPALPWXAFQHL-UHFFFAOYSA-N 1-[3-fluoro-4-methoxy-5-(trifluoromethyl)phenyl]ethanone Chemical compound C1(=C(OC)C(F)=CC(C(=O)C)=C1)C(F)(F)F ACJPALPWXAFQHL-UHFFFAOYSA-N 0.000 description 1
- BDIYAWLPLVWTJY-UHFFFAOYSA-N 1-[3-fluoro-5-(trifluoromethyl)phenyl]ethanone Chemical compound CC(=O)C1=CC(F)=CC(C(F)(F)F)=C1 BDIYAWLPLVWTJY-UHFFFAOYSA-N 0.000 description 1
- BTKKKPXWOUMHLS-OAHLLOKOSA-N 1-[5-fluoro-6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]-4-methoxypiperidine-4-carboxylic acid Chemical compound FC=1C(=NC=NC=1NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C)N1CCC(CC1)(C(=O)O)OC BTKKKPXWOUMHLS-OAHLLOKOSA-N 0.000 description 1
- 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 1
- YYLNWRWYEJBBQX-UHFFFAOYSA-N 2,4-dichloro-3-fluoropyridine Chemical compound FC1=C(Cl)C=CN=C1Cl YYLNWRWYEJBBQX-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- VEUWSIYQEAYSHI-UHFFFAOYSA-N 2-N-(6-chloro-2-methylpyrimidin-4-yl)-4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-N-(2-methoxyethyl)-5-N-propan-2-yl-1,3-thiazole-2,5-diamine Chemical compound ClC1=CC(=NC(=N1)C)NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)N(CCOC)C(C)C VEUWSIYQEAYSHI-UHFFFAOYSA-N 0.000 description 1
- KKDNWNACBWSPGV-QCUBGVIVSA-N 2-[1-[5-fluoro-6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]piperidin-4-yl]oxyacetic acid dihydrochloride Chemical compound Cl.Cl.C[C@@H]1CCCN1Cc1sc(Nc2ncnc(N3CCC(CC3)OCC(O)=O)c2F)nc1-c1cc(F)cc(c1)C(F)(F)F KKDNWNACBWSPGV-QCUBGVIVSA-N 0.000 description 1
- PMUPHAWWDMHEGI-LJQANCHMSA-N 2-[1-[6-[[4-[3-chloro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-ethylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]piperidin-4-yl]oxyacetic acid Chemical compound ClC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)CC)NC1=C(C(=NC=N1)N1CCC(CC1)OCC(=O)O)F PMUPHAWWDMHEGI-LJQANCHMSA-N 0.000 description 1
- LVFHKCSZLBXGLO-JQDLGSOUSA-N 2-[1-[6-[[4-[3-chloro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-ethylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]piperidin-4-yl]oxyacetic acid dihydrochloride Chemical compound Cl.Cl.CC[C@@H]1CCCN1Cc1sc(Nc2ncnc(N3CCC(CC3)OCC(O)=O)c2F)nc1-c1cc(Cl)cc(c1)C(F)(F)F LVFHKCSZLBXGLO-JQDLGSOUSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- TWNGFNKYGOFXSW-OAHLLOKOSA-N 2-[4-[6-[[4-[3-chloro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]piperazin-1-yl]acetic acid Chemical compound ClC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=C(C(=NC=N1)N1CCN(CC1)CC(=O)O)F TWNGFNKYGOFXSW-OAHLLOKOSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- MTBXNWHIHOUCQG-SJLPKXTDSA-N 3-[(2S)-4-[6-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]-2-(fluoromethyl)piperazin-1-yl]propanoic acid Chemical compound ClC1=C(C=C(C=C1)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=C(C(=NC=N1)N1C[C@H](N(CC1)CCC(=O)O)CF)F)C(F)(F)F MTBXNWHIHOUCQG-SJLPKXTDSA-N 0.000 description 1
- ULRVPHKRVABOFS-QGZVFWFLSA-N 3-[1-[6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-2-methylpyrimidin-4-yl]piperidin-4-yl]propanoic acid Chemical compound FC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=CC(=NC(=N1)C)N1CCC(CC1)CCC(=O)O ULRVPHKRVABOFS-QGZVFWFLSA-N 0.000 description 1
- GRIKTTBABHPZGN-GOSISDBHSA-N 3-[4-[2-(dimethylamino)-6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]piperazin-1-yl]propanoic acid Chemical compound CN(C1=NC(=CC(=N1)N1CCN(CC1)CCC(=O)O)NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C)C GRIKTTBABHPZGN-GOSISDBHSA-N 0.000 description 1
- WWFWWKPSJQQMBB-GOSISDBHSA-N 3-[4-[2-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyridin-4-yl]piperazin-1-yl]propanoic acid Chemical compound FC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=NC=CC(=C1)N1CCN(CC1)CCC(=O)O WWFWWKPSJQQMBB-GOSISDBHSA-N 0.000 description 1
- WHNRZIVDEIKIPZ-QGZVFWFLSA-N 3-[4-[3-fluoro-2-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyridin-4-yl]piperazin-1-yl]propanoic acid Chemical compound FC=1C(=NC=CC=1N1CCN(CC1)CCC(=O)O)NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C WHNRZIVDEIKIPZ-QGZVFWFLSA-N 0.000 description 1
- VPZWZDSCCSKBEH-MRXNPFEDSA-N 3-[4-[5-fluoro-6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-2-methylpyrimidin-4-yl]piperazin-1-yl]propanoic acid Chemical compound FC=1C(=NC(=NC=1NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C)C)N1CCN(CC1)CCC(=O)O VPZWZDSCCSKBEH-MRXNPFEDSA-N 0.000 description 1
- HFNVQRLEQTVFHL-QRIPLOBPSA-N 3-[4-[5-fluoro-6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]-2-(fluoromethyl)piperazin-1-yl]propanoic acid Chemical compound FC=1C(=NC=NC=1NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C)N1CC(N(CC1)CCC(=O)O)CF HFNVQRLEQTVFHL-QRIPLOBPSA-N 0.000 description 1
- GTAZPPJPDXQUQS-MRXNPFEDSA-N 3-[4-[6-[[4-[3-chloro-5-(trifluoromethoxy)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]piperazin-1-yl]propanoic acid Chemical compound ClC=1C=C(C=C(C=1)OC(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)O)F GTAZPPJPDXQUQS-MRXNPFEDSA-N 0.000 description 1
- YQUBAUCHZLIICM-MRXNPFEDSA-N 3-[4-[6-[[4-[3-chloro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]piperazin-1-yl]propanoic acid Chemical compound ClC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)O)F YQUBAUCHZLIICM-MRXNPFEDSA-N 0.000 description 1
- BXTGJHVUWHBNGV-UHFFFAOYSA-N 3-[4-[6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[2-methoxyethyl(propan-2-yl)amino]-1,3-thiazol-2-yl]amino]-2-methylpyrimidin-4-yl]piperazin-1-yl]propanoic acid Chemical compound FC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1N(CCOC)C(C)C)NC1=CC(=NC(=N1)C)N1CCN(CC1)CCC(=O)O BXTGJHVUWHBNGV-UHFFFAOYSA-N 0.000 description 1
- SWFUTPWVQOJPSD-QGZVFWFLSA-N 3-[4-[6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-2-methylpyrimidin-4-yl]piperazin-1-yl]propanoic acid Chemical compound FC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=CC(=NC(=N1)C)N1CCN(CC1)CCC(=O)O SWFUTPWVQOJPSD-QGZVFWFLSA-N 0.000 description 1
- ZRDFLTZABCKMFM-QGZVFWFLSA-N 3-[4-[6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-5-methoxypyrimidin-4-yl]piperazin-1-yl]propanoic acid Chemical compound FC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)O)OC ZRDFLTZABCKMFM-QGZVFWFLSA-N 0.000 description 1
- NKHGLKPOZNUVRE-QGZVFWFLSA-N 3-[4-[6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]piperazin-1-yl]propanoic acid Chemical compound FC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=CC(=NC=N1)N1CCN(CC1)CCC(=O)O NKHGLKPOZNUVRE-QGZVFWFLSA-N 0.000 description 1
- BHWVGYXVMXDARV-KRWDZBQOSA-N 3-[4-[6-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-5-[(3S)-3-methoxypiperidin-1-yl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]piperazin-1-yl]propanoic acid Chemical compound ClC1=C(C=C(C=C1)C=1N=C(SC=1N1C[C@H](CCC1)OC)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)O)F)C(F)(F)F BHWVGYXVMXDARV-KRWDZBQOSA-N 0.000 description 1
- CTOIALKSXMMFJW-UHFFFAOYSA-N 3-[4-[6-[[5-(4-cyclopropylpiperazin-1-yl)-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]piperazin-1-yl]propanoic acid Chemical compound C1(CC1)N1CCN(CC1)C1=C(N=C(S1)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)O)F)C1=CC(=CC(=C1)C(F)(F)F)F CTOIALKSXMMFJW-UHFFFAOYSA-N 0.000 description 1
- UMMPKPNRFVADND-UZLBHIALSA-N 3-[[(3S)-1-[5-fluoro-6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]pyrrolidin-3-yl]-methylamino]propanoic acid Chemical compound FC=1C(=NC=NC=1NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C)N1C[C@H](CC1)N(CCC(=O)O)C UMMPKPNRFVADND-UZLBHIALSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SVSUYEJKNSMKKW-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-prop-1-en-2-yl-1,3,2-dioxaborolane Chemical compound CC(=C)B1OC(C)(C)C(C)(C)O1 SVSUYEJKNSMKKW-UHFFFAOYSA-N 0.000 description 1
- IWPZWKNMDQSDQP-UHFFFAOYSA-N 4,6-dichloro-5-fluoro-2-methylpyrimidine Chemical compound CC1=NC(Cl)=C(F)C(Cl)=N1 IWPZWKNMDQSDQP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- TUCPWLUEMXXKNN-UHFFFAOYSA-N 4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-N-(2-methoxyethyl)-5-N-propan-2-yl-1,3-thiazole-2,5-diamine Chemical compound FC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1N(CCOC)C(C)C)N TUCPWLUEMXXKNN-UHFFFAOYSA-N 0.000 description 1
- CPLMPXXJXQKZBX-MRXNPFEDSA-N 4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-N-(4-piperazin-1-ylpyridin-2-yl)-1,3-thiazol-2-amine Chemical compound FC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=NC=CC(=C1)N1CCNCC1 CPLMPXXJXQKZBX-MRXNPFEDSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- JYIJZSRKYHZZBO-UHFFFAOYSA-N 5-bromo-1-fluoro-2-methoxy-3-(trifluoromethyl)benzene Chemical compound COC1=C(F)C=C(Br)C=C1C(F)(F)F JYIJZSRKYHZZBO-UHFFFAOYSA-N 0.000 description 1
- RFXPVNUCYNQFSJ-UHFFFAOYSA-N 6-methoxy-5-(trifluoromethyl)pyridine-3-carboxylic acid Chemical compound COC1=NC=C(C(O)=O)C=C1C(F)(F)F RFXPVNUCYNQFSJ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- QMJQAFCLGSTZEO-UHFFFAOYSA-N C(C)OC(CCN1C(CN(CC1)C(=O)OC(C)(C)C)CF)=O Chemical compound C(C)OC(CCN1C(CN(CC1)C(=O)OC(C)(C)C)CF)=O QMJQAFCLGSTZEO-UHFFFAOYSA-N 0.000 description 1
- REWCLAUOFLEELV-LLVKDONJSA-N C(C)OC(CCO[C@H]1CN(CC1)C(=O)OC(C)(C)C)=O Chemical compound C(C)OC(CCO[C@H]1CN(CC1)C(=O)OC(C)(C)C)=O REWCLAUOFLEELV-LLVKDONJSA-N 0.000 description 1
- HKKNEBULVWDLPX-LBPRGKRZSA-N C(C)OC(CN1[C@@H](CN(CC1)C(=O)OC(C)(C)C)COC)=O Chemical compound C(C)OC(CN1[C@@H](CN(CC1)C(=O)OC(C)(C)C)COC)=O HKKNEBULVWDLPX-LBPRGKRZSA-N 0.000 description 1
- AJZMXJOGIQZRQH-UHFFFAOYSA-N C1(CC1)C1=C(C=C(C=C1)C(C)=O)C(F)(F)F Chemical compound C1(CC1)C1=C(C=C(C=C1)C(C)=O)C(F)(F)F AJZMXJOGIQZRQH-UHFFFAOYSA-N 0.000 description 1
- PPLLRAUXMRJSJB-UHFFFAOYSA-N CC(Nc1nc(-c(cc2F)cc(C(F)(F)F)c2OC)c[s]1)=O Chemical compound CC(Nc1nc(-c(cc2F)cc(C(F)(F)F)c2OC)c[s]1)=O PPLLRAUXMRJSJB-UHFFFAOYSA-N 0.000 description 1
- GRFWWRJXRUMWLX-UHFFFAOYSA-N CC(Nc1nc(-c2cc(C(F)(F)F)cc(OC)c2)c(COC(C)=O)[s]1)=O Chemical compound CC(Nc1nc(-c2cc(C(F)(F)F)cc(OC)c2)c(COC(C)=O)[s]1)=O GRFWWRJXRUMWLX-UHFFFAOYSA-N 0.000 description 1
- YAFLKHKZFMKNCZ-UHFFFAOYSA-N CC(c1cc(C(F)(F)F)cc(C)c1)=O Chemical compound CC(c1cc(C(F)(F)F)cc(C)c1)=O YAFLKHKZFMKNCZ-UHFFFAOYSA-N 0.000 description 1
- PSLIYPDEMCPGAB-YKSBVNFPSA-N CCCCC[C@H](CC1)N(Cc2c(-c(cc3)cc(C(F)(F)F)c3Cl)nc(Nc(ncnc3N4CCN(CCC(O)=O)CC4)c3F)[s]2)[C@@H]1N Chemical compound CCCCC[C@H](CC1)N(Cc2c(-c(cc3)cc(C(F)(F)F)c3Cl)nc(Nc(ncnc3N4CCN(CCC(O)=O)CC4)c3F)[s]2)[C@@H]1N PSLIYPDEMCPGAB-YKSBVNFPSA-N 0.000 description 1
- MMDKPLUNUKFYMU-QUIRPCPPSA-N CCOC(/C=C/O[C@H]1CC(CCC(OC(C)(C)C)=O)CCC1)=O Chemical compound CCOC(/C=C/O[C@H]1CC(CCC(OC(C)(C)C)=O)CCC1)=O MMDKPLUNUKFYMU-QUIRPCPPSA-N 0.000 description 1
- HUPHRWTWAHOZBE-LSQMVHIFSA-N CCOC(CCN(CC1)[C@H](COC)CN1c(ncnc1Nc2nc(-c3cc(Cl)cc(C(F)(F)F)c3)c(CN([C@H](CC[Ne])CC3)[C@@H]3N)[s]2)c1F)=O Chemical compound CCOC(CCN(CC1)[C@H](COC)CN1c(ncnc1Nc2nc(-c3cc(Cl)cc(C(F)(F)F)c3)c(CN([C@H](CC[Ne])CC3)[C@@H]3N)[s]2)c1F)=O HUPHRWTWAHOZBE-LSQMVHIFSA-N 0.000 description 1
- XZOSIFBIRUMIAI-UHFFFAOYSA-N CCOC(CN(CC1)CCN1c(ncnc1Cl)c1F)=O Chemical compound CCOC(CN(CC1)CCN1c(ncnc1Cl)c1F)=O XZOSIFBIRUMIAI-UHFFFAOYSA-N 0.000 description 1
- VQHZVTWHYMUUST-FTJBHMTQSA-N CC[C@H]1N(Cc2c(-c3cc(C(F)(F)F)cc(Cl)c3)nc(Nc3ncnc(N4C[C@@H](COC)N(CCC([O](C)(C)CC)=O)CC4)c3F)[s]2)CCC1 Chemical compound CC[C@H]1N(Cc2c(-c3cc(C(F)(F)F)cc(Cl)c3)nc(Nc3ncnc(N4C[C@@H](COC)N(CCC([O](C)(C)CC)=O)CC4)c3F)[s]2)CCC1 VQHZVTWHYMUUST-FTJBHMTQSA-N 0.000 description 1
- CVDCEUBOBWNAHW-UHFFFAOYSA-N CC[O](C)C(CCN(CC1)CCN1c(nc(C)nc1Cl)c1F)=O Chemical compound CC[O](C)C(CCN(CC1)CCN1c(nc(C)nc1Cl)c1F)=O CVDCEUBOBWNAHW-UHFFFAOYSA-N 0.000 description 1
- FPLULCUZWPWJJI-UHFFFAOYSA-N CC[O](C)C(CCN(CC1)CCN1c1ncnc(Nc2nc(-c3cc(C(F)(F)F)cc(F)c3)c(N(C3)CC3OC)[s]2)c1F)=O Chemical compound CC[O](C)C(CCN(CC1)CCN1c1ncnc(Nc2nc(-c3cc(C(F)(F)F)cc(F)c3)c(N(C3)CC3OC)[s]2)c1F)=O FPLULCUZWPWJJI-UHFFFAOYSA-N 0.000 description 1
- FDOBPLDZWDNTBO-AUSIDOKSSA-N CC[O](C)C(CCN(CC1)[C@H](CF)CN1c(ncnc1Nc2nc(-c3cc(C(F)(F)F)cc(F)c3)c(CN3[C@H](C)CCC3)[s]2)c1F)=O Chemical compound CC[O](C)C(CCN(CC1)[C@H](CF)CN1c(ncnc1Nc2nc(-c3cc(C(F)(F)F)cc(F)c3)c(CN3[C@H](C)CCC3)[s]2)c1F)=O FDOBPLDZWDNTBO-AUSIDOKSSA-N 0.000 description 1
- BHIAMEMLEQPCLP-UHFFFAOYSA-N CN(C)Cc1c(-c2cc(C(F)(F)F)cc(F)c2)nc(N)[s]1 Chemical compound CN(C)Cc1c(-c2cc(C(F)(F)F)cc(F)c2)nc(N)[s]1 BHIAMEMLEQPCLP-UHFFFAOYSA-N 0.000 description 1
- RGZLPFDPESAXLQ-UHFFFAOYSA-N COC(C1)CN1c1c(-c2cc(C(F)(F)F)cc(F)c2)nc(N)[s]1 Chemical compound COC(C1)CN1c1c(-c2cc(C(F)(F)F)cc(F)c2)nc(N)[s]1 RGZLPFDPESAXLQ-UHFFFAOYSA-N 0.000 description 1
- KCYISZPYQNYXMI-UHFFFAOYSA-N COC1=C(C=C(C=N1)C(C)=O)C(F)(F)F Chemical compound COC1=C(C=C(C=N1)C(C)=O)C(F)(F)F KCYISZPYQNYXMI-UHFFFAOYSA-N 0.000 description 1
- PVIXGDPIXWEPPO-UHFFFAOYSA-N COCCN(CCOC)c1c(-c2cc(C(F)(F)F)cc(F)c2)nc(N)[s]1 Chemical compound COCCN(CCOC)c1c(-c2cc(C(F)(F)F)cc(F)c2)nc(N)[s]1 PVIXGDPIXWEPPO-UHFFFAOYSA-N 0.000 description 1
- NEWZCGVIACLVBI-UHFFFAOYSA-N COc(nc1)c(C(F)(F)F)cc1-c1c[s]c(N)n1 Chemical compound COc(nc1)c(C(F)(F)F)cc1-c1c[s]c(N)n1 NEWZCGVIACLVBI-UHFFFAOYSA-N 0.000 description 1
- IZWCBEFMODVHEM-YMJOLPCJSA-N C[C@@]1(CC2)C3(CC3)CCC1C(CC1)C2C(C)(C2)C1=CC(C1)([C@@H]1CN1)C2=CN2C1=C(C)Nc1c2cccc1 Chemical compound C[C@@]1(CC2)C3(CC3)CCC1C(CC1)C2C(C)(C2)C1=CC(C1)([C@@H]1CN1)C2=CN2C1=C(C)Nc1c2cccc1 IZWCBEFMODVHEM-YMJOLPCJSA-N 0.000 description 1
- YGNDMZIOAPVUJK-OQHSHRKDSA-N C[C@H]1N(Cc2c(-c3cc(C(F)(F)F)cc(F)c3)nc(NCc3ncnc(N4CC(CF)N(CCC(O)=O)CC4)c3F)[s]2)CCC1 Chemical compound C[C@H]1N(Cc2c(-c3cc(C(F)(F)F)cc(F)c3)nc(NCc3ncnc(N4CC(CF)N(CCC(O)=O)CC4)c3F)[s]2)CCC1 YGNDMZIOAPVUJK-OQHSHRKDSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007026 Calculus urethral Diseases 0.000 description 1
- 206010008674 Cholinergic syndrome Diseases 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- DZOLHQQYQHXMNV-WWPIYYJJSA-N Cl.Cl.CCOC(=O)CCN1CCNC[C@@H]1C Chemical compound Cl.Cl.CCOC(=O)CCN1CCNC[C@@H]1C DZOLHQQYQHXMNV-WWPIYYJJSA-N 0.000 description 1
- YZERMLZODRWXET-UFRNLTNDSA-N Cl.Cl.Cl.ClC1=C(C=C(C=C1)C=1N=C(SC1CN1[C@@H](CCC1)C)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)O)F)C(F)(F)F Chemical compound Cl.Cl.Cl.ClC1=C(C=C(C=C1)C=1N=C(SC1CN1[C@@H](CCC1)C)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)O)F)C(F)(F)F YZERMLZODRWXET-UFRNLTNDSA-N 0.000 description 1
- NMIGQXBUUZQNGP-YTNSDAIYSA-N Cl.Cl.Cl.ClC1=C(C=C(C=C1)C=1N=C(SC1CN1[C@@H](CCC1)C)NC1=NC=CC(=C1)N1CCN(CC1)CCC(=O)O)C(F)(F)F Chemical compound Cl.Cl.Cl.ClC1=C(C=C(C=C1)C=1N=C(SC1CN1[C@@H](CCC1)C)NC1=NC=CC(=C1)N1CCN(CC1)CCC(=O)O)C(F)(F)F NMIGQXBUUZQNGP-YTNSDAIYSA-N 0.000 description 1
- OHQSMTBDJWIHQX-UFRNLTNDSA-N Cl.Cl.Cl.ClC=1C=C(C=C(C1)C(F)(F)F)C=1N=C(SC1CN1[C@@H](CCC1)C)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)O)F Chemical compound Cl.Cl.Cl.ClC=1C=C(C=C(C1)C(F)(F)F)C=1N=C(SC1CN1[C@@H](CCC1)C)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)O)F OHQSMTBDJWIHQX-UFRNLTNDSA-N 0.000 description 1
- RMMVEKKBMVNAJU-NMRXSTGRSA-N Cl.Cl.Cl.FC=1C(=NC=CC1N1CCN(CC1)CCC(=O)O)NC=1SC(=C(N1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C Chemical compound Cl.Cl.Cl.FC=1C(=NC=CC1N1CCN(CC1)CCC(=O)O)NC=1SC(=C(N1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C RMMVEKKBMVNAJU-NMRXSTGRSA-N 0.000 description 1
- HZTXQDXTAHKHSP-NPRSDBGMSA-N Cl.Cl.Cl.FC=1C(=NC=NC1N1[C@@H](CNCC1)COC)NC=1SC(=C(N1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C Chemical compound Cl.Cl.Cl.FC=1C(=NC=NC1N1[C@@H](CNCC1)COC)NC=1SC(=C(N1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C HZTXQDXTAHKHSP-NPRSDBGMSA-N 0.000 description 1
- QTSQGOFFZHOBOA-NMRXSTGRSA-N Cl.Cl.Cl.FC=1C=C(C=C(C1)C(F)(F)F)C=1N=C(SC1CN1[C@@H](CCC1)C)NC1=CC(=NC(=N1)C)N1CCN(CC1)CCC(=O)O Chemical compound Cl.Cl.Cl.FC=1C=C(C=C(C1)C(F)(F)F)C=1N=C(SC1CN1[C@@H](CCC1)C)NC1=CC(=NC(=N1)C)N1CCN(CC1)CCC(=O)O QTSQGOFFZHOBOA-NMRXSTGRSA-N 0.000 description 1
- DMGNGIMIOZGCSO-OAQYLSRUSA-N ClC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)CC)NC1=C(C(=NC=N1)N1CCC(CC1)OCC(=O)OCC)F Chemical compound ClC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)CC)NC1=C(C(=NC=N1)N1CCC(CC1)OCC(=O)OCC)F DMGNGIMIOZGCSO-OAQYLSRUSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 238000006683 Mannich reaction Methods 0.000 description 1
- 229940121743 Muscarinic receptor agonist Drugs 0.000 description 1
- CBIWJHVAMKCBIQ-LLVKDONJSA-N N-(6-chloro-2-methylpyrimidin-4-yl)-4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-amine Chemical compound ClC1=CC(=NC(=N1)C)NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C CBIWJHVAMKCBIQ-LLVKDONJSA-N 0.000 description 1
- QHRWSLOVOMCOHQ-SNVBAGLBSA-N N-(6-chloro-5-fluoro-2-methylpyrimidin-4-yl)-4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-amine Chemical compound ClC1=C(C(=NC(=N1)C)NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C)F QHRWSLOVOMCOHQ-SNVBAGLBSA-N 0.000 description 1
- VOUMSGQPHGLWIJ-UHFFFAOYSA-N N-[4-[3-chloro-5-(trifluoromethoxy)phenyl]-1,3-thiazol-2-yl]acetamide Chemical compound ClC=1C=C(C=C(C=1)OC(F)(F)F)C=1N=C(SC=1)NC(C)=O VOUMSGQPHGLWIJ-UHFFFAOYSA-N 0.000 description 1
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101000600908 Rattus norvegicus Substance-P receptor Proteins 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 1
- 229960000669 acetylleucine Drugs 0.000 description 1
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- CTOUWUYDDUSBQE-UHFFFAOYSA-N benzyl piperazine-1-carboxylate Chemical compound C1CNCCN1C(=O)OCC1=CC=CC=C1 CTOUWUYDDUSBQE-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- BZRRQSJJPUGBAA-UHFFFAOYSA-L cobalt(ii) bromide Chemical compound Br[Co]Br BZRRQSJJPUGBAA-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- OLGCQWBDJAMYGT-XXBNENTESA-N ethyl 3-[(2S)-4-[5-fluoro-6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]-2-(methoxymethyl)piperazin-1-yl]propanoate Chemical compound FC=1C(=NC=NC=1NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C)N1C[C@H](N(CC1)CCC(=O)OCC)COC OLGCQWBDJAMYGT-XXBNENTESA-N 0.000 description 1
- ALSBWBGUKDTNQX-HXUWFJFHSA-N ethyl 3-[4-[2-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyridin-4-yl]piperazin-1-yl]propanoate Chemical compound ClC1=C(C=C(C=C1)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=NC=CC(=C1)N1CCN(CC1)CCC(=O)OCC)C(F)(F)F ALSBWBGUKDTNQX-HXUWFJFHSA-N 0.000 description 1
- FZRJUGZQFTWVOK-UHFFFAOYSA-N ethyl 3-[4-[5-fluoro-6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound FC=1C(=NC=NC=1NC=1SC=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)N1CCN(CC1)CCC(=O)OCC FZRJUGZQFTWVOK-UHFFFAOYSA-N 0.000 description 1
- ORUNZOXCQGABFC-GOSISDBHSA-N ethyl 3-[4-[5-fluoro-6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-2-methylpyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound FC=1C(=NC(=NC=1NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1[C@@H](CCC1)C)C)N1CCN(CC1)CCC(=O)OCC ORUNZOXCQGABFC-GOSISDBHSA-N 0.000 description 1
- GVQNZOZAJPSXJL-NRFANRHFSA-N ethyl 3-[4-[5-fluoro-6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(3S)-3-methoxypyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound FC=1C(=NC=NC=1NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)F)CN1C[C@H](CC1)OC)N1CCN(CC1)CCC(=O)OCC GVQNZOZAJPSXJL-NRFANRHFSA-N 0.000 description 1
- YARFMYSMSPTQHP-UHFFFAOYSA-N ethyl 3-[4-[5-fluoro-6-[[4-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound FC=1C(=NC=NC=1NC=1SC=C(N=1)C=1C=NC(=C(C=1)C(F)(F)F)OC)N1CCN(CC1)CCC(=O)OCC YARFMYSMSPTQHP-UHFFFAOYSA-N 0.000 description 1
- ILHRLMDSIAPNDL-OAQYLSRUSA-N ethyl 3-[4-[5-fluoro-6-[[5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-4-[3-prop-1-en-2-yl-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]amino]pyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound FC=1C(=NC=NC=1NC=1SC(=C(N=1)C1=CC(=CC(=C1)C(F)(F)F)C(=C)C)CN1[C@@H](CCC1)C)N1CCN(CC1)CCC(=O)OCC ILHRLMDSIAPNDL-OAQYLSRUSA-N 0.000 description 1
- ZIPNEHFBLKXPSO-GOSISDBHSA-N ethyl 3-[4-[6-[[4-[3-bromo-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound BrC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)OCC)F ZIPNEHFBLKXPSO-GOSISDBHSA-N 0.000 description 1
- FNMCFXDZQRRCJQ-GOSISDBHSA-N ethyl 3-[4-[6-[[4-[3-chloro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound ClC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)OCC)F FNMCFXDZQRRCJQ-GOSISDBHSA-N 0.000 description 1
- OKMIJJUXITYBLK-UHFFFAOYSA-N ethyl 3-[4-[6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[2-methoxyethyl(propan-2-yl)amino]-1,3-thiazol-2-yl]amino]-2-methylpyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound FC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1N(CCOC)C(C)C)NC1=CC(=NC(=N1)C)N1CCN(CC1)CCC(=O)OCC OKMIJJUXITYBLK-UHFFFAOYSA-N 0.000 description 1
- KOWGKCLNEBJNSY-LJQANCHMSA-N ethyl 3-[4-[6-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-2-methylpyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound FC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=CC(=NC(=N1)C)N1CCN(CC1)CCC(=O)OCC KOWGKCLNEBJNSY-LJQANCHMSA-N 0.000 description 1
- QGUCMRGELAINPK-GOSISDBHSA-N ethyl 3-[4-[6-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound ClC1=C(C=C(C=C1)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)OCC)F)C(F)(F)F QGUCMRGELAINPK-GOSISDBHSA-N 0.000 description 1
- JEUMPNBZXPZQPR-RTBURBONSA-N ethyl 3-[4-[6-[[5-[[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl]-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]amino]-5-fluoro-2-methylpyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound C[C@H]1N([C@@H](CC1)C)CC1=C(N=C(S1)NC1=C(C(=NC(=N1)C)N1CCN(CC1)CCC(=O)OCC)F)C1=CC(=CC(=C1)C(F)(F)F)F JEUMPNBZXPZQPR-RTBURBONSA-N 0.000 description 1
- ZEJDYOSRYFKJQX-RTBURBONSA-N ethyl 3-[4-[6-[[5-[[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl]-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound C[C@H]1N([C@@H](CC1)C)CC1=C(N=C(S1)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)OCC)F)C1=CC(=CC(=C1)C(F)(F)F)F ZEJDYOSRYFKJQX-RTBURBONSA-N 0.000 description 1
- ANFZRGMDGDYNGA-UHFFFAOYSA-N ethyl acetate;propan-2-ol Chemical compound CC(C)O.CCOC(C)=O ANFZRGMDGDYNGA-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- FMVJYQGSRWVMQV-UHFFFAOYSA-N ethyl propiolate Chemical compound CCOC(=O)C#C FMVJYQGSRWVMQV-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- MOTRZVVGCFFABN-UHFFFAOYSA-N hexane;2-propan-2-yloxypropane Chemical compound CCCCCC.CC(C)OC(C)C MOTRZVVGCFFABN-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- XQDBZKHPFFODOD-UHFFFAOYSA-N methyl 2-piperidin-4-yloxyacetate;hydrochloride Chemical compound Cl.COC(=O)COC1CCNCC1 XQDBZKHPFFODOD-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- UMCVTLHNNUEZDO-UHFFFAOYSA-N n-(2-methoxyethyl)propan-2-amine Chemical compound COCCNC(C)C UMCVTLHNNUEZDO-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical compound C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BXALDIXABJGGES-UNTBIKODSA-M sodium 3-[4-[2-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-3-fluoropyridin-4-yl]piperazin-1-yl]propanoate Chemical compound ClC1=C(C=C(C=C1)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=NC=CC(=C1F)N1CCN(CC1)CCC(=O)[O-])C(F)(F)F.[Na+] BXALDIXABJGGES-UNTBIKODSA-M 0.000 description 1
- NMKOYFALCVHYAD-GBNZRNLASA-M sodium 3-[4-[6-[[5-[[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl]-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]amino]-5-fluoro-2-methylpyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound C[C@H]1N([C@@H](CC1)C)CC1=C(N=C(S1)NC1=C(C(=NC(=N1)C)N1CCN(CC1)CCC(=O)[O-])F)C1=CC(=CC(=C1)C(F)(F)F)F.[Na+] NMKOYFALCVHYAD-GBNZRNLASA-M 0.000 description 1
- GGPZCWXDBUKXBG-GBNZRNLASA-M sodium 3-[4-[6-[[5-[[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl]-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]amino]-5-fluoropyrimidin-4-yl]piperazin-1-yl]propanoate Chemical compound C[C@H]1N([C@@H](CC1)C)CC1=C(N=C(S1)NC1=C(C(=NC=N1)N1CCN(CC1)CCC(=O)[O-])F)C1=CC(=CC(=C1)C(F)(F)F)F.[Na+] GGPZCWXDBUKXBG-GBNZRNLASA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- APCBTRDHCDOPNY-SSDOTTSWSA-N tert-butyl (3r)-3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](O)C1 APCBTRDHCDOPNY-SSDOTTSWSA-N 0.000 description 1
- FQFBLFWWIZKUEH-LBPRGKRZSA-N tert-butyl (3s)-4-(3-ethoxy-3-oxopropyl)-3-methylpiperazine-1-carboxylate Chemical compound CCOC(=O)CCN1CCN(C(=O)OC(C)(C)C)C[C@@H]1C FQFBLFWWIZKUEH-LBPRGKRZSA-N 0.000 description 1
- PNNKEMBSXAYCEP-UHFFFAOYSA-N tert-butyl 3-[4-(2-chloro-3-fluoropyridin-4-yl)piperazin-1-yl]propanoate Chemical compound ClC1=NC=CC(=C1F)N1CCN(CC1)CCC(=O)OC(C)(C)C PNNKEMBSXAYCEP-UHFFFAOYSA-N 0.000 description 1
- BWTRHKJAKYHTLL-UHFFFAOYSA-N tert-butyl 3-piperazin-1-ylpropanoate Chemical compound CC(C)(C)OC(=O)CCN1CCNCC1 BWTRHKJAKYHTLL-UHFFFAOYSA-N 0.000 description 1
- CKQJHRXIORRPFO-UHFFFAOYSA-N tert-butyl 4-(2-chloro-3-fluoropyridin-4-yl)piperazine-1-carboxylate Chemical compound ClC1=NC=CC(=C1F)N1CCN(CC1)C(=O)OC(C)(C)C CKQJHRXIORRPFO-UHFFFAOYSA-N 0.000 description 1
- LNNICSXTPTXPCH-UHFFFAOYSA-N tert-butyl 4-(3-ethoxy-3-oxopropyl)-3-(hydroxymethyl)piperazine-1-carboxylate Chemical compound C(C)OC(CCN1C(CN(CC1)C(=O)OC(C)(C)C)CO)=O LNNICSXTPTXPCH-UHFFFAOYSA-N 0.000 description 1
- PYQNNWOGSUNTJM-GOSISDBHSA-N tert-butyl 4-[2-[[4-[4-chloro-3-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]-3-fluoropyridin-4-yl]piperazine-1-carboxylate Chemical compound ClC1=C(C=C(C=C1)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC1=NC=CC(=C1F)N1CCN(CC1)C(=O)OC(C)(C)C)C(F)(F)F PYQNNWOGSUNTJM-GOSISDBHSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 201000009160 urethral calculus Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- YBCYJDNOPAFFOW-XOAARHKISA-N win-62577 Chemical compound C1=CC=C2N(C=C3C(C=C4CC[C@@H]5[C@@H]([C@]4(C3)C)CC[C@]3([C@H]5CC[C@@]3(O)C#C)C)=N3)C3=NC2=C1 YBCYJDNOPAFFOW-XOAARHKISA-N 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to a 2-aminothiazole derivative or a salt thereof which is expected as an active ingredient for a pharmaceutical composition, in particular, a pharmaceutical composition for treating bladder/urinary tract diseases related to bladder contractions via a muscarinic M 3 receptor.
- the important roles of the lower urinary tract are urine storage and voiding, which are regulated by a coordinated action of the bladder and the urethra. That is, during urine storage, the bladder smooth muscle is relaxed and the urethral sphincter is contracted, whereby a state in which urethral resistance is high is maintained and urinary continence is maintained. On the other hand, during voiding, the bladder smooth muscle is contracted, the urethra smooth muscle is relaxed, and contraction of the external urethral sphincter is also inhibited.
- Examples of the lower urinary tract disorder include urine storage dysfunction such as overactive bladder, in which urine cannot be retained during urine storage, and voiding dysfunction, in which urine cannot be drained sufficiently during voiding due to an increase in the urethral resistance or a decrease in the bladder contractile force. These two disorders may develop simultaneously in some cases.
- Voiding dysfunction is caused by a decrease in the bladder contractile force, an increase in urethral resistance or the like during voiding, and causes difficulty in voiding, straining during voiding, a weak urine stream, extension of voiding time, an increase in residual urine, a decrease in voiding efficiency, or the like.
- the decrease in the bladder contractile force during voiding is referred to as underactive bladder, acontractile bladder, or the like.
- the muscarinic receptors are currently classified into five subtypes, M 1 , M 2 , M 3 , M 4 , and M 5 , and it has been known that the subtypes involving the contraction in the bladder smooth muscle is mainly M 3 ( Pharmacological Reviews, 50: pp.279-290 (1998 ); The Journal of Neuroscience, 22: pp. 10627-10632 (2002 )).
- bethanechol chloride which is a non-selective muscarinic receptor agonist and distigmine bromide which is a cholinesterase inhibitor have been known.
- these drugs have cholinergic side effects such as diarrhea, abdominal pain, and perspiration.
- cholinergic crisis is occurred as a serious side effect, which require attention during use (Ubretid (registered trademark), tablet 5 mg, package insert, Torii Pharmaceutical Co., Ltd., and Besacholine (registered trademark) powder 5%, package insert, Eisai Co., Ltd.).
- voiding dysfunction associated with benign prostatic hyperplasia has been well-known, which is characterized in that the urethra is partially occluded by nodular enlargement of the prostatic tissue.
- an adrenergic ⁇ 1 receptor antagonist has been used as a therapeutic drug for voiding dysfunction associated with benign prostatic hyperplasia ( Pharmacology, 65: pp. 119-128 (2002 )).
- the effectiveness of the adrenaline ⁇ 1 receptor antagonist for voiding dysfunction that is not associated with benign prostatic hyperplasia is unclear ( Journal of Pharmacological Sciences, 112: pp. 121-127 (2010 )).
- residual urine after voiding may be observed in some cases.
- the increased residual urine may cause a decrease in effective bladder capacity, and thus cause overactive bladder symptoms such as urinary frequency or severe symptoms such as hydronephrosis in some cases.
- a compound represented by the following formula (A) disclosed in Patent Document 1 and a compound represented by the following formula (A1) disclosed in Patent Document 2 each have a Ba/F3 cell proliferative activity through a human c-myeloproliferative leukemia virus type P (c-Mpl), and have thrombocyte increasing activity.
- c-Mpl human c-myeloproliferative leukemia virus type P
- R 3 and Ar 1 represent an aromatic hetero ring which may be substituted, or the like.
- Patent Document 3 discloses that a compound represented by the following formula (B) has an AMP-activated protein kinase (AMPK) pathway activating action.
- AMPK AMP-activated protein kinase pathway activating action.
- ring B represents a heteroarylene or the like
- J represents -NR 13 - or the like
- D 1 , D 2 and D 3 each represent N, CH, or the like
- E represents -NR 1 R 2 or the like
- R 1 and R 2 may be combined with the adjacent nitrogen atom to form a heterocycloalkyl group
- R 4 represents aryl or the like which may be substituted
- T represents -NR 8 R 9 , heterocycloalkyl or the like.
- Non-Patent Document 1 discloses that a compound represented by the following formula (C1) is an allosteric enhancer of a muscarinic M 3 receptor.
- Non-Patent Document 2 discloses that WIN 62,577 represented by the following formula is a rat NK1 receptor antagonist and, at the same time, an allosteric enhancer of a muscarinic receptor.
- the present invention provides a novel compound which is expected as an active ingredient for a pharmaceutical composition, in particular, for a pharmaceutical composition for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M 3 receptor, which has a muscarinic M 3 receptor-positive allosteric modulator activity.
- a 2-aminothiazole derivative has an excellent muscarinic M 3 receptor-positive allosteric modulator activity and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M 3 receptor, thereby completing the present invention.
- the present invention relates to a compound of the formula (I) or a salt thereof, and a pharmaceutical composition comprising a compound of the formula (I) or a salt thereof and an excipient.
- the invention relates to a compound of the formula (I) or a salt thereof, and a pharmaceutical composition comprising a compound of the formula (I) or a salt thereof and an excipient.
- X is C-H or N
- Y is C-R 3e or N
- R 1 and R 2 are the same as each other or are different from each other, and are C 1-6 alkyl which may be substituted, or R 1 and R 2 may be combined with the adjacent nitrogen atom to form cyclic amino which may be substituted
- R 3a , R 3b , R 3c , R 3d , and R 3e are the same as each other or are different from each other, and are H, halogen, C 1-6 alkyl, halogeno C 1-6 alkyl, -O-C 1-6 alkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, or -O-halogeno C 1-6 alkyl
- R 4 is H, halogen, or -O-C
- Patent Document 1 the configuration of the compound disclosed in Patent Document 1 is different from that of the compound of the present application in that an acyl group is substituted to an amino group at 2-position of thiazole.
- Patent Document 1 neither discloses nor suggests an action on a muscarinic receptor or an action on bladder/urinary tract diseases.
- Patent Document 2 does not disclose a specific compound which is a compound of the formula (B) wherein ring B is thiazole, and neither discloses nor suggests an action on a muscarinic receptor or an action on bladder/urinary tract diseases.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising the compound of the formula (I) or a salt thereof, and a pharmaceutically acceptable excipient.
- the present invention relates to a pharmaceutical composition for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M 3 receptor, comprising the compound of the formula (I) or a salt thereof.
- the present invention relates to an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M 3 receptor, comprising the compound of the formula (I) or a salt thereof.
- the present invention relates to use of the compound of the formula (I) or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M 3 receptor; use of the compound of the formula (I) or a salt thereof for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M 3 receptor; the compound of the formula (I) or a salt thereof for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M 3 receptor; and a method for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M 3 receptor, comprising administering to a subject an effective amount of the compound of the formula (I) or a salt thereof.
- the "subject” is a human or a non-human animal in need of the prevention or treatment, and in one embodiment, a human in need of the prevention or treatment.
- the compound represented by the formula (I) or a salt thereof is expected as a preventing or treating agent for bladder/urinary tract diseases associated with bladder contractions via a muscarinic M 3 receptor, which has a muscarinic M 3 receptor-positive allosteric modulator activity.
- the positive allosteric modulator is a compound which binds to an allosteric site different from a ligand binding site, and has an effect of increasing the affinity of an agonist to a receptor by mainly causing a structural change in a receptor, and thus changing the signal level of an agonist.
- the positive allosteric modulator does not exhibit an agonistic effect by itself, and increases the effect of an endogenous agonist.
- the muscarinic M 3 receptor-positive allosteric modulator means a compound which enhances an effect via the muscarinic M 3 receptor by an agonist stimulation-dependent or nerve stimulation-dependent manner. Accordingly, only during voiding, the effect on enhancing bladder contraction is expected and the muscarinic M 3 receptor-positive allosteric modulator is possibly useful as an agent for improving various symptoms associated with voiding dysfunction. Further, by such a specific action during voiding, it is expected that it is possible to decrease cholinergic side effects, known to be induced with bethanechol chloride and distigmine bromide.
- the muscarinic M 3 receptor-positive allosteric modulator increases bladder contractile force during voiding, an effect in voiding dysfunction which is caused by an increase in urethral resistance can also be expected. A decrease in residual urine by such improvement of voiding dysfunction leads to an increase in the effective bladder capacity, and thus, it can be expected to improve urine storage functions as well as to decrease renal disorder.
- the muscarinic M 3 receptor-positive allosteric modulator is expected to be useful as an agent for preventing or treating bladder/urinary tract diseases related to bladder contractions via a muscarinic M 3 receptor.
- the present inventors have newly discovered a compound that acts as the modulator, thereby completing the present invention.
- examples of the "bladder/urinary tract diseases associated with bladder contractions via a muscarinic M 3 receptor" include voiding dysfunction or urine storage dysfunction in underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethra relaxation failure, detrusor-external urethral sphincter dyssynergia, overactive bladder, urinary frequency, nocturia, urinary incontinence, benign prostatic hyperplasia, interstitial cystitis, chronic prostatitis, urethral calculus, or the like, preferably, voiding dysfunction or urine storage dysfunction in underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, and neurogenic bladder.
- alkyl is linear alkyl and branched alkyl.
- C 1-6 alkyl is linear or branched alkyl having 1 to 6 carbon atoms, and specific examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, or n-hexyl.
- C 1-4 alkyl is preferably used.
- examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl; in one embodiment, a group selected from the group consisting of methyl, ethyl, isopropyl, and isobutyl; in one embodiment, methyl or ethyl; in one embodiment, methyl; and in another embodiment, ethyl.
- alkenyl is linear alkenyl and branched alkenyl.
- C 2-6 alkenyl is linear or branched alkenyl having 2 to 6 carbon atoms, and specific examples thereof include vinyl, propenyl, butenyl, pentenyl, 1-methylvinyl, 1-methyl-2-propenyl, 1,3-butadienyl, and 1,3-pentadienyl, and the like.
- examples thereof include C 2-4 alkenyl, and in one embodiment, vinyl or propenyl,
- alkylene is linear alkylene and branched alkylene.
- C 1-6 alkylene is linear or branched alkylene having 1 to 6 carbon atoms, and examples thereof include methylene, ethylene, propylene, tetramethylene, pentamethylene, hexamethylene, methyl methylene, ethylethylene, 1,2-dimethyl ethylene, or 1,1,2,2-tetramethyl ethylene, and the like.
- examples thereof include C 1-3 alkylene; in one embodiment, methylene or ethylene; in one embodiment, methylene; and in another embodiment, ethylene.
- halogeno-C 1-6 alkyl is C 1-6 alkyl substituted with at least one halogen atom; in one embodiment, C 1-6 alkyl substituted with 1 to 5 halogen atoms; in one embodiment, difluoromethyl or trifluoromethyl; and in one embodiment, trifluoromethyl.
- the "cycloalkyl” is a saturated hydrocarbon cyclic group.
- the "C 3-8 cycloalkyl” is a saturated hydrocarbon cyclic group having 3 to 8 ring members, and specific examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; in one embodiment, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is C 3-6 cycloalkyl; and in one embodiment, cyclopropyl.
- the "saturated hetero ring” is a 3- to 8-membered saturated ring, which has 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom as a ring-constituting atom, and may be bridged with C 1-6 alkylene, in which a sulfur atom as the ring-constituting atom may be oxidized.
- azepane diazepane, aziridine, azetidine, pyrrolidine, imidazolidine, piperidine, pyrazolidine, piperazine, azocane, thiomorpholine, thiazolidine, isothiazolidine, oxazolidine, morpholine, tetrahydrothiopyran, oxathiolane, oxirane, oxetane, dioxolane, tetrahydrofuran, tetrahydropyran, and 1,4-dioxane.
- the "cyclic amino” has at least one nitrogen atom, and is a 4- to 7-membered monovalent group having a bond at the ring-constituting nitrogen atom in the "saturated hetero ring".
- Specific examples thereof include azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, morpholinyl, thiomorpholinyl, piperazinyl, 1,4-diazepanyl, 1,4-oxazepanyl, or 1,4-thiazepanyl.
- examples thereof include pyrrolidinyl, piperidinyl, azetidinyl, morpholinyl, or piperazinyl, in one embodiment, pyrrolidinyl, piperidinyl, or piperazinyl, in one embodiment, pyrrolidinyl, in another embodiment, piperidinyl, and in another embodiment, piperazinyl.
- heterocyclylene has at least one nitrogen atom, and is a divalent group having a bond at the ring-constituting nitrogen atom and other ring-constituting atom in the "saturated hetero ring". Specific examples thereof include pyrrolidine-diyl, piperidine-diyl, or piperazine-diyl.
- halogen means fluoro, chloro, bromo, or iodo; in one embodiment, fluoro, chloro, or bromo; in one embodiment, fluoro or chloro; in one embodiment, fluoro; and in another embodiment, chloro.
- cyclic amino in “R 1 and R 2 may be combined with the adjacent nitrogen atom to form cyclic amino which may be substituted" of the formula (I), the examples thereof include azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, and in one embodiment, pyrrolidinyl.
- heterocyclylene in Q of the formula (I), the examples thereof include pyrrolidine-diyl, piperidine-diyl, or piperazine-diyl, in one embodiment, pyrrolidine-1,3-diyl, piperidine-1,4-diyl, or piperazine-1,4-diyl, in one embodiment, piperidine-diyl or piperazine-diyl, and in one embodiment, piperidine-1,4-diyl or piperazine-1,4-diyl.
- heterocyclylene in Q of the formula (I) is pyrrolidine-1,3-diyl or piperidine-1,4-diyl
- the 3-position of pyrrolidine or the 4-position of piperidine is each bonded to W.
- W of the formula (I) the examples thereof include a bond, C 1-6 alkylene, -O-C 1-6 alkylene, or -N(R N )-C 1-6 alkylene, and the O of "-O-C 1-6 alkylene” and N(R N ) of "-N(R N )-C 1-6 alkylene" are each bonded to Q.
- examples thereof include -CH 2 -CH 2 -, or -O-CH 2 -.
- the expression "which may be substituted” means "which is not substituted” or "which is substituted with 1 to 5 substituents”. Further, if it has a plurality of substituents, the substituents may be the same as or different from each other.
- Examples of the preferred substituent in "cyclic amino which may be substituted" and “heterocyclylene which may be substituted” include the following Group G.
- examples of the preferred substituent in "C 1-6 alkyl which may be substituted" include the groups described in (b) to (o) of the above-described Group G. In one embodiment, examples thereof include the substituent selected from the group consisting of -OH, -O-C 1-6 alkyl, and C 3-8 cycloalkyl.
- examples of the preferred substituent in "C 1-6 alkyl which may be substituted" of R 1 and R 2 include -O-C 1-6 alkyl or C 3-8 cycloalkyl. In one embodiment, examples thereof include methoxy or cyclopropyl, in one embodiment, methoxy, and in another embodiment, cyclopropyl.
- the examples thereof include the groups described in (a) to (d) of the above-described Group G
- the examples thereof include C 1-6 alkyl, -O-C 1-6 alkyl, or C 3-8 cycloalkyl, in one embodiment, C 1-6 alkyl, in one embodiment, methyl or ethyl, in one embodiment, methyl, and in another embodiment, ethyl.
- the examples thereof include the groups described in (a) to (c), and (f) of the above-described Group G.
- the examples thereof include C 1-6 alkyl which may be substituted with a group selected from the group consisting of -O-C 1-6 alkyl, -OH and halogen, -O-C 1-6 alkyl or halogen.
- the examples thereof include C 1-6 alkyl which is substituted with -O-C 1-6 alkyl, and in one embodiment, methoxymethyl.
- Examples of the specific compounds of the formula (I) include the following compounds or salts thereof:
- examples of the specific compounds of the formula (I) include the following compounds or salts thereof:
- tautomers or geometrical isomers thereof may exist, depending on the kinds of the substituents.
- the compound of the formula (I) may be described in only one form of isomers in some cases, but the present invention includes other isomers, isolated forms of the isomers, or a mixture thereof.
- the compounds of the formula (I) may have asymmetric carbon atoms or axis chirality in some cases, and correspondingly, the optical isomers or diastereomers thereof can exist.
- the present invention includes the isolated form of the optical isomer of the compound of the formula (I) or a mixture thereof.
- a pharmaceutically acceptable prodrug of the compound represented by the formula (I) is also included in the present invention.
- the pharmaceutically acceptable prodrug refers to a compound having a group which can be converted into an amino group, a hydroxyl group, a carboxyl group, or the like, by solvolysis or under a physiological condition.
- the groups forming the prodrug include those as described in Prog. Med., 5,2157-2161 (1985 ) or " Pharmaceutical Research and Development” (Hirokawa Publishing Company, 1990), vol. 7, Molecular Design, 163-198 , and " Methods and Principles in Medicinal Chemistry, vol. 47, Prodrugs and Targeted Delivery (Wiley-VCH, 2010 )".
- the salt of the compound of the formula (I) is a pharmaceutically acceptable salt of the compound of the formula (I), and the compounds of the formula (I) may form an acid addition salt or a salt with a base, depending on the kinds of the substituents in some cases.
- examples thereof include acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid, and with organic acids such as formic acid, acetic acid, propanoic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyl tartaric acid, ditoluoyl tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, and glutamic acid, and salts with metal cations such as sodium, potassium, magnesium, calcium, and aluminum, and with organic bases such as methylamine, ethylamine, ethanolamine, lysine, ornithine, and salts with various amino acids or
- the present invention also includes various hydrates or solvates, and crystal polymorph substances of the compound of the formula (I) and a salt thereof.
- the present invention also includes the compounds labeled with various radioactive or non-radioactive isotopes.
- the compound of the formula (I) or a salt thereof can be prepared by applying various known synthetic methods, using the characteristics based on their basic structures or the kinds of the substituents. At this time, depending on the types of the functional groups, it is in some cases effective from the viewpoint of the preparation techniques to protect the functional group with an appropriate protective group (a group which is capable of being easily converted into the functional group), during the steps from starting materials to intermediates.
- an appropriate protective group a group which is capable of being easily converted into the functional group
- the protective group include the protective groups as described in " Greene's Protective Groups in Organic Synthesis (4th edition, 2006)", edited by P. G. M. Wuts and T. W. Greene , and the like, which may be appropriately selected and used depending on the reaction conditions. In these methods, a desired compound can be obtained by introducing the protective group to carry out the reaction, and then, if desired, removing the protective group.
- the prodrug of the compound of the formula (I) can be prepared by introducing a specific group during the steps from starting materials to intermediates, in the same manner as for the above protective groups, or by further carrying out the reaction using the obtained compound of the formula (I).
- the reaction can be carried out by applying a method known to a person skilled in the art, such as common esterification, amidation, and dehydration.
- R represents C 1-6 alkyl or benzyl
- L 1 represents a leaving group
- A represents N or CH, which shall apply hereinafter).
- This production process is a method for producing a compound of the formula (Ia) in which Q is piperazine-1,4-diyl or piperidine-1,4-diyl among the compounds of the formula (I) which are the compounds of the present invention, from the compound of the formula (a).
- This step is a step of obtaining a compound of the formula (c) by reacting a compound of the formula (a) with the compound of the formula (b).
- the leaving group L 1 include a halogen group, a methanesulfonyloxy group, and a p-toluenesulfonyloxy group.
- This reaction is carried out using the compound of the formula (a) and the compound of the formula (b), by stirring the mixture under the temperature condition ranging from under cooling to under heating to reflux, preferably at 0 °C to 90°C, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction or without a solvent.
- solvent used herein examples include aromatic hydrocarbons such as benzene, toluene and xylene, ethers such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, and the like, halogenated hydrocarbons such as methylene chloride, 1,2-dichloroethane, chloroform, and the like, N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), ethyl acetate, acetonitrile, 1-methylpyrrolidin-2-one (NMP), and a mixture thereof.
- aromatic hydrocarbons such as benzene, toluene and xylene
- ethers such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, and the like
- halogenated hydrocarbons such as methylene chloride, 1,2-dichloro
- an organic base such as triethylamine, N,N-diisopropylethylamine, N-methylmorpholine, and the like or an inorganic base such as sodium hydride, potassium carbonate, sodium carbonate, potassium hydroxide, and the like.
- This step is a step of obtaining a compound of the formula (e) by reacting the compound of the formula (c) with a compound of the formula (d).
- the reaction conditions are the same as in Process 1 of Production Process 1. In addition, it is possible to switch the order of Process 1 and Process 2.
- This step is a step of obtaining a compound of formula (Ia) by deprotecting the compound of the formula (e).
- This reaction is carried out by using the compound of the formula (e) and a deprotecting reagent by stirring the mixture under the temperature condition ranging from under cooling to heating to reflux, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction or without a solvent.
- this reaction can also be carried out by subjecting the compound of the formula (e) to a hydrogenation reaction using a metal catalyst in a hydrogen atmosphere.
- the solvent used herein are not particularly limited, but include alcohols such as methanol, ethanol, n-propanol and the like, DMF, THF, and the like. Further, there are some cases where a mixed solvent of the solvent and water is highly suitable for the reaction.
- Examples of the deprotecting reagent are not particularly limited, but include bases such as an aqueous sodium hydroxide solution, an aqueous potassium hydroxide solution and the like, and acids such as hydrochloric acid, trifluoroacetic acid and the like.
- examples of the metal catalyst that can be used in the hydrogenation reaction include palladium on carbon and palladium hydroxide.
- This production process is a method for producing a compound of the compound of the formula (Ib) in which W is ethylene, and Q is piperazine-1,4-diyl among the compounds of the formula (I) which are the compounds of the present invention, from the compound of the formula (a).
- This step is a step of obtaining a compound of the formula (g) by a deprotecting after reacting a compound of the formula (a) with a compound of the formula (f).
- a leaving group L 2 include a halogen, a trifluoromethanesulfonyloxy group, and the like.
- examples of a protecting group P 0 include a t-butoxycarbonyl (Boc), and the like.
- the reaction is carried out by using the compound of the formula (a) and the compound of the formula (f) in equivalent amounts, or either thereof in an excess amount, by stirring the mixture under the temperature condition ranging from under cooling to under heating, preferably at room temperature to 150°C, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction, in the presence of a palladium catalyst, a ligand, and a base.
- a solvent which is inert to the reaction
- a palladium catalyst e.g., a palladium catalyst, a ligand, and a base.
- the solvent used herein are not particularly limited, but include aromatic hydrocarbons such as benzene, toluene, xylene and the like, N,N-dimethylformamide, acetonitrile, water, and a mixture thereof.
- Examples of the palladium catalyst include palladium acetate or tris(dibenzylideneacetone) dipalladium, and the like.
- examples of the ligand include 1,1'-bis(diphenylphosphino)ferrocene (dppf), 1,1'-binaphthalene-2,2'-diyl bis(diphenylphosphine) (BINAP), 2-dicyclohexylphosphino-2',4,'6'-triisopropylbiphenyl (XPhos), dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (SPhos), tricyclohexylphosphine, di-tert-butyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine, (9,9-dimethyl-9H-xanthene-4,5-diyl) bis(dipheny
- deprotecting the P 0 group can be carried out by referring " Protective Groups in Organic Synthesis” written by Wuts and Greene, 4th edition, John Wiley & Sons Inc., 2006 ".
- This step is a step of preparing a compound of the formula (i) by reacting the compound of the formula (g) with a compound of the formula (h).
- This reaction is carried out using the compound of the formula (g) and the compound of the formula (h) in equivalent amounts, or either thereof in an excess amount, by stirring the mixture under the temperature condition ranging from under cooling to under heating to reflux, preferably at 0°C to 100°C, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction.
- solvent used herein examples include aromatic hydrocarbons such as benzene, toluene, xylene and the like, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane and the like, halogenated hydrocarbons such as methylene chloride, 1,2-dichloroethane, chloroform and the like, DMF, NMP, DMSO, ethyl acetate, acetonitrile, ethanol, and a mixture thereof.
- aromatic hydrocarbons such as benzene, toluene, xylene and the like
- ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane and the like
- halogenated hydrocarbons such as methylene chloride, 1,2-dichloroethane, chloroform and the like
- DMF 1,2-dichloroethane, chloro
- an organic base such as piperidine, triethylamine, N,N-diisopropylethylamine, N-methylmorpholine and the like
- an inorganic base such as potassium carbonate, sodium carbonate, potassium hydroxide and the like.
- This step is a step of obtaining a compound of formula (Ib) by deprotecting the compound of the formula (i).
- the reaction conditions are the same as in Process 3 of Production Process 1.
- This production process is another preparation method for the compound of the formula (I).
- This step is a step of preparing a compound of the formula (k) by reacting a compound of the formula (a) with a compound of the formula (j).
- the reaction conditions are the same as in Process 1 of Production Process 2.
- This step is a step of obtaining a compound of formula (I) by deprotecting the compound of the formula (k).
- the reaction conditions are the same as in Process 3 of Production Process 1.
- This production process is a method for producing a compound of the formula (Ic) in which Q is piperazine-1,4-diyl or piperidine-1,4-diyl, and n is 1 among the compounds of the formula (I).
- This step is a step of obtaining a compound of the formula (n) by reacting a compound of the formula (m) with the compound of the formula (b).
- the reaction conditions are the same as in Process 1 of Production Process 1.
- This step is a step of obtaining a compound of the formula (o) by reacting the compound of the formula (n) with a compound of the formula (d).
- the reaction conditions are the same as in Process 1 of Production Process 1.
- This step is a step of obtaining a compound of the formula (q) by subjecting the compound of the formula (o) to a Mannich reaction by using a compound of the formula (p) and formaldehyde. It is possible to employ a method described in Journal of the American Chemical Society written by Albertson, N.F. 1948, 70, 669 and Bulletin of the Chemical Society of Japan written by Bhargava, P.N., Sharma, S.C. 1965, 38, 909 , or a method similar to that.
- This step is a step of preparing a compound of formula (Ic) by deprotecting the compound of the formula (q).
- the reaction conditions are the same as in Process 3 of Production Process 1.
- the protecting group P 1 include the protecting groups of the amino groups described in " Protective Groups in Organic Synthesis” written by Wuts and Greene, 4th edition, John Wiley & Sons Inc., 2006 , such as an acetyl group.
- This step is a step of obtaining a compound of the formula (m) having 2-aminothiazole from a compound of the formula (r). It is possible to obtain the compound of the formula (m) having 2-aminothiazole by reacting the compound of the formula (r) with a brominating agent such as trimethylphenylammonium tribromide, and then reacting with thiourea in a solvent which is inert to the reaction. It is possible to employ a method described in Journal of the American Chemical Society written by Dodson R.M. et al., 1945, 67, 2242 , or a method similar to that.
- a brominating agent such as trimethylphenylammonium tribromide
- This step is a step of protecting the amino group of the compound of the formula (m).
- the present reaction can be carried out with reference to " Protective Groups in Organic Synthesis” written by Wuts and Greene, 4th edition, John Wiley & Sons Inc., 2006 .
- This step is a step of preparing a compound of the formula (t) by introducing an acetoxymethyl group into the 5-position of thiazole in a compound of the formula (s).
- the step can be carried out by reacting a formaldehyde aqueous solution or a paraformaldehyde with a compound of the formula (s) in the presence of an acetic acid solvent under the temperature condition ranging from at room temperature to under heating, or from at room temperature to under refluxing.
- this reaction can also be carried out under microwave irradiation.
- reaction it is possible to carry out the reaction by adding acetic acid into a solvent which is inert to the reaction such as halogenated hydrocarbons, aromatic hydrocarbons, and ethers, instead of the acetic acid solvent.
- acetic acid solvent such as halogenated hydrocarbons, aromatic hydrocarbons, and ethers
- the reaction can also be carried out by further adding acetic anhydride.
- This step is a step of preparing a compound of the formula (u) by reacting the compound of the formula (p) with respect to and the compound of the formula (t) under a basic condition.
- the present reaction can be carried out by reacting the compound of the formula (t) with the compound of the formula (p) in the presence of an organic base such as triethylamine and N,N-diisopropylethylamine in an organic solvent which is inert to the reaction such as halogenated hydrocarbons, aromatic hydrocarbons, ethers, esters, acetonitrile, DMF, DMSO, and NMP.
- the compound of the formula (p) can also be used in an excess amount instead of the organic base.
- the reaction can be carried out under the temperature condition ranging from under cooling to at room temperature; from at room temperature to under heating; or from at room temperature to under refluxing.
- the step is a step of obtaining the compound of the formula (v) by removing the protecting group of the compound of the formula (u).
- this reaction can be carried out by referring " Protective Groups in Organic Synthesis” written by Wuts and Greene, 4th edition, John Wiley & Sons Inc., 2006 ".
- This step is a step of obtaining the compound of the formula (w) from the compound of the formula (m).
- This reaction is carried out by an ipso-substitution reaction by using the compound of the formula (p) after brominating the 5-position of thiazole in the compound of the formula (m) by using a brominating agent such as N-bromosuccinimide so as to obtain the compound of the formula (w).
- the compound of the formula (I) is isolated and purified as its free compound, or a salt, a hydrate, a solvate, or crystal polymorph substance thereof.
- the salt of the compound of the formula (I) can also be prepared by a conventional method.
- Isolation and purification are carried out by employing general chemical operations such as extraction, fractional crystallization, and various types of fractional chromatography.
- optical isomers can be prepared by selecting appropriate starting compound, or separated by using differences in the physicochemical properties among the isomers.
- the optical isomers can be obtained by means of general optical resolution methods of racemic compounds (for example, fractional crystallization introducing the compound into a diastereomer salt with an optically active base or acid; chromatography using a chiral column or the like; and others), or can also be prepared from appropriate optically active starting compound.
- a human muscarinic M 3 receptor gene (GenBank Accession No.: NM_000740.2) was introduced into an expression vector pcDNA3.1 (registered trademark) (Life Technologies).
- a vector expressing a human muscarinic M 3 receptor was introduced into a CHO-K1 cell (ATCC No.: CCL-61). The introduction was carried out according to the attached instructions, using a transfection reagent, Lipofectoamine (registered trademark) 2000 Reagent (Life Technologies). The cells were incubated in an alpha Modified Eagle Minimum Essential Medium ( ⁇ -MEM) including 2 mM L-glutamine, 10% fetal bovine serum, and 2.0 mg/mL Geneticin (registered trademark) (Life Technologies) for 4 weeks to acquire a drug-resistant clone.
- ⁇ -MEM alpha Modified Eagle Minimum Essential Medium
- Geneticin registered trademark
- the cells obtained in b) above were suspended in an ⁇ -MEM including 2 mM glutamine, 10% fetal bovine serum, and 0.2 mg/mL Geneticin (registered trademark) to the amount from 1.2 to 1.5 ⁇ 10 4 cells/well the day before the experiment, dispensed into a 384-well plate (Model No. 353962, BD Biosciences), and incubated overnight at 37°C and 5% CO 2 .
- ⁇ -MEM including 2 mM glutamine, 10% fetal bovine serum, and 0.2 mg/mL Geneticin (registered trademark) to the amount from 1.2 to 1.5 ⁇ 10 4 cells/well the day before the experiment, dispensed into a 384-well plate (Model No. 353962, BD Biosciences), and incubated overnight at 37°C and 5% CO 2 .
- the medium was replaced with a loading buffer (an assay buffer (Hank's balanced salt solution (HBSS) including 3.1 ⁇ M Fluo 4-AM (Dojindo Laboratories), 1 g/L BSA, 20 mM HEPES (pH 7.5), and 2.5 mM probenecid)), and incubated for about 2 hours at room temperature. Thereafter, the cells were washed with a plate washer ELx405(registered trademark) (BIO-TEK Instrument, Inc.) set with the assay buffer, and set in an intracellular Ca 2+ concentration measuring system (FLIPR tetra (registered trademark), Molecular Device). The test substances were dissolved by using DMSO.
- test substances final concentration of 1 ⁇ M or 10 ⁇ M
- carbachol Sigma, final concentration of 0.0024 nM to 10 ⁇ M
- the test substances were added to the cells in the device and after about 5 minutes, carbachol was added to the cells.
- An increase rate of the intracellular Ca 2+ concentration by carbachol was measured (excitement wavelength of 470 to 495 nm and a fluorescence wavelength of 515 to 575 nm).
- a shift toward a lower concentration side of a carbachol concentration-response curve by the test substance was used as an index. That is, a minimum value in the carbachol response was taken as 0%; a maximum value in the carbachol response was taken as 100% from the concentration-response curve of carbachol; the carbachol concentration exhibiting a 50% response was calculated as an EC 50 value, using a Sigmoid-Emax model non-linear regression method, and thus, the muscarinic M 3 receptor-positive allosteric modulator activity was determined by dividing the EC 50 value of carbachol in the absence of the test substance by the EC 50 value of carbachol in the presence of the test substance.
- the value of the muscarinic M 3 receptor-positive allosteric modulator activity becomes 10, showing that the test substance causes a 10-fold shift in the EC 50 value toward to the low concentration side.
- the columns of 10 ⁇ M (-fold shift) show the values in a case where the test substance is added to a final concentration of 10 ⁇ M and the columns of 1 ⁇ M (-fold shift) show the values in a case where the test substance is added to a final concentration of 1 ⁇ M.
- Example compounds of the present invention are shown in Tables 1 and 2. However, Ex represents Example Compound Nos. as described later (this shall apply hereinafter). [Table 1] Ex 10 ⁇ M (Fold shift) 1 ⁇ M (Fold shift) Ex 10 ⁇ M (Fold shift) 1 ⁇ M (Fold shift) 1 310 165 33 43 10 2 182 43 34 54 24 3 86 31 35 114 36 4 163 26 36 201 99 5 116 31 37 178 18 6 222 21 38 70 22 7 153 71 39 106 21 8 131 32 40 125 34 9 203 68 41 116 14 10 176 42 42 21 3 11 173 62 43 159 35 12 163 34 44 167 26 13 217 90 45 118 36 14 155 23 46 210 19 15 173 42 47 55 26 16 96 34 48 38 5 17 118 35 49 76 18 18 157 31 50 223 88 19 84 12 51 123 45 20 106
- Example compounds in Tables 1 and 2 shifted a carbachol concentration-response curve toward a lower concentration side when added at 1 ⁇ M and 10 ⁇ M.
- Example compounds from the viewpoint that the compounds alone do not change the intracellular Ca 2+ concentration, it was found that these compounds have no muscarinic M 3 receptor agonistic activity.
- the effect of the Example compounds of the present invention in the electrical field stimulation-induced contraction of the rat isolated bladder was measured by the following method. That is, a bladder specimen having a width of about 2 mm and a length of about 10 mm in the longitudinal direction from the bladder isolated from a Sprague-Dawley (SD) female rat (Japan SLC, Inc.) was prepared. The prepared bladder specimen was suspended in an organ bath filled with 10 mL of a Krebs-Henseleite solution. The Krebs-Henseleite solution was aerated at 95% O 2 and 5% CO 2 , and kept at 37°C.
- the contraction was caused twice with 60 mM KCl.
- the contraction was caused by carrying out electrical field stimulation at 20 V with an electrical stimulation device (Nihon Kohden) (a stimulation frequency of 8 Hz, a pulse width of 0.3 msec, and a stimulation time of 10 seconds).
- an electrical stimulation device Nihon Kohden
- a voltage was adjusted to obtain a contraction height of approximately 50% of the contractile response at 20 V.
- test substances dissolved in 100% DMSO in advance (final concentrations of 3 ⁇ M, 10 ⁇ M, and 30 ⁇ M) was added thereto.
- the test substances were cumulatively administered at the following concentrations after the low-concentration contractile response had been stabilized.
- the response was taken into a personal computer through a PowerLab (registered trademark) (AD Instruments, Inc.), and analyzed by LabChart (registered trademark) (AD Instruments, Inc.).
- AUC area under curve
- the enhancement rate % of pre of the isolated bladder contractions after treatment with the test substance was calculated.
- Example compounds alone which have been subjected to the present test, do not cause a contraction action in the isolated rat bladder, but have an action of enhancing electrical field stimulation-induced contraction.
- Example compounds of the present invention in the pelvic nerve electrical stimulation-induced elevation of intravesical pressure using rats as an action of nerve stimulation-dependent bladder contraction in vivo was measured by the following method. That is, SD female rats (Japan SLC, Inc.) were used and its lower abdomen was dissected at the midline under pentobarbital anesthesia (50 mg/kg ip). After ligating and cutting the ureter on both sides, a cannula (PE-50) for measuring the intravesical pressure was inserted into the bladder from the external urethral opening and fixed by a clip.
- PE-50 cannula
- the other side was connected to a pressure transducer to measure the intravesical pressure.
- the pelvic nerve in the vicinity of the bladder was peeled and an electrode for nerve stimulation (unique Medical) was placed.
- the abdominal cavity was filled with mineral oil (MP BIOMEDICALS).
- electrical stimulation stimulation voltage: 10 V, stimulation frequency: 8 Hz, pulse width: 0.3 msec, and stimulation time: 10 seconds
- stimulation voltage stimulation voltage: 10 V
- stimulation frequency 8 Hz
- pulse width 0.3 msec
- stimulation time 10 seconds
- the voltage was adjusted to elicit about 50% to 70% elevation of intravesical pressure elicited at 10 V.
- the increase in the intravesical pressure by electrical stimulation was stabilized three times or more, and the test substance (an administration amount of 3 mg/kg) was then administered from the catheter detained in the vein at a volume of 1 mL/kg, thus measuring an effect of the elevation of the intravesical pressure of the test substance for 1 hour.
- the test substance was dissolved in water supplemented with 10% DMSO and 10% Cremophor.
- the response was applied to a personal computer through a PowerLab (registered trademark) and analyzed by LabChart (registered trademark).
- the AUC of each elevation of the intravesical pressure was calculated, the intravesical pressure elevation rate (% of pre) after the treatment with the test substance was calculated by taking an average value of the values measured three times before the treatment with the test substance as 100%, and the maximum effect during a period within one hour after administration of the compound was considered as the effect of the test substance.
- Example compounds evaluated in the present test do not cause an elevation of the intravesical pressure in a state in which electrical stimulation is not given, and the compounds alone do not show elevation of the intravesical pressure.
- Example compounds listed in Table 4 alone do not show elevation of the intravesical pressure but have an action of enhancing effect on the pelvic nerve electrical stimulation-induced elevation of intravesical pressure in the anesthetized rats.
- the compound of the formula (I) has a muscarinic M 3 receptor-positive allosteric modulator activity, and further, it enhances the bladder contraction in a nerve stimulation-dependent manner in in vitro, as well as enhances an elevation in the intravesical pressure in a nerve stimulation-dependent manner in in vivo. Accordingly, the compound of the formula (I) can be used to prevent or treat bladder/urinary tract diseases associated with bladder contractions via a muscarinic M 3 receptor, in particular, voiding dysfunction or urine storage dysfunction in the bladder/urethral diseases.
- the compound of the formula (I) can be used for preventing or treating, for example, voiding dysfunction or urine storage dysfunction in underactive bladder, hypotonic bladder, acontraction bladder, detrusor underactivity, neurogenic bladder, urethra relaxation failure, detrusor-external urethral sphincter dyssynergia, overactive bladder, urinary frequency, nocturia, urinary incontinence, benign prostatic hyperplasia, interstitial cystitis, chronic prostatitis, and urinary tract stones.
- the compound of the formula (I) can be used for preventing or treating voiding dysfunction or urine storage dysfunction in underactive bladder, hypotonic bladder, acontraction bladder, detrusor underactivity, and neurogenic bladder.
- the compound of formula (I) can become a therapeutic drug that is more excellent in safety from the viewpoint that the compound alone does not show an agonistic effect on a muscarinic M 3 receptor, but shows an effect on enhancing the nerve stimulation-dependent bladder contraction, and accordingly, cholinergic side effects that have been reported in the existing drugs can be avoided.
- a pharmaceutical composition including one or two or more kinds of the compound of the formula (I) as an active ingredient can be prepared using an excipient which is usually used in the art, that is, an excipient for a pharmaceutical preparation, a carrier for a pharmaceutical preparation, and the like, according to a method usually used.
- Administration can be accomplished either by oral administration via tablets, pills, capsules, granules, powders, solutions, and the like, or parenteral administration via injections, such as intraarticular, intravenous, and intramuscular injections, suppositories, transdermal liquid preparations, ointments, transdermal patches, transmucosal liquid preparations, transmucosal patches, inhalers, and the like.
- parenteral administration via injections, such as intraarticular, intravenous, and intramuscular injections, suppositories, transdermal liquid preparations, ointments, transdermal patches, transmucosal liquid preparations, transmucosal patches, inhalers, and the like.
- a solid composition for oral administration tablets, powders, granules, and the like are used.
- one kind or two or more kinds of the active ingredients are mixed with at least one inactive excipient.
- the composition may contain inactive additives such as a lubricant, a disintegrating agent, a stabilizer, or a solubilization assisting agent. If necessary, tablets or pills may be coated with a sugar or with a film of a gastric or enteric coating substance.
- the liquid composition for oral administration includes pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, or the like, and also includes generally used inert diluents, for example, purified water or ethanol.
- the liquid composition may also include auxiliary agents such as a solubilization assisting agent, a moistening agent, and a suspending agent, sweeteners, flavors, aromatics, and antiseptics, in addition to the inert diluent.
- the injections for parenteral administration include sterile aqueous or non-aqueous solution preparations, suspensions, or emulsions.
- the aqueous solvent includes, for example, distilled water for injection and saline.
- the non-aqueous solvent include alcohols such as ethanol.
- Such a composition may further include a tonicity agent, an antiseptic, a moistening agent, an emulsifying agent, a dispersing agent, a stabilizing agent, or a solubilizing assisting agent. These are sterilized, for example, by filtration through a bacteria retaining filter, blending of a bactericide, or irradiation. In addition, these can also be used by preparing a sterile solid composition, and dissolving or suspending it in sterile water or a sterile solvent for injection prior to its use.
- agent for external use examples include ointments, hard plasters, creams, jellies, cataplasms, sprays, and lotions.
- the agent further contains generally used ointment bases, lotion bases, aqueous or non-aqueous liquid preparations, suspensions, emulsions, or the like.
- transmucosal agents such as an inhaler and a transnasal agent
- those in the form of a solid, liquid, or semi-solid state are used, and can be prepared in accordance with a method known in the related art.
- a known excipient and also a pH adjusting agent, an antiseptic, a surfactant, a lubricant, a stabilizing agent, a thickening agent, or the like may be appropriately added thereto.
- an appropriate device for inhalation or blowing can be used.
- a compound may be administered alone or as a powder of formulated mixture, or as a solution or suspension in combination with a pharmaceutically acceptable carrier, using a known device or sprayer such as a metered administration inhalation device.
- a dry powder inhaler or the like may be for single or multiple administration use, and a dry powder or a powder-containing capsule may be used.
- this may be in a form such as a pressurized aerosol spray that uses an appropriate propellant agent, for example, a suitable gas such as chlorofluoroalkanes, and carbon dioxide, or other forms.
- the daily dose is from about 0.001 mg/kg to 100 mg/kg, preferably from 0.1 mg/kg to 30 mg/kg, and more preferably from 0.1 mg/kg to 10 mg/kg, per body weight, administered in one portion or in 2 to 4 divided portions.
- the daily dose is suitably administered from about 0.0001 mg/kg to 10 mg/kg per body weight, once a day or two or more times a day.
- a transmucosal agent is administered at a dose from about 0.001 mg/kg to 100 mg/kg per body weight, once or plural times a day. The dose is appropriately decided in response to the individual case by taking the symptoms, the age, and the gender, and the like into consideration.
- a pharmaceutical composition of the present invention comprises 0.01% by weight to 100% by weight of, as an embodiment, 0.01% by weight to 50% by weight of, one or more of the compound of the formula (I) or a salt thereof which is the active ingredient.
- the compound of the formula (I) may be used in combination with various agents for treating or preventing diseases on which the compound of the formula (I) is considered to show the effect. Such combined preparations may be administered simultaneously, or separately and continuously, or at a desired time interval.
- the preparations to be co-administered may be a blend, or may be prepared individually.
- the production process for the compound of the formula (I) will be described in more detail with reference to Examples. Further, the present invention is not limited to the compounds described in the Examples below. Further, the production processes for the starting compounds will be described in Preparation Examples. In addition, the production processes for the compound of the formula (I) are not limited to the production processes of the specific Examples shown below, but the compound of the formula (I) can be prepared by a combination of these production processes or a method that is apparent to a person skilled in the art.
- nomenclature software such as ACD/Name (registered trademark, Advanced Chemistry Development, Inc.) may be used for nomenclature of compounds in some cases.
- PEx Preparation Example No.
- Ex Example No.
- PSyn Preparation method of Preparation Example compound (the number in the PSyn column indicates that the compound was produced by using the corresponding starting material in the same manner as the compound having the number as the number of Preparation Example compound.
- the compound in which the PSyn column is 2 means that it was prepared in the same manner as the compound of Preparation Example 2)
- Syn Preparation method of Example compounds (the number in the Syn column indicates that the compound was produced by using the corresponding starting material in the same manner as the compound having the number as the number of Example compound.
- the compound in which the Syn column is 2 means that it was prepared in the same manner as the compound of Example 2)
- Str Structural chemical formula (Me represents methyl, Et represents ethyl, i-Pr represents isopropyl, c-Pr represents cyclopropyl, tBu represents tert-butyl, Boc represents tert-butoxycarbonyl, and Ac represents acetyl)
- DAT Physicochemical data
- ESI+ m/z values in mass spectroscopy (Ionization method ESI, representing [M+H] + unless otherwise specified)
- ESI- m/z values in mass spectroscopy (Ionization method ESI, representing [M-H] - unless otherwise specified)
- APCI/ESI+ m/z values in mass spectroscopy
- APCI/ESI-MS atmospheric pressure chemical ionization method APCI, representing [M+H] + unless otherwise specified; in which
- a concentration of mol/L is represented by M.
- a 1 M aqueous sodium hydroxide solution means a 1 mol/L aqueous sodium hydroxide solution.
- N,N-diisopropylethylamine (1.2 mL) was added to a mixture of N 2 -(6-chloro-2-methylpyrimidin-4-yl)-4-[3-fluoro-5-(trifluoromethyl)phenyl]-N 5 -isopropyl-N 5 -(2-methoxyethyl)-1,3-thiazole-2,5-diamine (279 mg), ethyl 3-(piperazin-1-yl)propanoate dihydrochloride (440 mg), and 1-methylpyrrolidin-2-one (NMP) (6.0 mL) at room temperature. The reaction mixture was stirred at 80°C for 12 hours.
- NMP 1-methylpyrrolidin-2-one
- the reaction mixture was diluted with ethyl acetate and water, and filtered through a celite pad. A filtrate was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform-ethyl acetate), silica gel column chromatography (hexane-ethyl acetate), and silica gel column chromatography (chloroform-ethyl acetate) to obtain tert-butyl 3-(4- ⁇ 3-fluoro-2-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5- ⁇ [(2R)-2-methylpyrrolidin-1-yl]methyl ⁇ -1,3-thiazol-2-yl)amino]pyridin-4-yl ⁇ piperazin-1-yl)propanate (387 mg) as a solid.
- (2R)-2-methylpyrrolidine (0.15 mL) was added to a mixture of ethyl 3- ⁇ 4-[5-fluoro-6-( ⁇ 4-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-2-yl ⁇ amino)pyrimidin-4-yl]piperazin-1-yl ⁇ propanoate (400 mg), paraformaldehyde (65 mg), and acetic acid (6.0 mL), and stirred at 75°C for 2.5 hours. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with ethyl acetate and water.
- Paraformaldehyde 55 mg was added to a mixture of ethyl 3- ⁇ 4-[5-fluoro-6-( ⁇ 4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl ⁇ amino)pyrimidin-4-yl]piperazin-1-yl ⁇ propanoate (300 mg), (3S)-3-methoxypyrrolidine hydrochloride (110 mg), and acetic acid (5.0 mL) at room temperature. The reaction mixture was stirred at 85°C for 1 hour. The reaction mixture was added acetic anhydride (0.50 mL) and was stirred at 85°C for 4 hours.
- reaction liquid was concentrated under reduced pressure, and the residue was purified by basic silica gel column chromatography (hexane-ethyl acetate) to obtain ethyl 3-(4- ⁇ 2-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5- ⁇ [(2R)-2-methylpyrrolidin-1-yl]methyl ⁇ -1,3-thiazol-2-yl)amino]-3-fluoropyridin-4-yl ⁇ piperazin-1-yl)propanoate (137 mg) as a solid.
- N,N-diisopropylethylamine (0.55 mL) was added to a mixture of ⁇ 2-acetamide-4-[4-chloro-3-(trifluoromethyl)phenyl]-1,3-thiazole-5-yl ⁇ methyl acetate (525 mg), (2R)-2-methylpyrrolidine hydrochloride (201 mg), and N,N-dimethylformamide (DMF) (4.2 mL), and the reaction mixture was stirred at 120°C for 30 minutes under microwave irradiation.
- the obtained residue was purified by silica gel column chromatography (chloroform-methanol).
- the obtained solid was washed with diisopropyl ether, collected by filtration, and dried to obtain ⁇ 2-acetamide-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazole-5-yl ⁇ methyl acetate(2.6 g) as a solid.
- N-bromosuccinimide (190 mg) was added to a mixture of 4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine (250 mg), and DMF (6.0 mL) at 0°C, and the reaction mixture was stirred at room temperature for 1 hour.
- N-(2-methoxyethyl)propane-2-amine (0.17 mL) and potassium carbonate (420 mg), followed by stirring at 80°C for 1 hour.
- ethyl acetate and water followed by extraction with ethyl acetate, and the organic layer was dried over anhydrous sodium sulfate, and then concentrated under reduced pressure.
- Phenyltrimethylammonium tribromide (143 g) was added to a mixture of 1-[3-fluoro-5-(trifluoromethyl)phenyl]ethanone (78 g) and tetrahydrofuran (625 mL) was stirred at room temperature for 1 hour. The insoluble materials were separated by filtration, and then the filtrate was concentrated under reduced pressure. The obtained residue was mixed with ethanol (625 mL), and to the mixture was added thiourea (35 g), followed by stirring at 65°C to 75°C for 2 hours. The reaction mixture was ice-cooled, and then water (625 mL) was added thereto. To the mixture was added 1 M sodium hydroxide (600 mL), followed by stirring for 30 minutes.
- N-methylmorpholine (0.65 mL) was added to a mixture of tert-butyl (3R)-3-hydroxypyrrolidine-1-carboxylate (1.0 g), ethyl propiolate (1.9 mL), and methylene chloride (16 mL), and the reaction mixture was stirred at room temperature for 2.5 hours.
- the reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain tert-butyl (3R)-3- ⁇ [(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]oxy)pyrrolidine-1-carboxylate (1.1 g) as an oil.
- N,N-diisopropylethylamine (4.6 mL), and ethyl bromoacetate (2.1 mL) were added to a mixture of tert-butyl (3S)-3-(methoxymethyl)piperazine-1-carboxylate (2.0 g) and methylene chloride (45 mL), and the reaction mixture was stirred at room temperature for 23 hours. The reaction mixture was added water so as to separate the organic layer, and concentrated under reduced pressure.
- Trifluoroacetic acid (0.15 mL) was added to a mixture of zinc (2.0 g), cobalt bromide (II) (600 mg), and acetonitrile (30 mL) under an argon atmosphere, and the reaction mixture was stirred at room temperature for 15 minutes.
- 5-Bromo-1-fluoro-2-methoxy-3-(trifluoromethyl)benzene 5.0 g
- acetic anhydride 2.1 mL
- 1 M hydrochloric acid (30 mL) was added to the reaction mixture, and the mixture was extracted with diethyl ether. The organic layer was washed with water and saturated brine, and concentrated under reduced pressure.
- N,O-dimethylhydroxylamine hydrochloride (4.3 g), N-[3-(dimethylamino)propyl]-N'-ethylcarbodiimide hydrochloride (9.5 g), and N,N-diisopropylethylamine (30 mL) were added to a mixture of 6-methoxy-5-(trifluoromethyl)nicotinic acid (7.8 g) and methylene chloride (80 mL) under ice-cooling, and then the reaction mixture was stirred at room temperature for 17 hours. The reaction mixture was concentrated under reduced pressure, and to the residue were added ethyl acetate and water, followed by stirring for 30 minutes.
- reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane-ethyl acetate) and basic silica gel column chromatography (hexane-ethyl acetate) to obtain methyl [(1- ⁇ 5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5- ⁇ [(2R)-2-methylpyrrolidin-1-yl]methyl ⁇ -1,3-thiazol-2-yl)amino]pyrimidin-4-yl ⁇ piperidin-4-yl)oxy]acetate (57 mg) as a solid.
- Tripotassium phosphate (260 mg) was added to a mixture of ethyl 3-(4- ⁇ 6-[(4-[3-bromo-5-(trifluoromethyl)phenyl]-5- ⁇ [(2R)-2-methylpyrrolidin-1-yl]methyl ⁇ -1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl ⁇ piperazin-1-yl)propanoate (280 mg), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (135 mg), palladium acetate (II) (18 mg), tricyclohexylphosphine (45 mg), and dioxane (5.0 mL), and water (0.50 mL), and the reaction mixture was stirred at 95°C for 6 hours.
- reaction mixture was diluted with water, and then extracted with ethyl acetate.
- organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
- the residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain ethyl 3-(4- ⁇ 5-fluoro-6-[(5- ⁇ [(2R)-2-methylpyrrolidin-1-yl]methyl ⁇ -4-[3-(prop-1-en-2-yl)-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)amino]pyrimidin-4-yl ⁇ piperazin-1-yl)propanoate (170 mg) as a solid.
- the reaction mixture was cooled down to room temperature, and ethyl acetate and water were added.
- the mixture was extracted with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, and then concentrated under reduced pressure.
- the residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain an oil (538 mg).
- Phenyltrimethylammonium tribromide 44 g was added to a mixture of 1-[4-chloro-3-(trifluoromethyl)phenyl]ethanone (25 g) and tetrahydrofuran (300 mL), and the reaction mixture was stirred at room temperature for 2 hours. The insoluble materials were separated by filtration, and the filtrate was concentrated under reduced pressure. The obtained compound and ethanol (300 mL) were mixed, and thiourea (10 g) was added to the mixture, and then was stirred at 80°C for 5 hours. The reaction mixture was cooled to room temperature, and the precipitated solid was collected by filtration.
- the filtrate was concentrated under reduced pressure, and the precipitated solid was washed with ethyl acetate, and was collected by filtration.
- This solid was combined with the solid which was previously collected by filtration, and the combined solid was dispersed into ethyl acetate and a saturated aqueous sodium hydrogen carbonate solution so as to extract with ethyl acetate.
- the organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure.
- the obtained solid was washed with hexane, collected by filtration, and dried to obtain 4-[4-chloro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine (24 g) as a solid.
- N,N-diisopropylethylamine (2.0 mL) and ethyl 3-(piperazin-1-yl)propanoate dihydrochloride (750 mg) were added to the reaction mixture, and the reaction mixture was stirred at 80°C overnight.
- Water and ethyl acetate were added to the reaction liquid so as to separate the organic layer.
- the organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure.
- reaction mixture was cooled to room temperature, and then to the reaction mixture was added water and ethyl acetate, followed by extraction with ethyl acetate.
- the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure.
- the residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain an oil (412 mg).
- reaction mixture was diluted with ice-water containing 1 M hydrochloric acid (1.1 mL) and a saturated aqueous ammonium chloride solution and was extracted with ethyl acetate-isopropanol (4:1). The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. To the residue was added to tetrahydrofuran (8.0 mL) and 4 M hydrogen chloride dioxane solution (1.0 mL), followed by stirring at room temperature for 30 minutes.
- the reaction mixture was diluted with ice-water containing 1 M hydrochloric acid (0.75 mL) and a saturated aqueous ammonium chloride solution and was extracted with chloroform-isopropanol (4:1). The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. Tetrahydrofuran (4.0 mL) and 4 M hydrogen chloride dioxane solution (0.75 mL) were added to the residue under an argon atmosphere, and the reaction mixture was stirred at room temperature for 30 minutes.
- Tetrahydrofuran (4.0 ml) and 4 M hydrogen chloride dioxane solution (0.70 ml) were added to the obtained residue.
- the reaction mixture was concentrated under reduced pressure, and the obtained residue was washed with diethyl ether, and then was dried over under reduced pressure to obtain [(1- ⁇ 6-[(4-[3-chloro-5-(trifluoromethyl)phenyl]-5- ⁇ [(2R)-2-ethylpyrrolidin-1-yl]methyl ⁇ -1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl ⁇ piperidin-4-yl)oxy]acetic acid dihydrochloride (34 mg) as a solid.
- the compound of the formula (I) or a salt thereof is a muscarinic M 3 receptor-positive allosteric modulator, and can thus be used as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M 3 receptor.
Abstract
Description
- The present invention relates to a 2-aminothiazole derivative or a salt thereof which is expected as an active ingredient for a pharmaceutical composition, in particular, a pharmaceutical composition for treating bladder/urinary tract diseases related to bladder contractions via a muscarinic M3 receptor.
- The important roles of the lower urinary tract are urine storage and voiding, which are regulated by a coordinated action of the bladder and the urethra. That is, during urine storage, the bladder smooth muscle is relaxed and the urethral sphincter is contracted, whereby a state in which urethral resistance is high is maintained and urinary continence is maintained. On the other hand, during voiding, the bladder smooth muscle is contracted, the urethra smooth muscle is relaxed, and contraction of the external urethral sphincter is also inhibited. Examples of the lower urinary tract disorder include urine storage dysfunction such as overactive bladder, in which urine cannot be retained during urine storage, and voiding dysfunction, in which urine cannot be drained sufficiently during voiding due to an increase in the urethral resistance or a decrease in the bladder contractile force. These two disorders may develop simultaneously in some cases.
- Voiding dysfunction is caused by a decrease in the bladder contractile force, an increase in urethral resistance or the like during voiding, and causes difficulty in voiding, straining during voiding, a weak urine stream, extension of voiding time, an increase in residual urine, a decrease in voiding efficiency, or the like. The decrease in the bladder contractile force during voiding is referred to as underactive bladder, acontractile bladder, or the like. As a factor causing such a decrease in the bladder contractile force during voiding, for example, aging, diabetes mellitus, benign prostatic hyperplasia, neurological diseases such as Parkinson's disease and multiple sclerosis, spinal cord injury, neurological disorders by pelvic surgery, and the like have been known (Reviews in Urology, 15: pp. 11-22 (2013)).
- As a mechanism to cause bladder contraction during voiding, involvement of muscarinic receptor stimulation has been known. That is, during urination, the pelvic nerve which is a parasympathetic nerve governing the bladder is excited to release acetylcholine from nerve terminals. The released acetylcholine binds to a muscarinic receptor present in the bladder smooth muscle to cause contraction of the bladder smooth muscle (Journal of Pharmacological Sciences, 112: pp. 121-127 (2010)). The muscarinic receptors are currently classified into five subtypes, M1, M2, M3, M4, and M5, and it has been known that the subtypes involving the contraction in the bladder smooth muscle is mainly M3 (Pharmacological Reviews, 50: pp.279-290 (1998); The Journal of Neuroscience, 22: pp. 10627-10632 (2002)).
- As a therapeutic drug for a decrease in bladder contractile force during voiding, bethanechol chloride which is a non-selective muscarinic receptor agonist and distigmine bromide which is a cholinesterase inhibitor have been known. However, it has been known that these drugs have cholinergic side effects such as diarrhea, abdominal pain, and perspiration. In addition, there may be cases where cholinergic crisis is occurred as a serious side effect, which require attention during use (Ubretid (registered trademark), tablet 5 mg, package insert, Torii Pharmaceutical Co., Ltd., and Besacholine (registered trademark) powder 5%, package insert, Eisai Co., Ltd.).
- On the other hand, as a cause of an increase in urethral resistance, voiding dysfunction associated with benign prostatic hyperplasia has been well-known, which is characterized in that the urethra is partially occluded by nodular enlargement of the prostatic tissue. Currently, an adrenergic α1 receptor antagonist has been used as a therapeutic drug for voiding dysfunction associated with benign prostatic hyperplasia (Pharmacology, 65: pp. 119-128 (2002)). On the other hand, the effectiveness of the adrenaline α1 receptor antagonist for voiding dysfunction that is not associated with benign prostatic hyperplasia is unclear (Journal of Pharmacological Sciences, 112: pp. 121-127 (2010)).
- Furthermore, for voiding dysfunction caused by a decrease in bladder contractile force or an increase in urethral resistance, residual urine after voiding may be observed in some cases. The increased residual urine may cause a decrease in effective bladder capacity, and thus cause overactive bladder symptoms such as urinary frequency or severe symptoms such as hydronephrosis in some cases.
- There has been a demand for a more effective therapeutic drug for such bladder/urethral diseases due to a decrease in the bladder contractile force or an increase in urethral resistance during voiding, or symptoms thereof (Reviews in Urology, 15: pp. 11-22 (2013)).
- It is described that a compound represented by the following formula (A) disclosed in Patent Document 1 and a compound represented by the following formula (A1) disclosed in Patent Document 2 each have a Ba/F3 cell proliferative activity through a human c-myeloproliferative leukemia virus type P (c-Mpl), and have thrombocyte increasing activity.
- Patent Document 3 discloses that a compound represented by the following formula (B) has an AMP-activated protein kinase (AMPK) pathway activating action.
-
-
-
- [Patent Document 1] International Publication
2005/007651 - [Patent Document 2] International Publication
2003/062233 - [Patent Document 3] International Publication
2012/016217 -
- [Non-Patent Document 1] Molecular Pharmacology, 55: pp 778-786 (1999)
- [Non-Patent Document 2] Molecular Pharmacology, 62: pp 1492-1505 (2002)
- The present invention provides a novel compound which is expected as an active ingredient for a pharmaceutical composition, in particular, for a pharmaceutical composition for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, which has a muscarinic M3 receptor-positive allosteric modulator activity.
- The present inventors have found that a 2-aminothiazole derivative has an excellent muscarinic M3 receptor-positive allosteric modulator activity and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention.
-
- X is C-H or N,
- Y is C-R3e or N,
- R1 and R2 are the same as each other or are different from each other, and are C1-6 alkyl which may be substituted, or R1 and R2 may be combined with the adjacent nitrogen atom to form cyclic amino which may be substituted,
- R3a, R3b, R3c, and R3d are the same as each other or are different from each other, and are H, halogen, C1-6 alkyl, halogeno C1-6 alkyl, -O-C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl, or -O-halogeno C1-6 alkyl,
- in a case where Y is C-R3e, R3e is H, halogen, C1-6 alkyl, halogeno C1-6 alkyl, -O-C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl, or -O-halogeno C1-6 alkyl,
- R4 is H, halogen, or -O-C1-6 alkyl,
- R5 is H, C1-6 alkyl, or -NR51R52,
- Q is heterocyclylene which may be substituted,
- W is a bond, C1-6 alkylene, -O-C1-6 alkylene, or -N(RN)-C1-6 alkylene,
- R51 and R52 are the same as each other or are different from each other, and are H or C1-6 alkyl,
- RN is H or C1-6 alkyl, and
- n is 0 or 1).
- In addition, the invention relates to a compound of the formula (I) or a salt thereof, and a pharmaceutical composition comprising a compound of the formula (I) or a salt thereof and an excipient.
In which,
X is C-H or N,
Y is C-R3e or N,
R1 and R2 are the same as each other or are different from each other, and are C1-6 alkyl which may be substituted, or R1 and R2 may be combined with the adjacent nitrogen atom to form cyclic amino which may be substituted,
R3a, R3b, R3c, R3d, and R3e are the same as each other or are different from each other, and are H, halogen, C1-6 alkyl, halogeno C1-6 alkyl, -O-C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl, or -O-halogeno C1-6 alkyl,
R4 is H, halogen, or -O-C1-6 alkyl,
R5 is H, C1-6 alkyl, or -NR51R52,
Q is heterocyclylene which may be substituted,
W is a bond, C1-6 alkylene, -O-C1-6 alkylene, or -N(RN)-C1-6 alkylene,
R51 and 52 are the same as each other or are different from each other, and are H or C1-6 alkyl,
RN is H or C1-6 alkyl, and
n is 0 or 1. - Further, unless specifically described otherwise, when symbols in one formula in the present specification are also used in other formulae, same symbols denote same meanings.
- Further, the configuration of the compound disclosed in Patent Document 1 is different from that of the compound of the present application in that an acyl group is substituted to an amino group at 2-position of thiazole. In addition, Patent Document 1 neither discloses nor suggests an action on a muscarinic receptor or an action on bladder/urinary tract diseases.
- Furthermore, Patent Document 2 does not disclose a specific compound which is a compound of the formula (B) wherein ring B is thiazole, and neither discloses nor suggests an action on a muscarinic receptor or an action on bladder/urinary tract diseases.
- Further, the present invention relates to a pharmaceutical composition comprising the compound of the formula (I) or a salt thereof, and a pharmaceutically acceptable excipient. Furthermore, the present invention relates to a pharmaceutical composition for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, comprising the compound of the formula (I) or a salt thereof. Furthermore, the present invention relates to an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, comprising the compound of the formula (I) or a salt thereof.
- Moreover, the present invention relates to use of the compound of the formula (I) or a salt thereof for the manufacture of a pharmaceutical composition for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor; use of the compound of the formula (I) or a salt thereof for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor; the compound of the formula (I) or a salt thereof for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor; and a method for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, comprising administering to a subject an effective amount of the compound of the formula (I) or a salt thereof. Further, the "subject" is a human or a non-human animal in need of the prevention or treatment, and in one embodiment, a human in need of the prevention or treatment.
- The compound represented by the formula (I) or a salt thereof is expected as a preventing or treating agent for bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, which has a muscarinic M3 receptor-positive allosteric modulator activity.
- Hereinafter, the present invention will be described in detail.
- In general, "the positive allosteric modulator" is a compound which binds to an allosteric site different from a ligand binding site, and has an effect of increasing the affinity of an agonist to a receptor by mainly causing a structural change in a receptor, and thus changing the signal level of an agonist. In the living body, the positive allosteric modulator does not exhibit an agonistic effect by itself, and increases the effect of an endogenous agonist. As the advantages of positive allosteric modulator over the agonists, (1) being capable of avoiding the side effects since the positive allosteric modulator exhibits an enhancement in the endogenous agonist stimulation dependently, (2) having a possibility of obtaining high subtype selectivity since the positive allosteric modulator binds to a site other than a ligand binding site, (3) less probability of causing desensitization, which can be seen with the agonists and the like are pointed out (Pharmacological Reviews, 63: pp. 59-126 (2011)).
- In the present specification, "the muscarinic M3 receptor-positive allosteric modulator" means a compound which enhances an effect via the muscarinic M3 receptor by an agonist stimulation-dependent or nerve stimulation-dependent manner. Accordingly, only during voiding, the effect on enhancing bladder contraction is expected and the muscarinic M3 receptor-positive allosteric modulator is possibly useful as an agent for improving various symptoms associated with voiding dysfunction. Further, by such a specific action during voiding, it is expected that it is possible to decrease cholinergic side effects, known to be induced with bethanechol chloride and distigmine bromide. In addition, since the muscarinic M3 receptor-positive allosteric modulator increases bladder contractile force during voiding, an effect in voiding dysfunction which is caused by an increase in urethral resistance can also be expected. A decrease in residual urine by such improvement of voiding dysfunction leads to an increase in the effective bladder capacity, and thus, it can be expected to improve urine storage functions as well as to decrease renal disorder. Thus, the muscarinic M3 receptor-positive allosteric modulator is expected to be useful as an agent for preventing or treating bladder/urinary tract diseases related to bladder contractions via a muscarinic M3 receptor. The present inventors have newly discovered a compound that acts as the modulator, thereby completing the present invention.
- In the present specification, examples of the "bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor" include voiding dysfunction or urine storage dysfunction in underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethra relaxation failure, detrusor-external urethral sphincter dyssynergia, overactive bladder, urinary frequency, nocturia, urinary incontinence, benign prostatic hyperplasia, interstitial cystitis, chronic prostatitis, urethral calculus, or the like, preferably, voiding dysfunction or urine storage dysfunction in underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, and neurogenic bladder.
- The "alkyl" is linear alkyl and branched alkyl. Accordingly, the "C1-6 alkyl" is linear or branched alkyl having 1 to 6 carbon atoms, and specific examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, or n-hexyl. C1-4 alkyl is preferably used. In one embodiment, examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl; in one embodiment, a group selected from the group consisting of methyl, ethyl, isopropyl, and isobutyl; in one embodiment, methyl or ethyl; in one embodiment, methyl; and in another embodiment, ethyl.
- The "alkenyl" is linear alkenyl and branched alkenyl. Accordingly, the "C2-6 alkenyl" is linear or branched alkenyl having 2 to 6 carbon atoms, and specific examples thereof include vinyl, propenyl, butenyl, pentenyl, 1-methylvinyl, 1-methyl-2-propenyl, 1,3-butadienyl, and 1,3-pentadienyl, and the like. In one embodiment, examples thereof include C2-4 alkenyl, and in one embodiment, vinyl or propenyl,
- The "alkylene" is linear alkylene and branched alkylene. Accordingly, the "C1-6 alkylene" is linear or branched alkylene having 1 to 6 carbon atoms, and examples thereof include methylene, ethylene, propylene, tetramethylene, pentamethylene, hexamethylene, methyl methylene, ethylethylene, 1,2-dimethyl ethylene, or 1,1,2,2-tetramethyl ethylene, and the like. In one embodiment, examples thereof include C1-3 alkylene; in one embodiment, methylene or ethylene; in one embodiment, methylene; and in another embodiment, ethylene.
- The "halogeno-C1-6 alkyl" is C1-6 alkyl substituted with at least one halogen atom; in one embodiment, C1-6 alkyl substituted with 1 to 5 halogen atoms; in one embodiment, difluoromethyl or trifluoromethyl; and in one embodiment, trifluoromethyl.
- The "cycloalkyl" is a saturated hydrocarbon cyclic group. Accordingly, the "C3-8 cycloalkyl" is a saturated hydrocarbon cyclic group having 3 to 8 ring members, and specific examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; in one embodiment, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is C3-6 cycloalkyl; and in one embodiment, cyclopropyl.
- The "saturated hetero ring" is a 3- to 8-membered saturated ring, which has 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom as a ring-constituting atom, and may be bridged with C1-6 alkylene, in which a sulfur atom as the ring-constituting atom may be oxidized. Specific examples thereof include azepane, diazepane, aziridine, azetidine, pyrrolidine, imidazolidine, piperidine, pyrazolidine, piperazine, azocane, thiomorpholine, thiazolidine, isothiazolidine, oxazolidine, morpholine, tetrahydrothiopyran, oxathiolane, oxirane, oxetane, dioxolane, tetrahydrofuran, tetrahydropyran, and 1,4-dioxane.
- The "cyclic amino" has at least one nitrogen atom, and is a 4- to 7-membered monovalent group having a bond at the ring-constituting nitrogen atom in the "saturated hetero ring". Specific examples thereof include azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, morpholinyl, thiomorpholinyl, piperazinyl, 1,4-diazepanyl, 1,4-oxazepanyl, or 1,4-thiazepanyl. In one embodiment, examples thereof include pyrrolidinyl, piperidinyl, azetidinyl, morpholinyl, or piperazinyl, in one embodiment, pyrrolidinyl, piperidinyl, or piperazinyl, in one embodiment, pyrrolidinyl, in another embodiment, piperidinyl, and in another embodiment, piperazinyl.
- The "heterocyclylene" has at least one nitrogen atom, and is a divalent group having a bond at the ring-constituting nitrogen atom and other ring-constituting atom in the "saturated hetero ring". Specific examples thereof include pyrrolidine-diyl, piperidine-diyl, or piperazine-diyl.
- The "halogen" means fluoro, chloro, bromo, or iodo; in one embodiment, fluoro, chloro, or bromo; in one embodiment, fluoro or chloro; in one embodiment, fluoro; and in another embodiment, chloro.
- In one embodiment of the "cyclic amino" in "R1 and R2 may be combined with the adjacent nitrogen atom to form cyclic amino which may be substituted" of the formula (I), the examples thereof include azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl, and in one embodiment, pyrrolidinyl.
- In one embodiment of "heterocyclylene" in Q of the formula (I), the examples thereof include pyrrolidine-diyl, piperidine-diyl, or piperazine-diyl, in one embodiment, pyrrolidine-1,3-diyl, piperidine-1,4-diyl, or piperazine-1,4-diyl, in one embodiment, piperidine-diyl or piperazine-diyl, and in one embodiment, piperidine-1,4-diyl or piperazine-1,4-diyl.
- In addition, in a case where the "heterocyclylene" in Q of the formula (I) is pyrrolidine-1,3-diyl or piperidine-1,4-diyl, and the 3-position of pyrrolidine or the 4-position of piperidine is each bonded to W.
- In one embodiment of W of the formula (I), the examples thereof include a bond, C1-6 alkylene, -O-C1-6 alkylene, or -N(RN)-C1-6 alkylene, and the O of "-O-C1-6 alkylene" and N(RN) of "-N(RN)-C1-6 alkylene" are each bonded to Q.
- In one embodiment of W of the formula (I), examples thereof include -CH2-CH2-, or -O-CH2-.
- In the present specification, the expression "which may be substituted" means "which is not substituted" or "which is substituted with 1 to 5 substituents". Further, if it has a plurality of substituents, the substituents may be the same as or different from each other.
- Examples of the preferred substituent in "cyclic amino which may be substituted" and "heterocyclylene which may be substituted" include the following Group G.
-
- (a) C1-6 alkyl which may be substituted with at least one group selected from the group consisting of -OH, -O-(C1-6 alkyl), -CN, -SO2-(C1-6 alkyl), and halogen,
- (b) -OH,
- (c) -O-(C1-6 alkyl which may be substituted with at least one group selected from the group consisting of -OH, -O-(C1-6 alkyl), -CN, -SO2-(C1-6 alkyl), and halogen),
- (d) C3-8 cycloalkyl,
- (e) -O-(C3-8 cycloalkyl),
- (f) halogen,
- (g) -CN,
- (h) -SO2-(C1-6 alkyl),
- (i) -CO2-(C1-6 alkyl) and -COOH,
- (j) -CO-N(C1-6 alkyl)2, -CO-NH(C1-6 alkyl), and -CONH2,
- (k) -CO-(C1-6 alkyl),
- (l) -SO2-N(C1-6 alkyl)2, -SO2-NH(C1-6 alkyl), and -SO2NH2,
- (m) -N(C1-6 alkyl)2, -NH(C1-6 alkyl), and -NH2,
- (n) a saturated heterocyclic group,
- (o) an -O-saturated heterocyclic group, and
- (p) Oxo.
- In addition, examples of the preferred substituent in "C1-6 alkyl which may be substituted" include the groups described in (b) to (o) of the above-described Group G. In one embodiment, examples thereof include the substituent selected from the group consisting of -OH, -O-C1-6 alkyl, and C3-8 cycloalkyl.
- In one embodiment, examples of the preferred substituent in "C1-6 alkyl which may be substituted" of R1 and R2 include -O-C1-6 alkyl or C3-8 cycloalkyl. In one embodiment, examples thereof include methoxy or cyclopropyl, in one embodiment, methoxy, and in another embodiment, cyclopropyl.
- In one embodiment of the preferred substituent in "R1 and R2 are combined with the adjacent nitrogen atom to form cyclic amino which may be substituted", the examples thereof include the groups described in (a) to (d) of the above-described Group G In one embodiment, the examples thereof include C1-6 alkyl, -O-C1-6 alkyl, or C3-8 cycloalkyl, in one embodiment, C1-6 alkyl, in one embodiment, methyl or ethyl, in one embodiment, methyl, and in another embodiment, ethyl.
- In one embodiment of the acceptable substituent in "heterocyclylene which may be substituted" of Q, the examples thereof include the groups described in (a) to (c), and (f) of the above-described Group G. In one embodiment, the examples thereof include C1-6 alkyl which may be substituted with a group selected from the group consisting of -O-C1-6 alkyl, -OH and halogen, -O-C1-6 alkyl or halogen. In one embodiment, the examples thereof include C1-6 alkyl which is substituted with -O-C1-6 alkyl, and in one embodiment, methoxymethyl.
- One embodiment of the compound of the formula (I) or a salt thereof will be described as follows.
- (1) The compound of the formula (I) or a salt thereof in which X is C-H or N.
- (1-1) The compound of the formula (I) or a salt thereof in which X is C-H.
- (1-2) The compound of the formula (I) or a salt thereof in which X is N.
- (2) The compound of the formula (I) or a salt thereof in which Y is C-R3e or N.
- (2-1) The compound of the formula (I) or a salt thereof in which Y is C-R3e.
- (2-2) The compound of the formula (I) or a salt thereof in which Y is N.
- (3) The compound of the formula (I) or a salt thereof in which R1 and R2 are the same as each other or are different from each other, and are C1-6 alkyl which may be substituted, or R1 and R2 may be combined with the adjacent nitrogen atom to form cyclic amino which may be substituted.
- (3-1) The compound of the formula (I) or a salt thereof in which
- (i) R1 and R2 are the same as each other or are different from each other, and are C1-6 alkyl which may be substituted with -O-C1-6 alkyl or C3-8 cycloalkyl, or
- (ii) R1 and R2 are combined with the adjacent nitrogen atom to form cyclic amino which may be substituted, and the cyclic amino is azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl.
- (3-2) The compound of the formula (I) or a salt thereof in which R1 and R2 are the same as each other or are different from each other, and are C1-6 alkyl which may be substituted with -O-C1-6 alkyl or C3-8 cycloalkyl.
- (3-3) The compound of the formula (I) or a salt thereof in which R1 and R2 are combined with the adjacent nitrogen atom to form cyclic amino which may be substituted, and the cyclic amino is azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl.
- (3-4) The compound of the formula (I) or a salt thereof in which R1 and R2 are combined with the adjacent nitrogen atom to form cyclic amino which may be substituted with C1-6 alkyl, -O-C1-6 alkyl, or C3-8 cycloalkyl, and the cyclic amino is azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl.
- (3-5) The compound of the formula (I) or a salt thereof in which R1 and R2 are combined with the adjacent nitrogen atom to form pyrrolidine which is substituted with one or two C1-6 alkyl.
- (3-6) The compound of the formula (I) or a salt thereof in which R1 and R2 are combined with the adjacent nitrogen atom to form pyrrolidine which is substituted with one or two methyl.
- (3-7) The compound of the formula (I) or a salt thereof in which R1 and R2 are combined with the adjacent nitrogen atom to form pyrrolidine which is substituted with one methyl.
- (3-8) The compound of the formula (I) or a salt thereof in which R1 and R2 are combined with the adjacent nitrogen atom to form pyrrolidine which is substituted with two methyl.
- (4) The compound of the formula (I) or a salt thereof in which R3a, R3b, R3c, R3d, and R3e are the same as each other or are different from each other, and are H, halogen, C1-6 alkyl, halogeno C1-6 alkyl, -O-C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl, or -O-halogeno C1-6 alkyl.
- (4-A) The compound of the formula (I) or a salt thereof in which R3a, R3b, R3c, and R3d are the same as each other or are different from each other, and are H, halogen, C1-6 alkyl, halogeno C1-6 alkyl, -O-C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl, or -O-halogeno C1-6 alkyl, and
in a case where Y is C-R3e, R3e is H, halogen, C1-6 alkyl, halogeno C1-6 alkyl, -O-C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl, or -O-halogeno C1-6 alkyl. - (4-1) The compound of the formula (I) or a salt thereof in which Y is C-R3e, R3a, R3c, R3d and R3e are the same as each other or are different from each other, and are H or halogen, and R3b is halogeno C1-6 alkyl.
- (4-2) The compound of the formula (I) or a salt thereof in which Y is C-R3e, R3a, R3c, R3d, and R3e are the same as each other or are different from each other, and are H or halogen, and R3b is trifluoromethyl.
- (4-3) The compound of the formula (I) or a salt thereof in which Y is C-R3e, R3a and R3e are the same as each other or are different from each other, and are H, fluoro, or chloro, R3c and R3d are H, and R3b is trifluoromethyl.
- (4-4) The compound of the formula (I) or a salt thereof in which Y is C-R3e, R3a is chloro, R3b is trifluoromethyl, and R3c, R3d, and R3e are H.
- (4-5) The compound of the formula (I) or a salt thereof in which Y is C-R3e, R3a, R3c, and R3d are H, R3b is trifluoromethyl, and R3e is fluoro.
- (5) The compound of the formula (I) or a salt thereof in which R4 is H, halogen, or -O-C1-6 alkyl.
- (5-1) The compound of the formula (I) or a salt thereof in which R4 is H or halogen.
- (5-2) The compound of the formula (I) or a salt thereof in which R4 is H or fluoro.
- (5-3) The compound of the formula (I) or a salt thereof in which R4 is H.
- (5-4) The compound of the formula (I) or a salt thereof in which R4 is fluoro.
- (6) The compound of the formula (I) or a salt thereof in which R5 is H, C1-6 alkyl, or -NR51R52 and R51 and R52 are the same as each other or are different from each other, and are H or C1-6 alkyl.
- (6-1) The compound of the formula (I) or a salt thereof in which R5 is H, C1-6 alkyl, or -NR51R52, and R51 and R52 are the same as each other or are different from each other, and are C1-6 alkyl.
- (6-2) The compound of the formula (I) or a salt thereof in which R5 is H or C1-6 alkyl.
- (6-3) The compound of the formula (I) or a salt thereof in which R5 is H or methyl.
- (6-4) The compound of the formula (I) or a salt thereof in which R5 is H.
- (6-5) The compound of the formula (I) or a salt thereof in which R5 is methyl.
- (7) The compound of the formula (I) or a salt thereof in which Q is heterocyclylene which may be substituted.
- (7-1) The compound of the formula (I) or a salt thereof in which Q is heterocyclylene which may be substituted, and the heterocyclylene is pyrrolidine-diyl, piperidine-diyl, or piperazine-diyl.
- (7-1-A) The compound of the formula (I) or a salt thereof in which Q is heterocyclylene which may be substituted, and the heterocyclylene is pyrrolidine-1,3-diyl, piperidine-1,4-diyl, or piperazine-1,4-diyl.
- (7-2) The compound of the formula (I) or a salt thereof in which Q is heterocyclylene which may be substituted with C1-6 alkyl which may be substituted with a group selected from the group consisting of -O-C1-6 alkyl, -OH and halogen, -O-C1-6 alkyl or halogen, and the heterocyclylene is piperidine-diyl or piperazine-diyl.
- (7-3) The compound of the formula (I) or a salt thereof in which Q is heterocyclylene which may be substituted with -C1-6 alkylene-O-C1-6 alkyl, and the heterocyclylene is piperidine-diyl or piperazine-diyl.
- (7-3-A) The compound of the formula (I) or a salt thereof in which Q is heterocyclylene which may be substituted with -C1-6 alkylene-O-C1-6 alkyl, and the heterocyclylene is piperidine-1,4-diyl or piperazine-1,4-diyl.
- (7-4) The compound of the formula (I) or a salt thereof in which Q is heterocyclylene which may be substituted with methoxymethyl, and the heterocyclylene is piperidine-diyl or piperazine-diyl.
- (7-4-A) The compound of the formula (I) or a salt thereof in which Q is heterocyclylene which may be substituted with methoxymethyl, and the heterocyclylene is piperidine-1,4-diyl or piperazine-1,4-diyl.
- (7-5) The compound of the formula (I) or a salt thereof in which Q is i) piperidine-1,4-diyl, or ii) piperazine-1,4-diyl which may be substituted with methoxymethyl.
- (7-6) The compound of the formula (I) or a salt thereof in which Q is piperidine-1,4-diyl.
- (7-7) The compound of the formula (I) or a salt thereof in which Q is piperazine-1,4-diyl which may be substituted with methoxymethyl.
- (8) The compound of the formula (I) or a salt thereof in which W is a bond, C1-6 alkylene, -O-C1-6 alkylene, or -N(RN)-C1-6 alkylene, and RN is H or C1-6 alkyl.
- (8-1) The compound of the formula (I) or a salt thereof in which W is a bond, C1-6 alkylene, -O-C1-6 alkylene, or -N(RN)-C1-6 alkylene, and RN is C1-6 alkyl.
- (8-2) The compound of the formula (I) or a salt thereof in which W is C1-6 alkylene or -O-C1-6 alkylene.
- (8-3) The compound of the formula (I) or a salt thereof in which W is -CH2-CH2- or -O-CH2-.
- (8-4) The compound of the formula (I) or a salt thereof in which W is -CH2-CH2-.
- (8-5) The compound of the formula (I) or a salt thereof in which W is -O-CH2-.
- (9) The compound of the formula (I) or a salt thereof in which n is 0 or 1.
- (9-1) The compound of the formula (I) or a salt thereof in which n is 0.
- (9-2) The compound of the formula (I) or a salt thereof in which n is 1.
- (10) The compound of the formula (I) or a salt thereof, which is a combination of any two or more of the groups, which are not inconsistent with each other, among some embodiments of each group described in (1) to (9-2) above. Examples thereof include the compounds or salts thereof shown below.
- (10-1) The compound of the formula (I) or a salt thereof in which
X is as described in (1) above,
Y is as described in (2) above,
R1 and R2 are as described in (3-1) above,
R3a, R3b, R3c, R3d, and R3e are as described in (4) above,
R4 is as described in (5) above,
R5 is as described in (6) above,
Q is as described in (7-1) above,
W is as described in (8-1) above, and
n is as described in (9) above. - (10-1-A) The compound of the formula (I) or a salt thereof in which
X is as described in (1) above,
Y is as described in (2) above,
R1 and R2 are as described in (3-1) above,
R3a, R3b, R3c, R3d, and R3e are as described in (4-A) above, R4 is as described in (5) above,
R5 is as described in (6) above,
Q is as described in (7-1-A) above,
W is as described in (8-1) above, and
n is as described in (9) above. - (10-2) The compound of the formula (I) or a salt thereof in which
X is as described in (1-2) above,
Y is as described in (2-1) above,
R1 and R2 are as described in (3-4) above,
R3a, R3b, R3c, R3d, and R3e are as described in (4-1) above,
R4 is as described in (5-1) above,
R5 is as described in (6-2) above,
Q is as described in (7-3) above,
W is as described in (8-2) above, and
n is as described in (9-2) above. - (10-2-A) The compound of the formula (I) or a salt thereof in which
X is as described in (1-2) above,
Y is as described in (2-1) above,
R1 and R2 are as described in (3-4) above
R3a, R3b, R3c, R3d, and R3e are as described in (4-1) above,
R4 is as described in (5-1) above,
R5 is as described in (6-2) above,
Q is as described in (7-3-A) above,
W is as described in (8-2) above, and
n is as described in (9-2) above. - (10-3) The compound of the formula (I) described in (10-2) or a salt thereof in which
R1 and R2 are as described in (3-5) above,
R3a, R3b, R3c, R3d, and R3e are as described in (4-2) above, and
W is as described in (8-3) above. - (10-3-A) The compound of the formula (I) described in (10-2-A) or a salt thereof in which
R1 and R2 are as described in (3-5) above,
R3a, R3b, R3c, R3d, and R3e are as described in (4-2) above, and
W is as described in (8-3) above. - Examples of the specific compounds of the formula (I) include the following compounds or salts thereof:
- 3-(4-{6-[(5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperazin-1-yl)propanoic acid,
- 3-(4-{6-[(5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)amino]-5-fluoro-2-methylpyrimidin-4-yl}piperazin-1-yl)propanoic acid,
- 3-(4-{6-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl-1,3}-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperazin-1-yl)propanoic acid,
- 3-[(2S)-4-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}-2-(methoxymethyl)piperazin-1-yl]propanoic acid),
- [(1-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperidin-4-yl) oxy]acetic acid,
- 3-[(2S)-4-{6-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}-2-(methoxymethyl)piperazin-1-yl]propanoic acid,
- [(1-{6-[(4-[3-chloro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperidin-4-yl)oxy]acetic acid,
- 3-(4-{6-[(4-[3-chloro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperazin-1-yl)propanoic acid,
- 3-(4-{6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl}piperazin-1-yl)propanoic acid,
- 3-(4-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperazin-1-yl)propanoic acid, and
- 3-(4-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl}piperazin-1-yl)propanoic acid.
- In another embodiment, examples of the specific compounds of the formula (I) include the following compounds or salts thereof:
- 3-(4-{6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperazin-1-yl)propanoic acid,
- 3-(4-{2-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyridin-4-yl}piperazin-1-yl)propanoic acid,
- 3-(4-{6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-methoxypyrimidin-4-yl}piperazin-1-yl)propanoic acid,
- 3-(4-{3-fluoro-2-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyridin-4-yl}piperazin-1-yl)propanoic acid,
- 3-{4-[6-({4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[isopropyl(2-methoxyethyl)amino]-1,3-thiazol-2-yl}amino)-2-methyl pyrimidin-4-yl]piperazin-1-yl}propanoic acid,
- 3-{4-[6-({4-[4-chloro-3-(trifluoromethyl)phenyl]-5-[(3S)-3-methoxypiperidin-1-yl]-1,3-thiazol-2-yl}amino)-5-fluoropyrimidin-4-yl]piperazin-1-yl}propanoic acid,
- N-[(3S)-1-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}pyrrolidin-3-yl]-N-methyl-β-alanine,
- 1-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methyl pyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}-4-methoxypiperidine-4-carboxylic acid,
- 3-[4-(5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}-2-(fluoromethyl)piperazin-1-yl]propanoic acid,
- 3-(4-{6-[(4-[3-chloro-5-(trifluoromethoxy)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperazin-1-yl)propanoic acid,
- 3-[(2S)-4-{6-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}-2-(fluoromethyl)piperazin-1-yl]propanoic acid,
- (4-{6-[(4-[3-chloro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperazin-1-yl)acetic acid,
- 3-(1-{6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl}piperidin-4-yl)propanoic acid,
- 3-(4-{2-(dimethylamino)-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperazin-1-yl)propanoic acid,
- 3-{[(3R)-1-{6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino)-2-methylpyrimidin-4-yl}pyrrolidin-3-yl]oxy}propanoic acid,
- 3-{4-[6-({5-(4-cyclopropylpiperazin-1-yl)-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}amino)-5-fluoropyrimidin-4-yl]piperazin-1-yl}propanoic acid, and
- 3-(4-{5-fluoro-6-[(4-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperazin-1-yl)propanoic acid.
- With regard to the compound of the formula (I), tautomers or geometrical isomers thereof may exist, depending on the kinds of the substituents. In the present specification, the compound of the formula (I) may be described in only one form of isomers in some cases, but the present invention includes other isomers, isolated forms of the isomers, or a mixture thereof.
- Furthermore, some of the compounds of the formula (I) may have asymmetric carbon atoms or axis chirality in some cases, and correspondingly, the optical isomers or diastereomers thereof can exist. The present invention includes the isolated form of the optical isomer of the compound of the formula (I) or a mixture thereof.
- In addition, a pharmaceutically acceptable prodrug of the compound represented by the formula (I) is also included in the present invention. The pharmaceutically acceptable prodrug refers to a compound having a group which can be converted into an amino group, a hydroxyl group, a carboxyl group, or the like, by solvolysis or under a physiological condition. Examples of the groups forming the prodrug include those as described in Prog. Med., 5,2157-2161 (1985) or "Pharmaceutical Research and Development" (Hirokawa Publishing Company, 1990), vol. 7, Molecular Design, 163-198, and "Methods and Principles in Medicinal Chemistry, vol. 47, Prodrugs and Targeted Delivery (Wiley-VCH, 2010)".
- Moreover, the salt of the compound of the formula (I) is a pharmaceutically acceptable salt of the compound of the formula (I), and the compounds of the formula (I) may form an acid addition salt or a salt with a base, depending on the kinds of the substituents in some cases. Specifically, examples thereof include acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid, and with organic acids such as formic acid, acetic acid, propanoic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyl tartaric acid, ditoluoyl tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, and glutamic acid, and salts with metal cations such as sodium, potassium, magnesium, calcium, and aluminum, and with organic bases such as methylamine, ethylamine, ethanolamine, lysine, ornithine, and salts with various amino acids or derivatives of amino acids such as acetyl leucine, lysine, and ornithine, ammonium salts, and others.
- In addition, the present invention also includes various hydrates or solvates, and crystal polymorph substances of the compound of the formula (I) and a salt thereof. In addition, the present invention also includes the compounds labeled with various radioactive or non-radioactive isotopes.
- The compound of the formula (I) or a salt thereof can be prepared by applying various known synthetic methods, using the characteristics based on their basic structures or the kinds of the substituents. At this time, depending on the types of the functional groups, it is in some cases effective from the viewpoint of the preparation techniques to protect the functional group with an appropriate protective group (a group which is capable of being easily converted into the functional group), during the steps from starting materials to intermediates. Examples of the protective group include the protective groups as described in "Greene's Protective Groups in Organic Synthesis (4th edition, 2006)", edited by P. G. M. Wuts and T. W. Greene, and the like, which may be appropriately selected and used depending on the reaction conditions. In these methods, a desired compound can be obtained by introducing the protective group to carry out the reaction, and then, if desired, removing the protective group.
- In addition, the prodrug of the compound of the formula (I) can be prepared by introducing a specific group during the steps from starting materials to intermediates, in the same manner as for the above protective groups, or by further carrying out the reaction using the obtained compound of the formula (I). The reaction can be carried out by applying a method known to a person skilled in the art, such as common esterification, amidation, and dehydration.
- Hereinbelow, typical preparation methods of the compound of the formula (I) will be described. Each of the production processes can also be carried out with reference to the documents appended to the description herein. Further, the preparation methods of the present invention are not limited to the examples as shown below.
-
- This production process is a method for producing a compound of the formula (Ia) in which Q is piperazine-1,4-diyl or piperidine-1,4-diyl among the compounds of the formula (I) which are the compounds of the present invention, from the compound of the formula (a).
- This step is a step of obtaining a compound of the formula (c) by reacting a compound of the formula (a) with the compound of the formula (b). Here, examples of the leaving group L1 include a halogen group, a methanesulfonyloxy group, and a p-toluenesulfonyloxy group.
- This reaction is carried out using the compound of the formula (a) and the compound of the formula (b), by stirring the mixture under the temperature condition ranging from under cooling to under heating to reflux, preferably at 0 °C to 90°C, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction or without a solvent. Examples of the solvent used herein are not particularly limited, but include aromatic hydrocarbons such as benzene, toluene and xylene, ethers such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, and the like, halogenated hydrocarbons such as methylene chloride, 1,2-dichloroethane, chloroform, and the like, N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), ethyl acetate, acetonitrile, 1-methylpyrrolidin-2-one (NMP), and a mixture thereof. It may be advantageous in some cases for the smooth progress of the reaction to carry out the reaction in the presence of an organic base such as triethylamine, N,N-diisopropylethylamine, N-methylmorpholine, and the like or an inorganic base such as sodium hydride, potassium carbonate, sodium carbonate, potassium hydroxide, and the like.
-
- "Organic Functional Group Preparations" written by S. R. Sandler and W. Karo, 2nd edition, Vol. 1, Academic Press Inc., 1991
- "Courses in Experimental Chemistry (5th edition)" edited by The Chemical Society of Japan, Vol. 14 (2005) (Maruzen).
- This step is a step of obtaining a compound of the formula (e) by reacting the compound of the formula (c) with a compound of the formula (d). The reaction conditions are the same as in Process 1 of Production Process 1. In addition, it is possible to switch the order of Process 1 and Process 2.
- This step is a step of obtaining a compound of formula (Ia) by deprotecting the compound of the formula (e).
- This reaction is carried out by using the compound of the formula (e) and a deprotecting reagent by stirring the mixture under the temperature condition ranging from under cooling to heating to reflux, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction or without a solvent. In the case where R is benzyl, this reaction can also be carried out by subjecting the compound of the formula (e) to a hydrogenation reaction using a metal catalyst in a hydrogen atmosphere. Examples of the solvent used herein are not particularly limited, but include alcohols such as methanol, ethanol, n-propanol and the like, DMF, THF, and the like. Further, there are some cases where a mixed solvent of the solvent and water is highly suitable for the reaction. Examples of the deprotecting reagent are not particularly limited, but include bases such as an aqueous sodium hydroxide solution, an aqueous potassium hydroxide solution and the like, and acids such as hydrochloric acid, trifluoroacetic acid and the like. In addition, examples of the metal catalyst that can be used in the hydrogenation reaction include palladium on carbon and palladium hydroxide.
-
- This production process is a method for producing a compound of the compound of the formula (Ib) in which W is ethylene, and Q is piperazine-1,4-diyl among the compounds of the formula (I) which are the compounds of the present invention, from the compound of the formula (a).
- This step is a step of obtaining a compound of the formula (g) by a deprotecting after reacting a compound of the formula (a) with a compound of the formula (f). Here, examples of a leaving group L2 include a halogen, a trifluoromethanesulfonyloxy group, and the like. In addition, examples of a protecting group P0 include a t-butoxycarbonyl (Boc), and the like.
- The reaction is carried out by using the compound of the formula (a) and the compound of the formula (f) in equivalent amounts, or either thereof in an excess amount, by stirring the mixture under the temperature condition ranging from under cooling to under heating, preferably at room temperature to 150°C, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction, in the presence of a palladium catalyst, a ligand, and a base. Examples of the solvent used herein are not particularly limited, but include aromatic hydrocarbons such as benzene, toluene, xylene and the like, N,N-dimethylformamide, acetonitrile, water, and a mixture thereof. Examples of the palladium catalyst include palladium acetate or tris(dibenzylideneacetone) dipalladium, and the like. In addition, examples of the ligand include 1,1'-bis(diphenylphosphino)ferrocene (dppf), 1,1'-binaphthalene-2,2'-diyl bis(diphenylphosphine) (BINAP), 2-dicyclohexylphosphino-2',4,'6'-triisopropylbiphenyl (XPhos), dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (SPhos), tricyclohexylphosphine, di-tert-butyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine, (9,9-dimethyl-9H-xanthene-4,5-diyl) bis(diphenylphosphine), and the like. Further, examples of the base include sodium tert-butoxide, lithium hexamethyldisilazide, potassium phosphate, and the like.
- In addition, deprotecting the P0 group can be carried out by referring "Protective Groups in Organic Synthesis" written by Wuts and Greene, 4th edition, John Wiley & Sons Inc., 2006".
-
- Wolfe, J. P.; Wagaw, S.; Marcoux, J. F.; Buchwald, S. L. Acc. Chem. Res. 1998, 31,805
- Harwig, J. F. Acc. Chem. Res. 1998, 31, 852.
- This step is a step of preparing a compound of the formula (i) by reacting the compound of the formula (g) with a compound of the formula (h).
- This reaction is carried out using the compound of the formula (g) and the compound of the formula (h) in equivalent amounts, or either thereof in an excess amount, by stirring the mixture under the temperature condition ranging from under cooling to under heating to reflux, preferably at 0°C to 100°C, usually for 0.1 hours to 5 days, in a solvent which is inert to the reaction. Examples of the solvent used herein are not particularly limited, but include aromatic hydrocarbons such as benzene, toluene, xylene and the like, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane and the like, halogenated hydrocarbons such as methylene chloride, 1,2-dichloroethane, chloroform and the like, DMF, NMP, DMSO, ethyl acetate, acetonitrile, ethanol, and a mixture thereof. It may be advantageous in some cases for the smooth progress of the reaction to carry out the reaction in the presence of an organic base such as piperidine, triethylamine, N,N-diisopropylethylamine, N-methylmorpholine and the like, or an inorganic base such as potassium carbonate, sodium carbonate, potassium hydroxide and the like.
- "Courses in Experimental Chemistry (5th edition)" edited by The Chemical Society of Japan, Vol. 16 (2005) (Maruzen).
- This step is a step of obtaining a compound of formula (Ib) by deprotecting the compound of the formula (i). The reaction conditions are the same as in Process 3 of Production Process 1.
-
- This production process is another preparation method for the compound of the formula (I).
- This step is a step of preparing a compound of the formula (k) by reacting a compound of the formula (a) with a compound of the formula (j). The reaction conditions are the same as in Process 1 of Production Process 2.
- This step is a step of obtaining a compound of formula (I) by deprotecting the compound of the formula (k). The reaction conditions are the same as in Process 3 of Production Process 1.
-
- This production process is a method for producing a compound of the formula (Ic) in which Q is piperazine-1,4-diyl or piperidine-1,4-diyl, and n is 1 among the compounds of the formula (I).
- This step is a step of obtaining a compound of the formula (n) by reacting a compound of the formula (m) with the compound of the formula (b). The reaction conditions are the same as in Process 1 of Production Process 1.
- This step is a step of obtaining a compound of the formula (o) by reacting the compound of the formula (n) with a compound of the formula (d). The reaction conditions are the same as in Process 1 of Production Process 1.
- This step is a step of obtaining a compound of the formula (q) by subjecting the compound of the formula (o) to a Mannich reaction by using a compound of the formula (p) and formaldehyde. It is possible to employ a method described in Journal of the American Chemical Society written by Albertson, N.F. 1948, 70, 669 and Bulletin of the Chemical Society of Japan written by Bhargava, P.N., Sharma, S.C. 1965, 38, 909, or a method similar to that.
- This step is a step of preparing a compound of formula (Ic) by deprotecting the compound of the formula (q). The reaction conditions are the same as in Process 3 of Production Process 1.
-
- This production process is a method for producing a compound of the formula (v) in which n = 1, a compound of the formula (w) in which n = 0, and the compound of the formula (m) which is a starting material of Production Process 4 among the compounds of the formula (a) which are starting materials in the above-described Production Processes 1 to 3. Here, examples of the protecting group P1 include the protecting groups of the amino groups described in "Protective Groups in Organic Synthesis" written by Wuts and Greene, 4th edition, John Wiley & Sons Inc., 2006, such as an acetyl group.
- This step is a step of obtaining a compound of the formula (m) having 2-aminothiazole from a compound of the formula (r). It is possible to obtain the compound of the formula (m) having 2-aminothiazole by reacting the compound of the formula (r) with a brominating agent such as trimethylphenylammonium tribromide, and then reacting with thiourea in a solvent which is inert to the reaction. It is possible to employ a method described in Journal of the American Chemical Society written by Dodson R.M. et al., 1945, 67, 2242, or a method similar to that.
- This step is a step of protecting the amino group of the compound of the formula (m). Here, the present reaction can be carried out with reference to "Protective Groups in Organic Synthesis" written by Wuts and Greene, 4th edition, John Wiley & Sons Inc., 2006.
- This step is a step of preparing a compound of the formula (t) by introducing an acetoxymethyl group into the 5-position of thiazole in a compound of the formula (s). The step can be carried out by reacting a formaldehyde aqueous solution or a paraformaldehyde with a compound of the formula (s) in the presence of an acetic acid solvent under the temperature condition ranging from at room temperature to under heating, or from at room temperature to under refluxing. In addition, this reaction can also be carried out under microwave irradiation. Note that, it is possible to carry out the reaction by adding acetic acid into a solvent which is inert to the reaction such as halogenated hydrocarbons, aromatic hydrocarbons, and ethers, instead of the acetic acid solvent. In addition, the reaction can also be carried out by further adding acetic anhydride.
- This step is a step of preparing a compound of the formula (u) by reacting the compound of the formula (p) with respect to and the compound of the formula (t) under a basic condition. The present reaction can be carried out by reacting the compound of the formula (t) with the compound of the formula (p) in the presence of an organic base such as triethylamine and N,N-diisopropylethylamine in an organic solvent which is inert to the reaction such as halogenated hydrocarbons, aromatic hydrocarbons, ethers, esters, acetonitrile, DMF, DMSO, and NMP. In addition, the compound of the formula (p) can also be used in an excess amount instead of the organic base. The reaction can be carried out under the temperature condition ranging from under cooling to at room temperature; from at room temperature to under heating; or from at room temperature to under refluxing.
- The step is a step of obtaining the compound of the formula (v) by removing the protecting group of the compound of the formula (u). Here, this reaction can be carried out by referring "Protective Groups in Organic Synthesis" written by Wuts and Greene, 4th edition, John Wiley & Sons Inc., 2006".
- This step is a step of obtaining the compound of the formula (w) from the compound of the formula (m). This reaction is carried out by an ipso-substitution reaction by using the compound of the formula (p) after brominating the 5-position of thiazole in the compound of the formula (m) by using a brominating agent such as N-bromosuccinimide so as to obtain the compound of the formula (w).
- The compound of the formula (I) is isolated and purified as its free compound, or a salt, a hydrate, a solvate, or crystal polymorph substance thereof. The salt of the compound of the formula (I) can also be prepared by a conventional method.
- Isolation and purification are carried out by employing general chemical operations such as extraction, fractional crystallization, and various types of fractional chromatography.
- Various isomers can be prepared by selecting appropriate starting compound, or separated by using differences in the physicochemical properties among the isomers. For example, the optical isomers can be obtained by means of general optical resolution methods of racemic compounds (for example, fractional crystallization introducing the compound into a diastereomer salt with an optically active base or acid; chromatography using a chiral column or the like; and others), or can also be prepared from appropriate optically active starting compound.
- The pharmacological activity of the compound of the formula (I) was confirmed by the following test.
- A human muscarinic M3 receptor gene (GenBank Accession No.: NM_000740.2) was introduced into an expression vector pcDNA3.1 (registered trademark) (Life Technologies).
- A vector expressing a human muscarinic M3 receptor was introduced into a CHO-K1 cell (ATCC No.: CCL-61). The introduction was carried out according to the attached instructions, using a transfection reagent, Lipofectoamine (registered trademark) 2000 Reagent (Life Technologies). The cells were incubated in an alpha Modified Eagle Minimum Essential Medium (α-MEM) including 2 mM L-glutamine, 10% fetal bovine serum, and 2.0 mg/mL Geneticin (registered trademark) (Life Technologies) for 4 weeks to acquire a drug-resistant clone.
- The cells obtained in b) above were suspended in an α-MEM including 2 mM glutamine, 10% fetal bovine serum, and 0.2 mg/mL Geneticin (registered trademark) to the amount from 1.2 to 1.5 × 104 cells/well the day before the experiment, dispensed into a 384-well plate (Model No. 353962, BD Biosciences), and incubated overnight at 37°C and 5% CO2. The medium was replaced with a loading buffer (an assay buffer (Hank's balanced salt solution (HBSS) including 3.1 µM Fluo 4-AM (Dojindo Laboratories), 1 g/L BSA, 20 mM HEPES (pH 7.5), and 2.5 mM probenecid)), and incubated for about 2 hours at room temperature. Thereafter, the cells were washed with a plate washer ELx405(registered trademark) (BIO-TEK Instrument, Inc.) set with the assay buffer, and set in an intracellular Ca2+ concentration measuring system (FLIPRtetra (registered trademark), Molecular Device). The test substances were dissolved by using DMSO. The test substances (final concentration of 1 µM or 10 µM) and carbachol (Sigma, final concentration of 0.0024 nM to 10 µM) which had each been diluted in the assay buffer in advance were set in a FLIPRtetra (registered trademark). The test substances were added to the cells in the device and after about 5 minutes, carbachol was added to the cells. An increase rate of the intracellular Ca2+ concentration by carbachol was measured (excitement wavelength of 470 to 495 nm and a fluorescence wavelength of 515 to 575 nm).
- For the muscarinic M3 receptor-positive allosteric modulator activity, a shift toward a lower concentration side of a carbachol concentration-response curve by the test substance was used as an index. That is, a minimum value in the carbachol response was taken as 0%; a maximum value in the carbachol response was taken as 100% from the concentration-response curve of carbachol; the carbachol concentration exhibiting a 50% response was calculated as an EC50 value, using a Sigmoid-Emax model non-linear regression method, and thus, the muscarinic M3 receptor-positive allosteric modulator activity was determined by dividing the EC50 value of carbachol in the absence of the test substance by the EC50 value of carbachol in the presence of the test substance. For example, when the EC50 value of carbachol in the absence of the test substance was 0.1 µM and the EC50 value of carbachol in the presence of the test substance was 0.01 µM, the value of the muscarinic M3 receptor-positive allosteric modulator activity becomes 10, showing that the test substance causes a 10-fold shift in the EC50 value toward to the low concentration side. In Tables below, the columns of 10 µM (-fold shift) show the values in a case where the test substance is added to a final concentration of 10 µM and the columns of 1 µM (-fold shift) show the values in a case where the test substance is added to a final concentration of 1 µM.
- The muscarinic M3 receptor-positive allosteric modulator activity (-fold shift) of Example compounds of the present invention are shown in Tables 1 and 2. However, Ex represents Example Compound Nos. as described later (this shall apply hereinafter).
[Table 1] Ex 10 µM (Fold shift) 1 µM (Fold shift) Ex 10 µM (Fold shift) 1 µM (Fold shift) 1 310 165 33 43 10 2 182 43 34 54 24 3 86 31 35 114 36 4 163 26 36 201 99 5 116 31 37 178 18 6 222 21 38 70 22 7 153 71 39 106 21 8 131 32 40 125 34 9 203 68 41 116 14 10 176 42 42 21 3 11 173 62 43 159 35 12 163 34 44 167 26 13 217 90 45 118 36 14 155 23 46 210 19 15 173 42 47 55 26 16 96 34 48 38 5 17 118 35 49 76 18 18 157 31 50 223 88 19 84 12 51 123 45 20 106 17 52 92 14 21 139 33 53 126 31 22 59 10 54 119 35 23 82 16 55 123 35 24 102 9 56 127 62 25 61 6 57 144 54 26 158 23 58 289 70 27 114 30 59 259 120 28 23 4 60 61 24 29 78 12 61 74 29 30 141 35 62 137 32 31 92 23 63 150 61 32 218 123 64 120 24 [Table 2] Ex 10 µM (Fold shift) 1 µM (Fold shift) Ex 10 µM (Fold shift) 1 µM (Fold shift) 65 318 59 84 100 48 66 155 34 85 169 69 67 328 102 86 74 28 68 625 196 87 15 2 69 114 54 88 22 4 70 117 49 89 118 19 71 215 63 90 236 65 72 167 172 91 42 11 73 369 84 92 84 29 74 140 45 93 51 7 75 129 98 94 54 19 76 128 26 95 163 38 77 65 32 96 58 8 78 81 14 97 67 12 79 99 16 98 91 10 80 365 141 99 90 25 81 55 12 100 261 59 82 303 94 101 78 36 83 162 41 102 110 32 - Example compounds in Tables 1 and 2 shifted a carbachol concentration-response curve toward a lower concentration side when added at 1 µM and 10 µM. In addition, for all Example compounds, from the viewpoint that the compounds alone do not change the intracellular Ca2+ concentration, it was found that these compounds have no muscarinic M3 receptor agonistic activity.
- As an effect on the nerve stimulation-dependent bladder contraction in in vitro, the effect of the Example compounds of the present invention in the electrical field stimulation-induced contraction of the rat isolated bladder was measured by the following method. That is, a bladder specimen having a width of about 2 mm and a length of about 10 mm in the longitudinal direction from the bladder isolated from a Sprague-Dawley (SD) female rat (Japan SLC, Inc.) was prepared. The prepared bladder specimen was suspended in an organ bath filled with 10 mL of a Krebs-Henseleite solution. The Krebs-Henseleite solution was aerated at 95% O2 and 5% CO2, and kept at 37°C. After carrying out stabilization at an initial tension of 1 g, the contraction was caused twice with 60 mM KCl. After stabilization of the specimen with a Krebs-Henseleite solution, the contraction was caused by carrying out electrical field stimulation at 20 V with an electrical stimulation device (Nihon Kohden) (a stimulation frequency of 8 Hz, a pulse width of 0.3 msec, and a stimulation time of 10 seconds). By repeating the transmural electrical stimulation at an interval of 2 minutes, a voltage was adjusted to obtain a contraction height of approximately 50% of the contractile response at 20 V. After the contraction by electrical field stimulation had been stabilized, 10 µL of the test substances dissolved in 100% DMSO in advance (final concentrations of 3 µM, 10 µM, and 30 µM) was added thereto. The test substances were cumulatively administered at the following concentrations after the low-concentration contractile response had been stabilized. The response was taken into a personal computer through a PowerLab (registered trademark) (AD Instruments, Inc.), and analyzed by LabChart (registered trademark) (AD Instruments, Inc.). When the area under the response (area under curve, AUC) in each contraction response was calculated and the value before treatment with the test substance was taken as 100%, the enhancement rate (% of pre) of the isolated bladder contractions after treatment with the test substance was calculated.
- The enhancement rates of the isolated bladder contractions by 10 µM of some Example compounds are shown in Table 3.
- Furthermore, it was separately confirmed that all the Example compounds which have been subjected to the present test do not cause contraction in a state in which there is no electrical stimulation and the compounds alone do not show a bladder contraction action.
[Table 3] Ex Enhancement rate of extracted bladder contractions (% of pre) 1 120 3 136 4 127 8 193 9 187 10 271 11 219 12 166 13 127 14 169 17 199 18 199 19 161 91 124 - From the above, it was confirmed that the Example compounds alone, which have been subjected to the present test, do not cause a contraction action in the isolated rat bladder, but have an action of enhancing electrical field stimulation-induced contraction.
- The effect of the Example compounds of the present invention in the pelvic nerve electrical stimulation-induced elevation of intravesical pressure using rats as an action of nerve stimulation-dependent bladder contraction in vivo was measured by the following method. That is, SD female rats (Japan SLC, Inc.) were used and its lower abdomen was dissected at the midline under pentobarbital anesthesia (50 mg/kg ip). After ligating and cutting the ureter on both sides, a cannula (PE-50) for measuring the intravesical pressure was inserted into the bladder from the external urethral opening and fixed by a clip. After injecting about 200 µL of saline through the cannula that had been inserted into the bladder, the other side was connected to a pressure transducer to measure the intravesical pressure. Under a stereoscopic microscope observation, the pelvic nerve in the vicinity of the bladder was peeled and an electrode for nerve stimulation (unique Medical) was placed. The abdominal cavity was filled with mineral oil (MP BIOMEDICALS). After placing in a post-operative stabilization period, the pelvic nerve was subjected to electrical stimulation (stimulation voltage: 10 V, stimulation frequency: 8 Hz, pulse width: 0.3 msec, and stimulation time: 10 seconds) to elicit the elevation of intravesical pressure, using an electrical stimulator (Nihon Kohden). By repeating the electrical stimulation at an interval of 2 minutes while adjusting the voltage, the voltage was adjusted to elicit about 50% to 70% elevation of intravesical pressure elicited at 10 V. Thereafter, by repeating the electrical stimulation at an interval of 10 minutes, the increase in the intravesical pressure by electrical stimulation was stabilized three times or more, and the test substance (an administration amount of 3 mg/kg) was then administered from the catheter detained in the vein at a volume of 1 mL/kg, thus measuring an effect of the elevation of the intravesical pressure of the test substance for 1 hour. The test substance was dissolved in water supplemented with 10% DMSO and 10% Cremophor.
- The response was applied to a personal computer through a PowerLab (registered trademark) and analyzed by LabChart (registered trademark). The AUC of each elevation of the intravesical pressure was calculated, the intravesical pressure elevation rate (% of pre) after the treatment with the test substance was calculated by taking an average value of the values measured three times before the treatment with the test substance as 100%, and the maximum effect during a period within one hour after administration of the compound was considered as the effect of the test substance.
- The elevation rates (% of pre) of the intravesical pressure when some Example compounds were administered at 3 mg/kg are shown in Table 4.
[Table 4] Ex Increase rate of intravesical pressure (% of pre) Ex Increase rate of intravesical pressure (% of pre) 1 197 38 142 2 143 39 123 3 146 40 212 4 178 43 177 5 146 45 182 8 178 51 129 9 200 53 145 10 169 54 150 11 181 55 189 12 152 58 175 13 186 59 225 14 121 63 198 15 130 65 174 16 111 67 169 17 144 68 172 18 153 69 150 19 125 70 151 20 118 71 197 21 116 77 140 26 125 86 164 27 123 91 144 29 145 92 105 30 124 94 114 31 138 97 143 32 232 98 139 34 159 99 121 35 154 100 145 36 191 - In addition, it was confirmed that the Example compounds evaluated in the present test do not cause an elevation of the intravesical pressure in a state in which electrical stimulation is not given, and the compounds alone do not show elevation of the intravesical pressure.
- From the above, it was confirmed that the Example compounds listed in Table 4 alone do not show elevation of the intravesical pressure but have an action of enhancing effect on the pelvic nerve electrical stimulation-induced elevation of intravesical pressure in the anesthetized rats.
- As shown in the results of each the tests above, it was confirmed that the compound of the formula (I) has a muscarinic M3 receptor-positive allosteric modulator activity, and further, it enhances the bladder contraction in a nerve stimulation-dependent manner in in vitro, as well as enhances an elevation in the intravesical pressure in a nerve stimulation-dependent manner in in vivo. Accordingly, the compound of the formula (I) can be used to prevent or treat bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, in particular, voiding dysfunction or urine storage dysfunction in the bladder/urethral diseases. The compound of the formula (I) can be used for preventing or treating, for example, voiding dysfunction or urine storage dysfunction in underactive bladder, hypotonic bladder, acontraction bladder, detrusor underactivity, neurogenic bladder, urethra relaxation failure, detrusor-external urethral sphincter dyssynergia, overactive bladder, urinary frequency, nocturia, urinary incontinence, benign prostatic hyperplasia, interstitial cystitis, chronic prostatitis, and urinary tract stones. In particular, the compound of the formula (I) can be used for preventing or treating voiding dysfunction or urine storage dysfunction in underactive bladder, hypotonic bladder, acontraction bladder, detrusor underactivity, and neurogenic bladder.
- In addition, the compound of formula (I) can become a therapeutic drug that is more excellent in safety from the viewpoint that the compound alone does not show an agonistic effect on a muscarinic M3 receptor, but shows an effect on enhancing the nerve stimulation-dependent bladder contraction, and accordingly, cholinergic side effects that have been reported in the existing drugs can be avoided.
- A pharmaceutical composition including one or two or more kinds of the compound of the formula (I) as an active ingredient can be prepared using an excipient which is usually used in the art, that is, an excipient for a pharmaceutical preparation, a carrier for a pharmaceutical preparation, and the like, according to a method usually used.
- Administration can be accomplished either by oral administration via tablets, pills, capsules, granules, powders, solutions, and the like, or parenteral administration via injections, such as intraarticular, intravenous, and intramuscular injections, suppositories, transdermal liquid preparations, ointments, transdermal patches, transmucosal liquid preparations, transmucosal patches, inhalers, and the like.
- As a solid composition for oral administration, tablets, powders, granules, and the like are used. In such a solid composition, one kind or two or more kinds of the active ingredients are mixed with at least one inactive excipient. In a conventional method, the composition may contain inactive additives such as a lubricant, a disintegrating agent, a stabilizer, or a solubilization assisting agent. If necessary, tablets or pills may be coated with a sugar or with a film of a gastric or enteric coating substance.
- The liquid composition for oral administration includes pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, or the like, and also includes generally used inert diluents, for example, purified water or ethanol. The liquid composition may also include auxiliary agents such as a solubilization assisting agent, a moistening agent, and a suspending agent, sweeteners, flavors, aromatics, and antiseptics, in addition to the inert diluent.
- The injections for parenteral administration include sterile aqueous or non-aqueous solution preparations, suspensions, or emulsions. The aqueous solvent includes, for example, distilled water for injection and saline. Examples of the non-aqueous solvent include alcohols such as ethanol. Such a composition may further include a tonicity agent, an antiseptic, a moistening agent, an emulsifying agent, a dispersing agent, a stabilizing agent, or a solubilizing assisting agent. These are sterilized, for example, by filtration through a bacteria retaining filter, blending of a bactericide, or irradiation. In addition, these can also be used by preparing a sterile solid composition, and dissolving or suspending it in sterile water or a sterile solvent for injection prior to its use.
- Examples of the agent for external use include ointments, hard plasters, creams, jellies, cataplasms, sprays, and lotions. The agent further contains generally used ointment bases, lotion bases, aqueous or non-aqueous liquid preparations, suspensions, emulsions, or the like.
- As the transmucosal agents such as an inhaler and a transnasal agent, those in the form of a solid, liquid, or semi-solid state are used, and can be prepared in accordance with a method known in the related art. For example, a known excipient, and also a pH adjusting agent, an antiseptic, a surfactant, a lubricant, a stabilizing agent, a thickening agent, or the like may be appropriately added thereto. For the administration, an appropriate device for inhalation or blowing can be used. For example, a compound may be administered alone or as a powder of formulated mixture, or as a solution or suspension in combination with a pharmaceutically acceptable carrier, using a known device or sprayer such as a metered administration inhalation device. A dry powder inhaler or the like may be for single or multiple administration use, and a dry powder or a powder-containing capsule may be used. Alternatively, this may be in a form such as a pressurized aerosol spray that uses an appropriate propellant agent, for example, a suitable gas such as chlorofluoroalkanes, and carbon dioxide, or other forms.
- Usually, in the case of oral administration, the daily dose is from about 0.001 mg/kg to 100 mg/kg, preferably from 0.1 mg/kg to 30 mg/kg, and more preferably from 0.1 mg/kg to 10 mg/kg, per body weight, administered in one portion or in 2 to 4 divided portions. In the case of intravenous administration, the daily dose is suitably administered from about 0.0001 mg/kg to 10 mg/kg per body weight, once a day or two or more times a day. In addition, a transmucosal agent is administered at a dose from about 0.001 mg/kg to 100 mg/kg per body weight, once or plural times a day. The dose is appropriately decided in response to the individual case by taking the symptoms, the age, and the gender, and the like into consideration.
- Although there are differences depending on a route of administration, a dosage form, an administration site, and a type of the excipient or additive, a pharmaceutical composition of the present invention comprises 0.01% by weight to 100% by weight of, as an embodiment, 0.01% by weight to 50% by weight of, one or more of the compound of the formula (I) or a salt thereof which is the active ingredient.
- The compound of the formula (I) may be used in combination with various agents for treating or preventing diseases on which the compound of the formula (I) is considered to show the effect. Such combined preparations may be administered simultaneously, or separately and continuously, or at a desired time interval. The preparations to be co-administered may be a blend, or may be prepared individually.
- Hereinbelow, the production process for the compound of the formula (I) will be described in more detail with reference to Examples. Further, the present invention is not limited to the compounds described in the Examples below. Further, the production processes for the starting compounds will be described in Preparation Examples. In addition, the production processes for the compound of the formula (I) are not limited to the production processes of the specific Examples shown below, but the compound of the formula (I) can be prepared by a combination of these production processes or a method that is apparent to a person skilled in the art.
- Further, in the present specification, nomenclature software such as ACD/Name (registered trademark, Advanced Chemistry Development, Inc.) may be used for nomenclature of compounds in some cases.
- Moreover, the following abbreviations may be used in Examples, Preparation Examples, and Tables below in some cases.
- PEx: Preparation Example No., Ex: Example No., PSyn: Preparation method of Preparation Example compound (the number in the PSyn column indicates that the compound was produced by using the corresponding starting material in the same manner as the compound having the number as the number of Preparation Example compound. For example, the compound in which the PSyn column is 2 means that it was prepared in the same manner as the compound of Preparation Example 2), Syn: Preparation method of Example compounds (the number in the Syn column indicates that the compound was produced by using the corresponding starting material in the same manner as the compound having the number as the number of Example compound. For example, the compound in which the Syn column is 2 means that it was prepared in the same manner as the compound of Example 2), Str: Structural chemical formula (Me represents methyl, Et represents ethyl, i-Pr represents isopropyl, c-Pr represents cyclopropyl, tBu represents tert-butyl, Boc represents tert-butoxycarbonyl, and Ac represents acetyl), DAT: Physicochemical data, ESI+: m/z values in mass spectroscopy (Ionization method ESI, representing [M+H]+ unless otherwise specified), ESI-: m/z values in mass spectroscopy (Ionization method ESI, representing [M-H]- unless otherwise specified), APCI/ESI+: m/z values in mass spectroscopy (APCI/ESI-MS (atmospheric pressure chemical ionization method APCI, representing [M+H]+ unless otherwise specified; in which APCI/ESI means simultaneous measurement of APCI and ESI)), EI: m/z values in mass spectroscopy (ionization method EI, representing [M]+ unless otherwise specified), CI: m/z values in mass spectroscopy (Ionization method CI, representing [M+H]+ unless otherwise specified), NMR-CDC13: δ (ppm) of peaks in 1H-NMR in CDCl3, NMR-DMSO-d6: δ (ppm) of peaks in 1H-NMR in DMSO-d6, s: singlet (spectrum), d: doublet (spectrum), t: triplet (spectrum), q: quartet (spectrum) br: broad (spectrum) (e.g.: brs), m: multiplet (spectrum). Further, HCl in the structural formula indicates that the compound is a monohydrochloride; and 2HCl indicates that the compound is a dihydrochloride.
- In addition, for the sake of convenience, a concentration of mol/L is represented by M. For example, a 1 M aqueous sodium hydroxide solution means a 1 mol/L aqueous sodium hydroxide solution.
- Sodium hydride (90 mg, 60% oil dispersion) was added to a mixture of 5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine (300 mg), 4,6-dichloro-5-fluoro-2-methylpyrimidine (175 mg), and dehydrated tetrahydrofuran (6.0 mL) in an argon atmosphere under ice-methanol bath cooling, followed by stirring at 0°C for 30 minutes. The resultant was extracted with ethyl acetate after adding ice-water to the reaction mixture. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain 6-chloro-N-(5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)-5-fluoro-2-methylpyrimidin-4-amine (407 mg) as a solid.
- N,N-diisopropylethylamine (1.2 mL) was added to a mixture of N2-(6-chloro-2-methylpyrimidin-4-yl)-4-[3-fluoro-5-(trifluoromethyl)phenyl]-N5-isopropyl-N5-(2-methoxyethyl)-1,3-thiazole-2,5-diamine (279 mg), ethyl 3-(piperazin-1-yl)propanoate dihydrochloride (440 mg), and 1-methylpyrrolidin-2-one (NMP) (6.0 mL) at room temperature. The reaction mixture was stirred at 80°C for 12 hours. Ethyl acetate and water were added the reaction mixture so as to separate the organic layer. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain ethyl 3-{4-[6-({4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[isopropyl(2-methoxyethyl)amino]-1,3-thiazol-2-yl}amino)-2-methylpyrimidin-4-yl]piperazin-1-yl}propanoate (303 mg) as a solid.
- A mixture of 6-chloro-5-fluoro-N-(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)-2-methylpyrimidin-4-amine (662 mg), ethyl 3-(piperazin-1-yl)propanate dihydrochloride (1.7 g), N,N-diisopropylethylamine (4.0 mL), and NMP (10 mL) was stirred at 80°C for 4 hours. Ethyl acetate and water were added the reaction mixture so as to separate the organic layer. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) and silica gel column chromatography (chloroform-ethyl acetate) to obtain ethyl 3-(4-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl}piperazin-1-yl)propanoate (353mg) as a solid.
- A mixture of ethyl 3-[(2S)-4-(6-chloro-5-fluoropyrimidin-4-yl)-2-(methoxymethyl)piperazin-1-yl]propanoate (145 mg), 4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-amine (150 mg), tris(dibenzylideneacetone) dipalladium (110 mg), 1,1'-binaphthalene-2,2'-diyl bis(diphenylphosphine) (150 mg), cesium carbonate (520 mg), and toluene (3.0 mL) was stirred at 100°C for 5 hours under an argon atmosphere. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane-ethyl acetate) and basic silica gel column chromatography (hexane-ethyl acetate) to obtain ethyl 3-[(2S)-4-{6-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}-2-(methoxymethyl)piperazin-1-yl]propanoate (192 mg) as a solid.
- A mixture of tert-butyl 3-[4-(2-chloro-3-fluoropyridin-4-yl)piperazin-1-yl]propanate (497 mg), 4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-amine (500 mg), tris(dibenzylideneacetone) dipalladium (640 mg), 1,1'-binaphthalene-2,2'-diyl bis(diphenylphosphine) (900 mg), cesium carbonate (1.9 g), and NMP (15 mL) was stirred at 100°C for 6 hours under an argon atmosphere. The reaction mixture was diluted with ethyl acetate and water, and filtered through a celite pad. A filtrate was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform-ethyl acetate), silica gel column chromatography (hexane-ethyl acetate), and silica gel column chromatography (chloroform-ethyl acetate) to obtain tert-butyl 3-(4-{3-fluoro-2-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5- {[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyridin-4-yl}piperazin-1-yl)propanate (387 mg) as a solid.
- (2R)-2-methylpyrrolidine (0.15 mL) was added to a mixture of ethyl 3-{4-[5-fluoro-6-({4-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-2-yl}amino)pyrimidin-4-yl]piperazin-1-yl}propanoate (400 mg), paraformaldehyde (65 mg), and acetic acid (6.0 mL), and stirred at 75°C for 2.5 hours. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with ethyl acetate and water. To the reaction mixture was added a saturated aqueous sodium hydrogen carbonate solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain ethyl 3-(4-{5-fluoro-6-[(4-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-5-{[(2R)-2-methylpyrrolidin-1-yl] methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperazin-1-yl)propanoate (328 mg) as a solid.
- Paraformaldehyde (55 mg) was added to a mixture of ethyl 3-{4-[5-fluoro-6-({4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}amino)pyrimidin-4-yl]piperazin-1-yl}propanoate (300 mg), (3S)-3-methoxypyrrolidine hydrochloride (110 mg), and acetic acid (5.0 mL) at room temperature. The reaction mixture was stirred at 85°C for 1 hour. The reaction mixture was added acetic anhydride (0.50 mL) and was stirred at 85°C for 4 hours. To the reaction mixture was added water, followed by extraction with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by neutral silica gel column chromatography (hexane-ethyl acetate) and neutral silica gel column chromatography (chloroform-methanol) to obtain ethyl 3-(4-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(3S)-3-methoxypyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperazin-1-yl)propanoate (150 mg) as a solid.
- A mixture of N-(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)-3-fluoro-4-(piperazin-1-yl)pyridin-2-amine (300 mg), ethyl acrylate (0.50 mL), and ethanol (10 mL) was stirred at 100°C for 15 minutes under microwave irradiation. The reaction liquid was concentrated under reduced pressure, and the residue was purified by basic silica gel column chromatography (hexane-ethyl acetate) to obtain ethyl 3-(4-{2-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-3-fluoropyridin-4-yl}piperazin-1-yl)propanoate (137 mg) as a solid.
- A mixture of tert-butyl 4-{2-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-3-fluoropyridin-4-yl}piperazine-1-carboxylate (457 mg), and 4 M hydrogen chloride dioxane solution (13 mL) was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and chloroform and saturated aqueous sodium hydrogen carbonate solution were added to the residue. The organic layer was separated, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (chloroform-methanol) to obtain N-(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)-3-fluoro-4-(piperazin-1-yl)pyridin-2-amine (302 mg) as a solid.
- 4 M hydrogen chloride ethyl acetate solution (2.2 mL) was added to a mixture of tert-butyl (3S)-4-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}-3-(methoxymethyl)piperazine-1-carboxylate (154 mg) and tetrahydrofuran (0.64 mL), and the reaction mixture was stirred at room temperature for 6 hours. The reaction mixture was concentrated under reduced pressure to obtain 5-fluoro-N-(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)-6-[(2S)-2-(methoxymethyl)piperazin-1-yl]pyrimidin-4-amine trihydrochloride (159 mg) as a solid.
- 6 M aqueous sodium hydroxide solution (1.0 mL) was added to a mixture of N-(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)acetamide (240 mg) and ethanol (4 mL), and the reaction mixture was stirred at 100°C for 4 hours under an argon atmosphere. To the reaction mixture was added water, followed by extraction with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was purified by basic silica gel column chromatography (hexane-ethyl acetate) to obtain 4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-amine (164 mg) as a solid.
- A mixture of N-(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)acetamide (1.4 g), ethanol (10 mL), and a 6 M aqueous sodium hydroxide solution (5.0 mL) was stirred at 120°C for 15 minutes under microwave irradiation. To the reaction mixture was added water, followed by extraction with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain 4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-amine (1.0 g) as an oil.
- A mixture of N-(5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)acetamide (916 mg), and concentrated sulfuric acid (8.0 mL) and water (2.0 mL) was stirred at 100°C for 1 hour. The reaction mixture was cooled to 5°C and alkalified by the addition of a 5 M aqueous sodium hydroxide solution and a saturated aqueous sodium hydrogen carbonate solution. The mixture was extracted with chloroform, and the organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (hexane-ethyl acetate) to obtain 5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine (685 mg) as a solid.
- A mixture of N-{4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}acetamide (2.8 g), acetic acid (20 mL), 36% formaldehyde aqueous solution (3.6 mL), and acetic anhydride (4.4 mL) was stirred at 170°C for 30 minutes under microwave irradiation. The reaction mixture was concentrated under reduced pressure, and then the obtained solid was washed with methanol, and collected by filtration. The obtained solid (1.8 g) and NMP (20 mL), (2R)-2-methylpyrrolidone (608 mg), and N,N-diisopropylethylamine (2.5 mL) were mixed, and the reaction mixture was stirred at 100°C for 30 minutes. The reaction mixture was cooled to room temperature, and water was added to the reaction mixture and was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain N-(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)acetamide (1.4 g) as a solid.
- A mixture of {2-acetamide-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazole-5-yl}methyl acetate (1.0 g), (-)-(2R,5R)-2,5-dimethylpyrrolidine hydrochloride (600 mg), N,N-diisopropylethylamine (2.0 mL), and NMP (10 mL) was stirred at 100°C for 3 hours. The reaction mixture was diluted with ethyl acetate, and the organic layer was washed with water and saturated brine. The obtained organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform-ethyl acetate) to obtain an oil. To the obtain oil (1.4 g) was added to ethyl acetate and water, followed by extraction with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain N-(5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)acetamide (965 mg) as a solid.
- N,N-diisopropylethylamine (0.55 mL) was added to a mixture of {2-acetamide-4-[4-chloro-3-(trifluoromethyl)phenyl]-1,3-thiazole-5-yl}methyl acetate (525 mg), (2R)-2-methylpyrrolidine hydrochloride (201 mg), and N,N-dimethylformamide (DMF) (4.2 mL), and the reaction mixture was stirred at 120°C for 30 minutes under microwave irradiation. To the reaction mixture was added (2R)-2-methylpyrrolidine hydrochloride (244 mg) and N,N-diisopropylethylamine (0.69 mL) was stirred at 140°C for 30 minutes under microwave irradiation. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by basic silica gel column chromatography (hexane-ethyl acetate) to obtain N-(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)acetamide (245 mg) as an oil.
- A mixture of N-{4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}acetamide (6.0 g), acetic acid (30 mL), 36% formaldehyde aqueous solution (7.5 mL), and acetic anhydride (9.0 mL) was stirred at 170°C for 15 minutes under microwave irradiation. The reaction mixture was concentrated under reduced pressure. Ethyl acetate was added to the obtained residue, and the organic layer was washed with saturated aqueous sodium hydrogen carbonate solution, water, and saturated brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform-methanol). The obtained solid was washed with diisopropyl ether, collected by filtration, and dried to obtain {2-acetamide-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazole-5-yl}methyl acetate(2.6 g) as a solid.
- A mixture of N-{4-[3-chloro-5-(trifluoromethoxy)phenyl]-1,3-thiazol-2-yl}acetamide (3.8 g), 37% formaldehyde aqueous solution (5.1 mL), acetic anhydride (11 mL), and acetic acid (19 mL) was heated to reflux overnight. The reaction mixture was concentrated under reduced pressure, and the obtained residue was washed with hexane-diisopropyl ether to obtain {2-acetamide-4-[3-chloro-5-(trifluoromethoxy)phenyl]-1,3-thiazole-5-yl}methyl acetate (2.4 g) as a solid.
- A mixture of 4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine (2.8 g), pyridine (10 mL), and acetic anhydride (4.0 mL) was stirred at 60°C for 1 hour. The reaction mixture was cooled to room temperature, water was added to the reaction mixture, and the obtained solid was collected by filtration. The obtained solid was washed with methanol, was collected by filtration, and dried to obtain N-{4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}acetamide (2.9 g) as a solid.
- N-bromosuccinimide (190 mg) was added to a mixture of 4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine (250 mg), and DMF (6.0 mL) at 0°C, and the reaction mixture was stirred at room temperature for 1 hour. To the reaction mixture was added N-(2-methoxyethyl)propane-2-amine (0.17 mL) and potassium carbonate (420 mg), followed by stirring at 80°C for 1 hour. To the reaction mixture was added ethyl acetate and water, followed by extraction with ethyl acetate, and the organic layer was dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain 4-[3-fluoro-5-(trifluoromethyl)phenyl]-N5-isopropyl-N5-(2-methoxyethyl)-1,3-thiazole-2,5-diamine (241 mg) as an oil.
- Phenyltrimethylammonium tribromide (143 g) was added to a mixture of 1-[3-fluoro-5-(trifluoromethyl)phenyl]ethanone (78 g) and tetrahydrofuran (625 mL) was stirred at room temperature for 1 hour. The insoluble materials were separated by filtration, and then the filtrate was concentrated under reduced pressure. The obtained residue was mixed with ethanol (625 mL), and to the mixture was added thiourea (35 g), followed by stirring at 65°C to 75°C for 2 hours. The reaction mixture was ice-cooled, and then water (625 mL) was added thereto. To the mixture was added 1 M sodium hydroxide (600 mL), followed by stirring for 30 minutes. The solid was collected by filtration, 70% ethanol water (600 mL) was added thereto, and the mixture was dissolved at 76°C. The obtained solution was cooled to room temperature and was stirred overnight. The mixture was ice-cooled, stirred for 2 hours, and then the precipitated solid was collected by filtration and was dried over under reduced pressure to obtain 4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine (57 g) as a solid.
- Ethyl 3-[(2S)-2-(methoxymethyl)piperazin-1-yl]propanoate dihydrochloride (400 mg), and N,N-diisopropylethylamine (1.1 mL) were sequentially added to a mixture of 4,6-dichloro-5-fluoropyrimidine (220 mg) and NMP (3.3 mL), and the reaction mixture was stirred at 80°C for 1 hour. The reaction mixture was diluted with ethyl acetate, and washed with water. The organic layer was dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain ethyl 3-[(2S)-4-(6-chloro-5-fluoropyrimidin-4-yl)-2-(methoxymethyl)piperazin-1-yl]propanoate (434 mg) as an oil.
- A mixture of 2,4-dichloro-3-fluoropyridine (800 mg), tert-butyl piperazine-1-carboxylate (1.8 g), potassium carbonate (2.7 g), and NMP (16 mL) was stirred at 80°C overnight, and then was stirred at 100°C for 4 hours. The reaction mixture was diluted with ethyl acetate and water. The organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain tert-butyl 4-(2-chloro-3-fluoropyridin-4-yl)piperazine-1-carboxylate (612 mg) as a solid.
- A mixture of benzyl piperazine-1-carboxylate (15 mL), tert-butyl acrylate (15 mL), and ethanol (50 mL) was stirred at 100°C for 5 hours. The reaction mixture was diluted with diethyl ether (100 mL), water (50 mL), and 1 M hydrochloric acid (100 mL), and the aqueous layer was separated. Ethyl acetate (500mL) and 1 M aqueous sodium hydroxide solution (100 mL) were added to the aqueous layer, the organic layer was separated, and the mixture was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain benzyl 4-(3-tert-butoxy-3-oxopropyl)piperazine-1-carboxylate (29 g) as an oil.
- A mixture of tert-butyl (3S)-3-(methoxymethyl)piperazine-1-carboxylate (633 mg), ethyl acrylate (0.39 mL), and ethanol (1.9 mL) was stirred at 80°C for 3 hours under microwave irradiation. The reaction mixture was cooled to room temperature, and then was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain tert-butyl (3S)-4-(3-ethoxy-3-oxopropyl)-3-(methoxymethyl)piperazine-1-carboxylate (444 mg) as an oil.
- N-methylmorpholine (0.65 mL) was added to a mixture of tert-butyl (3R)-3-hydroxypyrrolidine-1-carboxylate (1.0 g), ethyl propiolate (1.9 mL), and methylene chloride (16 mL), and the reaction mixture was stirred at room temperature for 2.5 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain tert-butyl (3R)-3-{[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]oxy)pyrrolidine-1-carboxylate (1.1 g) as an oil.
- 10% palladium on carbon (414 mg, 50% water contained) was added to a mixture of tert-butyl (3R)-3-{[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]oxy}pyrrolidine-1-carboxylate (1.1 g), and ethanol (22 mL) under an argon atmosphere. The reaction mixture was stirred for 14 hours under a hydrogen atmosphere (1 atm). The reaction mixture was filtered through a celite pad, and the filtrate was concentrated under reduced pressure so as to obtain tert-butyl (3R)-3-(3-ethoxy-3-oxopropoxy)pyrrolidine-1-carboxylate (1.1 g) as an oil.
- A mixture of tert-butyl 4-(3-ethoxy-3-oxopropyl)-3-(hydroxymethyl)piperazine-1-carboxylate (1.0 g) and methylene chloride (10 mL) was added dropwise to a mixture of bis(2-methoxyethyl)aminosulfur trifluoride (0.81 mL) and methylene chloride (10 mL) at - 70°C for 20 minutes under a nitrogen atmosphere so that the internal temperature does not exceed -60°C. The reaction mixture was stirred at room temperature for 8 hours. To the reaction mixture was added a saturated aqueous sodium hydrogen carbonate solution, followed by extraction with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform) to obtain tert-butyl 4-(3-ethoxy-3-oxopropyl)-3-(fluoromethyl)piperazine-1-carboxylate (278 mg) as an oil.
- N,N-diisopropylethylamine (4.6 mL), and ethyl bromoacetate (2.1 mL) were added to a mixture of tert-butyl (3S)-3-(methoxymethyl)piperazine-1-carboxylate (2.0 g) and methylene chloride (45 mL), and the reaction mixture was stirred at room temperature for 23 hours. The reaction mixture was added water so as to separate the organic layer, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain tert-butyl (3S)-4-(2-ethoxy-2-oxoethyl)-3-(methoxymethyl)piperazine-1-carboxylate (2.3 g) as an oil.
- 4 M hydrogen chloride ethyl acetate solution (6.0 mL) was added to a mixture of tert-butyl (3S)-4-(3-ethoxy-3-oxopropyl)-3-methylpiperazine-1-carboxylate (1.2 g) and ethanol (6.0 mL), and stirred at 80°C for 1.5 hours. The reaction liquid was cooled to room temperature and was stirred overnight. The solid was collected by filtration and dried to obtain ethyl 3-[(2S)-2-methylpiperazin-1-yl]propanoate dihydrochloride (995 mg) as a solid.
- 4 M hydrogen chloride ethyl acetate solution (1.9 mL) was added to a mixture of tert-butyl (3S)-4-(3-ethoxy-3-oxopropyl)-3-(methoxymethyl)piperazine-1-carboxylate (444 mg) and ethanol (2.2 mL), and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to obtain ethyl 3-[(2S)-2-(methoxymethyl)piperazin-1-yl]propanoate dihydrochloride (401 mg) as a solid.
- A mixture of benzyl 4-(3-tert-butoxy-3-oxopropyl)piperazine-1-carboxylate (29 g), 10% palladium on carbon (6.0 g, 50% water contained), and ethanol (300 mL) was stirred at room temperature for 3 hours under a hydrogen atmosphere (1 atm). The reaction mixture was filtered through a celite pad, and the filtrate was concentrated under reduced pressure so as to obtain tert-butyl 3-(piperazin-1-yl)propanate (19 g) as an oil.
- A mixture of 1-[4-chloro-3-(trifluoromethyl)phenyl]ethanone (1.0 g), cyclopropylboronic acid (780 mg), dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (185 mg), tripotassium phosphate (3.0 g), palladium acetate (II) (51 mg), toluene (10 mL), and water (1.0 mL) was stirred at 100°C for 3 hours under an argon atmosphere, and then cooled to room temperature. Ethyl acetate and water were added to the reaction mixture, insoluble materials were removed by filtration, and then the filtrate was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified with silica gel column chromatography (hexane-ethyl acetate) to obtain 1-[4-cyclopropyl-3-(trifluoromethyl)phenyl]ethanone (1.0 g) as an oil.
- Trifluoroacetic acid (0.15 mL) was added to a mixture of zinc (2.0 g), cobalt bromide (II) (600 mg), and acetonitrile (30 mL) under an argon atmosphere, and the reaction mixture was stirred at room temperature for 15 minutes. 5-Bromo-1-fluoro-2-methoxy-3-(trifluoromethyl)benzene (5.0 g) and acetic anhydride (2.1 mL) were added to the reaction mixture, and the reaction mixture was stirred at room temperature for 17 hours. 1 M hydrochloric acid (30 mL) was added to the reaction mixture, and the mixture was extracted with diethyl ether. The organic layer was washed with water and saturated brine, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane-diethyl ether) to obtain 1-[3-fluoro-4-methoxy-5-(trifluoromethyl)phenyl]ethanone (1.6 g) as an oil.
- 3 M methylmagnesium bromide diethyl ether solution (7.0 mL) was added to a mixture of N,6-dimethoxy-N-methyl-5-(trifluoromethyl)nicotinamide (3.7 g) and tetrahydrofuran (40 mL) under ice-cooling, and the reaction mixture was stirred for one hour. To the reaction mixture was added a saturated aqueous ammonium chloride solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain 1-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]ethanone (3.0 g) as an oil.
- Sodium hydride (90 mg, 60% oil dispersion) was added to a mixture of 5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine (300 mg), 4,6-dichloro-5-fluoropyrimidine (165 mg), and dehydrated tetrahydrofuran (6.0 mL) in an argon atmosphere under ice-methanol bath cooling, followed by stirring at 0°C for 30 minutes. The resultant was extracted with ethyl acetate after adding ice water to the reaction mixture. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain 6-chloro-N-(5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)-5-fluoropyrimidin-4-amine (391 mg) as a solid.
- N,O-dimethylhydroxylamine hydrochloride (4.3 g), N-[3-(dimethylamino)propyl]-N'-ethylcarbodiimide hydrochloride (9.5 g), and N,N-diisopropylethylamine (30 mL) were added to a mixture of 6-methoxy-5-(trifluoromethyl)nicotinic acid (7.8 g) and methylene chloride (80 mL) under ice-cooling, and then the reaction mixture was stirred at room temperature for 17 hours. The reaction mixture was concentrated under reduced pressure, and to the residue were added ethyl acetate and water, followed by stirring for 30 minutes. The mixture was extracted with ethyl acetate, the organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to N,6-dimethoxy-N-methyl-5-(trifluoromethyl)nicotinamide (5.0 g) as an oil.
- A mixture of methyl {[1-(6-chloro-5-fluoropyrimidin-4-yl)piperidin-4-yl]oxy}acetate (106 mg), 4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-amine (125 mg), tris(dibenzylideneacetone) dipalladium (95 mg), 1,1'-binaphthalene-2,2'-diyl bis(diphenylphosphine) (130 mg), cesium carbonate (230 mg), and toluene (2.5 mL) was stirred at 100°C for 6 hours under an argon atmosphere. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane-ethyl acetate) and basic silica gel column chromatography (hexane-ethyl acetate) to obtain methyl [(1-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperidin-4-yl)oxy]acetate (57 mg) as a solid.
- Tripotassium phosphate (260 mg) was added to a mixture of ethyl 3-(4-{6-[(4-[3-bromo-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperazin-1-yl)propanoate (280 mg), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (135 mg), palladium acetate (II) (18 mg), tricyclohexylphosphine (45 mg), and dioxane (5.0 mL), and water (0.50 mL), and the reaction mixture was stirred at 95°C for 6 hours. The reaction mixture was diluted with water, and then extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain ethyl 3-(4-{5-fluoro-6-[(5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-4-[3-(prop-1-en-2-yl)-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperazin-1-yl)propanoate (170 mg) as a solid.
- A mixture of 4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-amine (500 mg), tert-butyl 4-(2-chloropyridin-4-yl)piperazine-1-carboxylate (500 mg), tris(dibenzylideneacetone) dipalladium (320 mg), di-tert-butyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (350 mg), cesium carbonate (1.8 g), toluene (10 mL), and water (1.0 mL) was stirred at 100°C for 1 hour under an argon atmosphere. The reaction mixture was cooled down to room temperature, and ethyl acetate and water were added. The mixture was extracted with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain an oil (538 mg).
- 4 M hydrogen chloride dioxane solution (12 mL) was added to a mixture of the obtained oil (538 mg) and tetrahydrofuran (2.0 mL), and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and saturated aqueous sodium hydrogen carbonate solution (15 mL) and water were added to the residue. The mixture was extracted with chloroform-isopropanol, the organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform-methanol) to obtain N-(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)-4-(piperazin-1-yl)pyridin-2-amine (300 mg) as a solid.
- A mixture of N-{4-[4-chloro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}acetamide (5.5 g), acetic acid (55 mL), 36% formaldehyde aqueous solution (6.8 mL) and acetic anhydride (5.0 mL) was stirred at 170°C for 30 minutes under microwave irradiation. The reaction mixture was concentrated under reduced pressure. Isopropanol was added to the obtained residue, and the precipitated solid was collected by filtration and dried to obtain methyl {2-acetamide-4-[4-chloro-3-(trifluoromethyl)phenyl]-1,3-thiazole-5-yl}acetate (4.1 g) as a solid.
- A mixture of 4-[4-chloro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine (6.0 g), pyridine (36 mL), and acetic anhydride (9.0 mL) was stirred at 60°C for 4 hours. Water was added to the reaction mixture, and the generated solid was collected by filtration and dried under reduced pressure to obtain N-{4-[4-chloro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}acetamide (5.5 g) as a solid.
- Phenyltrimethylammonium tribromide (44 g) was added to a mixture of 1-[4-chloro-3-(trifluoromethyl)phenyl]ethanone (25 g) and tetrahydrofuran (300 mL), and the reaction mixture was stirred at room temperature for 2 hours. The insoluble materials were separated by filtration, and the filtrate was concentrated under reduced pressure. The obtained compound and ethanol (300 mL) were mixed, and thiourea (10 g) was added to the mixture, and then was stirred at 80°C for 5 hours. The reaction mixture was cooled to room temperature, and the precipitated solid was collected by filtration. The filtrate was concentrated under reduced pressure, and the precipitated solid was washed with ethyl acetate, and was collected by filtration. This solid was combined with the solid which was previously collected by filtration, and the combined solid was dispersed into ethyl acetate and a saturated aqueous sodium hydrogen carbonate solution so as to extract with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The obtained solid was washed with hexane, collected by filtration, and dried to obtain 4-[4-chloro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-amine (24 g) as a solid.
- Methyl (piperidin-4-yl-oxy)acetate hydrochloride (151 mg) and N,N-diisopropylethylamine (0.60 mL) were sequentially added to a mixture of 4,6-dichloro-5-fluoropyrimidine (120 mg) and NMP (1.8 mL), and then the reaction mixture was stirred at 80°C for 2 hours. The reaction liquid was diluted with ethyl acetate, and washed with water. The organic layer was dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain methyl {[1-(6-chloro-5-fluoropyrimidin-4-yl)piperidin-4-yl]oxy}acetate (217 mg) as an oil.
- 1 M aqueous sodium hydroxide solution (1.7 mL) was added to a mixture of ethyl 3-[(2S)-4-{6-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}-2-(methoxymethyl)piperazin-1-yl]propanoate (192 mg), ethanol (1.0 mL), and tetrahydrofuran (1.0 mL), and the reaction mixture was stirred at room temperature for 2 hours. To the reaction mixture was added 1 M hydrochloric acid (1.7 mL) for neutralization, followed by extraction with chloroform-isopropanol (4:1). The organic layer was dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. Tetrahydrofuran (5.0 mL) and 4 M hydrogen chloride dioxane solution (0.28 mL) were added to the residue. The mixture was concentrated under reduced pressure to obtain 3-[(2S)-4-{6-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}-2-(methoxymethyl)piperazin-1-yl]propanoic acid trihydrochloride (160 mg) as a solid.
- A mixture of ethyl 3-(4-{2-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-3-fluoropyridin-4-yl}piperazin-1-yl)propanoate (137 mg), tetrahydrofuran (3.0 mL), ethanol (3.0 mL), and 1 M aqueous sodium hydroxide solution (1.2 mL) was stirred at 60°C for 2.5 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by ODS column chromatography (acetonitrile-water) to obtain sodium 3-(4-{2-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-3-fluoropyridin-4-yl}piperazin-1-yl)propanoate (103 mg) as a solid.
- A mixture of 6-chloro-N-(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)-2-methylpyrimidin-4-amine (453 mg), N,N-diisopropylethylamine (2.0 mL), ethyl 3-(piperazin-1-yl)propanoate dihydrochloride (750 mg), and NMP (10 mL) was stirred at 80°C for 1 hour. N,N-diisopropylethylamine (2.0 mL) and ethyl 3-(piperazin-1-yl)propanoate dihydrochloride (750 mg) were added to the reaction mixture, and the reaction mixture was stirred at 80°C overnight. Water and ethyl acetate were added to the reaction liquid so as to separate the organic layer. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain ethyl 3 -(4-{6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl}piperazin-1-yl)propanoate as a solid.
- 1 M aqueous sodium hydroxide solution (5.0 mL) was added to a mixture of the obtained solid, tetrahydrofuran (5.0 mL), and ethanol (5.0 mL), and the reaction mixture was stirred at 60°C for 1 hour. 1 M hydrochloric acid (5.0 mL), chloroform, and methanol were added to the reaction mixture so as to separate the organic layer. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform-methanol) twice to obtain a solid. 4 M hydrogen chloride dioxane solution (0.70 mL) was added to a mixture of the obtained solid and ethyl acetate, and the mixture was concentrated under reduced pressure. The residue was washed with ethyl acetate, and dried over under the reduced pressure to obtain 3-(4-{6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methyl pyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl}piperazin-1-yl)propanoic acid trihydrochloride (525 mg) as a solid.
- Amixture of 6-chloro-N-(5-{[(2R,5R)-2,5-dimethyl pyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)-5-fluoro-2-methylpyrimidin-4-amine (392 mg), ethyl 3-(piperazin-1-yl)propanoate dihydrochloride (590 mg), N,N-diisopropylethylamine (1.3 mL), and NMP (6.0 mL) was stirred at 80°C for 2 hours. The reaction mixture was cooled to room temperature, and then water and ethyl acetate were added thereto. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) twice to obtain ethyl 3-(4-{6-[(5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)amino]-5-fluoro-2-methylpyrimidin-4-yl}piperazin-1-yl)propanoate as an oil (243 mg).
- 1 M aqueous sodium hydroxide solution (2.0 mL) was added to a mixture of the obtained oil (243 mg) and ethanol (4.0 mL) and tetrahydrofuran (4.0 mL), and the reaction mixture was stirred at 50°C for 30 minutes. The reaction mixture was cooled to room temperature, and then concentrated under reduced pressure. The residue was purified by ODS column chromatography (acetonitrile-water) to obtain sodium 3-(4-{6-[(5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)amino]-5-fluoro-2-methylpyrimidin-4-yl}piperazin-1-yl)propanoate (149 mg) as a solid.
- A mixture of tert-butyl 3-(4-{3-fluoro-2-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyridin-4-yl}piperazin-1-yl)propanoate (387 mg), and 4 M hydrogen chloride dioxane solution (18 mL) was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure. The obtained residue was washed with ethyl acetate, and was dried over under reduced pressure to obtain 3-(4-{3-fluoro-2-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyridin-4-yl}piperazin-1-yl)propanoic acid trihydrochloride (394 mg) as a solid.
- A mixture of tert-butyl 4-(2-chloropyridin-4-yl)piperazine-1-carboxylate (300 mg), 4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-amine (322 mg), (9,9-dimethyl-9H-xanthene-4,5-diyl) bis(diphenylphosphine) (500 mg), cesium carbonate (1.2 g), tris(dibenzylideneacetone) dipalladium (400 mg), toluene (7.0 mL), and water (0.70 mL) was stirred at 100°C for 4 hours under argon atmosphere. The reaction mixture was cooled to room temperature, and then to the reaction mixture was added water and ethyl acetate, followed by extraction with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain an oil (412 mg).
- 4 M hydrogen chloride dioxane solution (6.0 mL) was added to a mixture of the obtained oil (412 mg) and tetrahydrofuran (1.0 mL), and then was stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure, and to the obtained residue was added a saturated aqueous sodium hydrogen carbonate solution, followed by extraction with chloroform-isopropanol. The organic layer was dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform-methanol) to obtain an oil (323 mg).
- Ethyl acrylate (0.13 mL) was added to a mixture of the obtained oil (323 mg) and ethanol (5.0 mL), and then was stirred at 100°C for 30 minutes in a sealed tube under microwave irradiation. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by basic silica gel column chromatography (hexane-ethyl acetate) to obtain ethyl 3-(4-{2-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyridin-4-yl}piperazin-1-yl)propanoate as an oil (168 mg).
- 1 M aqueous sodium hydroxide solution (1.5 mL) was added to a mixture of the obtained oil (168 mg) and ethanol (2.0 mL) and tetrahydrofuran (2.0 mL), and then was stirred at 50°C for 30 minutes. The reaction mixture was cooled to room temperature, and then to the reaction mixture was added 1 M hydrochloric acid (1.5 mL) and water (20 mL), followed by extraction with chloroform-isopropanol. The organic layer was dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. 4 M hydrogen chloride dioxane solution (2.0 mL) was added to a mixture of the obtained residue and tetrahydrofuran (20 mL), and then concentrated under reduced pressure. Acetonitrile and water were added to the residue, and the obtained solid was collected by filtration, was washed with acetonitrile, and then dried at 50°C under the reduced pressure to obtain 3-(4-{2-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyridin-4-yl}piperazin-1-yl)propanoic acid trihydrochloride (118 mg) as a solid.
- 1 M aqueous sodium hydroxide solution (1.5 mL) was added to a mixture of ethyl 3-(4-{5-fluoro-6-[(4-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperazin-1-yl)propanoate (325 mg) and methanol (3.0 mL), and the reaction mixture was stirred at room temperature for 3 hours. Acetic acid (0.086 mL) was added to the reaction mixture. To the obtained mixture was added water and chloroform-isopropanol (3: 1), followed by stirring. The organic layer was separated, and the aqueous layer was extracted with chloroform-isopropanol (3:1). The organic layers were combined, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure. To the residue was added acetonitrile (5.0 mL), followed by stirring at room temperature for 1 hour. The solid was collected by filtration, and then was dried over under reduced pressure to obtain 3-(4-{5-fluoro-6-[(4-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperazin-1-yl)propanoic acid (270 mg) as a solid.
- Amixture of 6-chloro-N-(5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)-5-fluoropyrimidin-4-amine (373 mg), ethyl 3-(piperazin-1-yl)propanoate dihydrochloride (580 mg), N,N-diisopropylethylamine (1.3 mL), and NMP (6.0 mL) was stirred at 80°C for two hours. The reaction mixture was cooled to room temperature, and then water and ethyl acetate were added thereto. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) twice to obtain ethyl 3-(4-{6-[(5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperazin-1-yl)propanoate (257 mg) as an oil.
- 1 M aqueous sodium hydroxide solution (2.0 mL) was added to a mixture of the obtained oil (257 mg), ethanol (4.0 mL), and tetrahydrofuran (4.0 mL) was stirred at 50°C for 30 minutes. The reaction mixture was cooled to room temperature, and then concentrated under reduced pressure. The residue was purified by ODS column chromatography (acetonitrile-water) to obtain sodium 3-(4-{6-[(5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperazin-1-yl)propanoate (189 mg) as a solid.
- 1 M aqueous sodium hydroxide solution (1.0 mL) was added to a mixture of ethyl 3-(4-{6-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperazin-1-yl)propanoate (195 mg), ethanol (1.0 mL), and tetrahydrofuran (2.0 mL), and the reaction mixture was stirred at room temperature for 3.5 hours. The reaction mixture was diluted with ice-water containing 1 M hydrochloric acid (1.1 mL) and a saturated aqueous ammonium chloride solution and was extracted with ethyl acetate-isopropanol (4:1). The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. To the residue was added to tetrahydrofuran (8.0 mL) and 4 M hydrogen chloride dioxane solution (1.0 mL), followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure, and the obtained residue was washed with diethyl ether, and dried over under reduced pressure to obtain 3-(4-{6-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperazin-1-yl)propanoic acid trihydrochloride (193 mg) as a solid.
- 1 M aqueous sodium hydroxide solution (1.6 mL) was added to a mixture of ethyl 3-[(2S)-4-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}-2-(methoxymethyl)piperazin-1-yl]propanoate (172 mg), ethanol (1.4 mL), and tetrahydrofuran (1.4 mL), and the reaction mixture was stirred at 60°C for one hour. To the reaction mixture was added 1 M hydrochloric acid (1.6 mL) for neutralization, followed by extraction with chloroform-isopropanol (4:1). The organic layer was dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. Tetrahydrofuran (5.0 mL) and 4 M hydrogen chloride dioxane solution (0.25 mL) were added to the residue. The mixture was concentrated under reduced pressure to obtain 3-[(2S)-4-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}-2-(methoxymethyl)piperazin-1-yl]propanoic acid trihydrochloride (180 mg) as a solid.
- 1 M aqueous sodium hydroxide solution (0.75 mL) was added to a mixture of ethyl 3-(4-{6-[(4-[3-chloro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperazin-1-yl)propanoate (150 mg), ethanol (0.75 mL), and tetrahydrofuran (1.5 mL), and the reaction mixture was stirred at room temperature for 3.5 hours. The reaction mixture was diluted with ice-water containing 1 M hydrochloric acid (0.75 mL) and a saturated aqueous ammonium chloride solution and was extracted with chloroform-isopropanol (4:1). The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. Tetrahydrofuran (4.0 mL) and 4 M hydrogen chloride dioxane solution (0.75 mL) were added to the residue under an argon atmosphere, and the reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure to obtain 3-(4-{6-[(4-[3-chloro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperazin-1-yl)propanoic acid trihydrochloride (152 mg) as a solid.
- 1 M aqueous sodium hydroxide solution (0.58 mL) was added to a mixture of methyl [(1-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperidin-4-yl)oxy]acetate (57 mg), ethanol (0.42 mL), and tetrahydrofuran (0.42 mL), and the reaction mixture was stirred at 60°C for 1 hour. To the reaction mixture was added 1 M hydrochloric acid (0.58 mL) for neutralization, followed by extraction with chloroform-isopropanol (4:1). The organic layer was dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. Tetrahydrofuran (5.0 mL) and 4 M hydrogen chloride dioxane solution (0.090 mL) were added to the residue. The mixture was concentrated under reduced pressure to obtain [(1-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperidin-4-yl)oxy]acetic acid dihydrochloride (60 mg) as a solid.
- 1 M aqueous sodium hydroxide solution (1.3 mL) was added to a mixture of ethyl [(1-{6-[(4-[3-chloro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperidin-4-yl)oxy]acetate (172 mg), ethanol (2.0 mL), and tetrahydrofuran (2.0 mL), and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was purified by ODS column chromatography (0.1% formic acid-acetonitrile). Tetrahydrofuran (4.0 ml) and 4 M hydrogen chloride dioxane solution (0.70 ml) were added to the obtained residue. The reaction mixture was concentrated under reduced pressure, and the obtained residue was washed with diethyl ether, and then was dried over under reduced pressure to obtain [(1-{6-[(4-[3-chloro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperidin-4-yl)oxy]acetic acid dihydrochloride (34 mg) as a solid.
- Compounds of Preparation Examples and Examples, which were indicated in the following tables, were produced by using the same method as that of the Preparation Examples or Examples.
[Table 5] PEx PSyn Str DAT 1 1 ESI+: 518, 520 2 2 APCI/ESI+: 654 3 3 APCI/ESI+: 654 [Table 6] PEx PSyn Str DAT 4 4 ESI-: 698, 700 5 5 APCI/ESI+: 667 6 6 ESI+: 653 7 7 APCI/ESI+: 656 [Table 7] PEx PSyn Str DAT 8 8 APCI/ESI+: 655 9 9 APCI/ESI+: 555 10 10 ESI+: 584 11 11 ESI+: 376, 378 [Table 8] PEx PSyn Str DAT 12 12 ESI+: 360 13 13 ESI+: 374 14 14 ESI+: 402 [Table 9] PEx PSyn Str DAT 15 15 ESI+: 416 16 16 ESI+: 418, 420 17 17 ESI+: 377 18 18 APCI/ESI+: 409 [Table 10] PEx PSyn Str DAT 19 19 ESI+: 305 20 20 APCI/ESI+: 378 21 21 ESI+: 263 22 22 ESI+: 361, 363 23 23 ESI+: 316, 318 24 24 APCI/ESI+: 349 [Table 11] PEx PSyn Str DAT 25 25 ESI+: 331 26 26 ESI+: 308 [(M+Na)+] 27 27 NMR-CDCl3: 1.26 (3 H, t, J = 7.2 Hz), 1.46 (9 H, s), 1.83 - 2.04 (2 H, m), 2.55 (2 H, t, J = 6.5 Hz), 3.30 - 3.47 (4 H, m), 3.65 - 3.75 (2 H, m), 3.99 - 4.07 (1 H, m), 4.15 (2 H, q, J = 7.2 Hz) 28 28 ESI+: 319 29 29 ESI+: 317 30 30 ESI+: 201 [Table 12] PEx PSyn Str DAT 31 31 ESI+: 231 32 32 ESI+: 215 33 33 EI+: 228[M+] 34 34 ESI+: 237 35 35 ESI+: 220 36 36 ESI+: 504, 506 [Table 13] PEx PSyn Str DAT 37 1 ESI+: 472, 474 38 1 ESI+: 486, 488 39 1 APCI/ESI+: 502, 504 [Table 14] PEx PSyn Str DAT 40 1 APCI/ESI+: 504 41 1 APCI/ESI+: 490 42 1 ESI+: 488, 490 [Table 15] PEx PSyn Str DAT 43 1 ESI+: 468, 470 44 1 ESI+: 484, 486 45 1 ESI+: 502, 504 46 1 ESI+: 474, 476 [Table 16] PEx PSyn Str DAT 47 1 ESI+: 492, 494 48 1 ESI+: 492, 494 49 1 ESI+: 500, 502 50 1 APCI/ESI+: 502 [Table 17] PEx PSyn Str DAT 51 1 APCI/ESI+: 515 52 1 APCI/ESI+: 504 53 1 ESI+: 502, 504 [Table 18] PEx PSyn Str DAT 54 1 APCI/ESI+: 478 55 1 ESI+: 522, 524 56 1 APCI/ESI+: 524 57 1 ESI+: 522, 524 [Table 19] PEx PSyn Str DAT 58 1 APCI/ESI+: 506, 508 59 1 ESI+: 406, 408 60 1 ESI+: 407, 409 61 1 APCI/ESI+: 393 [Table 20] PEx PSyn Str DAT 62 62 ESI+: 265 63 2 APCI/ESI+: 652 64 2 ESI+: 641 65 2 ESI+: 628 [Table 21] PEx PSyn Str DAT 66 2 ESI+: 672, 674 67 2 APCI/ESI+: 674 68 2 ESI+: 686, 688 69 2 APCI/ESI+: 557 [Table 22] PEx PSyn Str DAT 70 2 APCI/ESI+: 543 71 2 ESI+: 556 72 3 ESI+: 622 73 3 ESI+: 636 [Table 23] PEx PSyn Str DAT 74 3 ESI+: 650 75 3 ESI+: 622 76 3 APCI/ESI-: 638 [Table 24] PEx PSyn Str DAT 77 3 ESI+: 650 78 3 ESI+: 636 79 5 APCI/ESI+: 655 [Table 25] PEx PSyn Str DAT 80 3 ESI+: 621 81 3 APCI/ESI+: 665 82 3 ESI+: 621 [Table 26] PEx PSyn Str DAT 83 3 ESI+: 637 84 3 ESI+: 623 85 3 APCI/ESI+: 656 [Table 27] PEx PSyn Str DAT 86 4 ESI+: 654 87 4 ESI+: 654 88 4 ESI-: 654 [Table 28] PEx PSyn Str DAT 89 4 ESI+: 670, 672 90 4 ESI+: 670 91 4 ESI+: 627 92 4 APCI/ESI+: 628 [Table 29] PEx PSyn Str DAT 93 4 ESI+: 670 94 4 ESI+: 684 95 4 ESI+: 670 [Table 30] PEx PSyn Str DAT 96 4 ESI+: 668 97 4 ESI+: 672 98 4 APCI/ESI+: 667 99 4 ESI+: 656 [Table 31] PEx PSyn Str DAT 100 4 APCI/ESI+: 669 101 4 ESI-: 682 102 5 APCI/ESI-: 660 103 5 APCI/ESI+: 672 [Table 32] PEx PSyn Str DAT 104 104 ESI+: 627 105 4 ESI+: 670, 672 106 4 ESI+: 684, 686 [Table 33] PEx PSyn Str DAT 107 4 ESI+: 684 108 4 ESI+: 641 109 4 ESI-: 668, 670 [Table 34] PEx PSyn Str DAT 110 4 ESI+: 700 111 4 APCI/ESI+: 668 112 4 APCI/ESI+: 668 113 4 ESI+: 672 [Table 35] PEx PSyn Str DAT 114 4 ESI+: 688, 690 115 4 ESI+: 670, 672 116 4 ESI+: 684, 686 117 4 ESI+: 672 [Table 36] PEx PSyn Str DAT 118 4 ESI+: 684, 686 119 4 ESI-: 682, 684 120 4 ESI+: 670, 672 121 4 ESI+: 657, 659 [Table 37] PEx PSyn Str DAT 122 4 ESI+: 671, 673 123 4 ESI+: 698 124 4 ESI+: 714, 716 125 4 ESI+: 671, 673 [Table 38] PEx PSyn Str DAT 126 4 ESI-: 712, 714 127 4 ESI-: 698 128 4 ESI+: 714 [Table 39] PEx PSyn Str DAT 129 4 ESI+: 714, 716 130 5 ESI+: 642 131 4 ESI+: 670, 672 132 4 ESI+: 684, 686 [Table 40] PEx PSyn Str DAT 133 4 ESI-: 682, 684 134 4 APCI/ESI+: 714 135 135 ESI+: 662 136 4 ESI+: 670 [Table 41] PEx PSyn Str DAT 137 4 ESI+: 686 138 5 ESI-: 638 139 5 APCI/ESI+: 681 140 5 ESI+: 624 [Table 42] PEx PSyn Str DAT 141 5 APCI/ESI+: 653 142 5 APCI/ESI+: 653 143 6 APCI/ESI+: 668 [Table 43] PEx PSyn Str DAT 144 6 APCI/ESI+: 668 145 6 APCI/ESI+: 668 146 6 ESI+: 667 [Table 44] PEx PSvn Str DAT 147 6 ESI+: 667 148 8 ESI+: 621 149 8 ESI+: 685 [Table 45] PEx PSyn Str DAT 150 8 APCI/ESI+: 653 151 8 APCI/ESI+: 653 152 152 ESI+: 521 [Table 46] PEx PSyn Str DAT 153 9 APCI/ESI+: 553 154 9 APCI/ESI+: 553 155 11 ESI+: 390, 392 156 11 APCI/ESI+: 390 [Table 47] PEx PSvn Str DAT 157 11 APCI/ESI+: 382 158 11 ESI+: 348 159 11 ESI+: 360 160 11 ESI+: 348 [Table 48] PEx PSyn Str DAT 161 11 ESI+: 390, 392 162 11 ESI+: 390, 392 163 11 ESI+: 390, 392 164 11 APCI/ESI+: 392, 394 [Table 49] PEx PSyn Str DAT 165 11 ESI+: 390, 392 166 12 ESI+: 372 167 12 ESI+: 376, 378 168 12 ESI+: 374 [Table 50] PEx PSyn Str DAT 169 12 ESI+: 356 170 12 NMR-DMSO-d6: 1.11 (3H, d, J = 6 Hz), 1.30 - 1.41 (1H, m), 1.59 - 1.69 (2H, m), 1.87 - 1.98 (1H, m), 2.05 - 2.15 (1H, m), 2.35 - 2.45 (1H, m), 2.94 - 3.02 (1H, m), 3.18 (1H, d, J = 14Hz), 3.97 (3H, d, J = 2 Hz), 3.98 (1H, d, J = 14 Hz), 6.98 (2H, brs), 7.85 - 7.89 (1H, m), 8.02 (1H,dd, J = 13,2Hz) [Table 51] PEx PSyn Str DAT 171 12 ESI+: 420, 422 172 15 ESI+: 432 173 15 ESI+: 414 174 15 ESI+: 416 [Table 52] PEx PSyn Str DAT 175 15 ESI+: 424 176 15 ESI+: 398 177 15 APCI/ESI+: 432 [Table 53] PEx PSyn Str DAT 178 15 ESI+: 462, 464 179 15 ESI+: 432, 434 180 15 ESI+: 390 181 15 ESI+: 402 [Table 54] PEx PSyn Str DAT 182 15 ESI+: 390 183 15 ESI+: 432, 434 184 15 ESI+: 432, 434 185 15 ESI+: 432, 434 [Table 55] PEx PSyn Str DAT 186 15 APCI/ESI+: 434 187 15 ESI+: 432, 434 188 16 ESI+: 418, 420 189 189 ESI+: 393, 395 [Table 56] PEx PSyn Str DAT 190 17 ESI+: 389 191 17 ESI+: 393, 395 192 17 ESI+: 373 193 17 ESI+: 399 194 17 APCI/ESI+: 407 [Table 57] PEx PSyn Str DAT 195 17 ESI+: 437, 439 196 196 ESI+: 321, 323 197 19 ESI+: 317 198 19 ESI+: 321 199 19 ESI+: 301 [Table 58] PEx PSyn Str DAT 200 19 ESI+: 327 201 19 ESI+: 335 202 19 ESI+: 365, 367 203 19 APCI/ESI+: 337 204 20 APCI/ESI+: 376 [Table 59] PEx PSyn Str DAT 205 20 ESI+: 392, 394 206 20 ESI+: 392, 394 207 20 APCI/ESI+: 376 208 20 APCI/ESI+: 334 [Table 60] PEx PSyn Str DAT 209 20 APCI/ESI+: 394 210 20 APCI/ESI+: 348 211 20 ESI+: 387 212 20 APCI/ESI+: 389 [Table 61] PEx PSyn Str DAT 213 213 ESI+: 279, 281 214 21 ESI+: 279, 281 215 21 ESI+: 295, 297 216 21 ESI+: 275 217 21 ESI+: 285 218 21 ESI+: 293 [Table 62] PEx PSyn Str DAT 219 21 ESI+: 259 220 21 ESI+: 323, 325 221 21 ESI+: 276 222 22 ESI+: 317, 319 223 22 ESI+: 331, 333 [Table 63] PEx PSyn Str DAT 224 22 ESI+: 347, 349 225 22 ESI+: 304, 306 226 22 ESI+: 331, 333 227 22 ESI+: 331, 333 228 228 ESI+: 304, 306 229 22 ESI+: 349, 351 230 22 ESI+: 361 [Table 64] PEx PSyn Str DAT 231 22 ESI+: 361, 363 232 22 ESI+: 349, 351 233 22 ESI+: 349, 351 234 22 ESI+: 318, 320 235 22 APCI/ESI+: 303 236 22 ESI+: 347, 349 [Table 65] PEx PSyn Str DAT 237 22 ESI+: 347, 349 238 23 ESI+: 344, 346 239 23 ESI+: 330, 332 240 23 ESI+: 330, 332 241 23 ESI+: 298, 300 242 24 ESI+: 301 [Table 66] PEx PSyn Str DAT 243 24 ESI+: 301 244 24 ESI+: 301 245 24 ESI+: 317 246 24 ESI+: 317 247 25 ESI+: 331 248 25 ESI+: 317 249 28 ESI+: 319 250 28 ESI+: 319 [Table 67] PEx PSyn Str DAT 251 29 ESI+: 317 252 30 ESI+: 201 253 31 CI+: 201 254 31 ESI+: 188 255 31 ESI+: 219 256 31 ESI+: 231 257 31 ESI+: 219 [Table 68] PEx PSyn Str DAT 258 31 ESI+: 219 259 31 ESI+: 217 260 31 ESI+: 217 261 31 ESI+: 217 262 34 EI+: 202[M+] [Table 69] Ex Str 1 2 3 [Table 70] Ex Str 4 5 6 [Table 71] Ex Str 7 8 9 [Table 72] Ex Str 10 11 12 [Table 73] Ex Str 13 14 15 16 [Table 74] Ex Str 17 18 19 [Table 75] Ex Str 20 21 22 23 [Table 76] Ex Str 24 25 26 [Table 77] Ex Str 27 28 29 [Table 78] Ex Str 30 31 32 33 [Table 79] Ex Str 34 35 36 37 [Table 80] Ex Str 38 39 40 41 [Table 81] Ex Str 42 43 44 45 [Table 82] Ex Str 46 47 48 49 [Table 83] Ex Str 50 51 52 53 [Table 84] Ex Str 54 55 56 57 [Table 85] Ex Str 58 59 60 61 [Table 86] Ex Str 62 63 64 65 [Table 87] Ex Str 66 67 68 69 [Table 88] Ex Str 70 71 72 [Table 89] Ex Str 73 74 75 [Table 90] Ex Str 76 77 78 79 [Table 91] Ex Str 80 81 82 83 [Table 92] Ex Str 84 85 86 [Table 93] Ex Str 87 88 89 90 [Table 94] Ex Str 91 92 93 94 [Table 95] Ex Str 95 96 97 98 [Table 96] Ex Str 99 100 101 [Table 97] Ex Str 102 [Table 98] Ex Syn DAT 1 1 ESI+: 672 NMR-DMSO-d6: 1.29 - 1.40 (3H, m), 1.52 - 1.71 (1H, m), 1.82 - 1.97 (2H, m), 2.11 - 2.23 (1H, m), 2.72 - 2.92 (2H, m), 2.99 - 3.18 (1H, m), 3.18 - 3.95 (16H, m), 4.21 - 4.59 (3H, m), 4.71 - 4.81 (1H, m), 7.87 (1H, d, J = 8.4 Hz), 8.03 (1H, dd, J = 8.3, 1.9 Hz), 8.15 (1H, d, J = 1.9 Hz), 8.31 (1H, s), 10.36 (1H, brs), 10.74 (1H, brs), 12.02 (1H, brs) 2 2 ESI-: 625, 627 3 3 ESI+: 608 NMR-DMSO-d6: 1.38 (3H, d, J=6.4 Hz), 1.60 - 1.74 (1H, m), 1.85 - 1.96 (2H, m), 2.10 - 2.24 (1H, m), 2.48 (3H, s), 2.88 (2H, t, J = 7.6 Hz), 3.00 - 3.18 (3H, m), 3.30 - 3.46 (5H, m), 3.49 - 3.62 (3H, m), 3.70 - 4.20 (2H, m), 4.28 - 4.48 (3H, m), 4.70 - 4.80 (1H, m), 6.14 (1H, s), 7.76 - 7.82 (1H, m), 7.87 - 7.96 (2H, m), 10.65 (1H, brs), 11.26 (1H, brs), 11.75 (1H, brs) 4 4 ESI-: 638 NMR-DMSO-d6: 0.97 (6H, d, J = 6.2 Hz), 1.28 - 1.39 (2H, m), 1.89 - 2.01 (2H, m), 2.07 - 2.13 (2H, m), 2.34 (3H, s), 2.38 - 2.58 (7H, m), 3.00 - 3.10 (2H, m), 3.50 - 3.60 (4H, m), 3.67 (1H, d, J = 14.4 Hz), 3.96 (1H, d, J = 14.4 Hz), 7.55 - 7.61 (1H, m), 8.06 - 8.15 (2H, m) 5 5 ESI+: 611 NMR-DMSO-d6: 1.38 (3H, d, J = 6.4 Hz), 1.58 - 1.74 (1H, m), 1.85 - 1.97 (2H, m), 2.10 - 2.23 (1H, m), 2.91 (2H, t, J = 7.7 Hz), 3.09 - 3.28 (3H, m), 3.30 - 3.64 (8H, m), 3.64 - 4.30 (4H, m), 4.38 - 4.48 (1H, m), 4.66 - 4.79 (1H, m), 6.80 (1H, t, J = 6.0 Hz), 7.76 - 7.82 (1H, m), 7.90 - 8.01 (3H, m), 10.70 (1H, brs), 11.20 - 11.90 (2H, m) 6 6 ESI-: 607, 609 [Table 99] Ex Syn DAT 7 7 ESI+: 625 NMR-DMSO-d6: 1.11 (3H, d, J = 6.2 Hz), 1.29 - 1.47 (1H, m), 1.56 - 1.70 (2H, m), 1.87 - 2.02 (1H, m), 2.05 - 2.20 (1H, m), 2.37 - 2.46 (3H, m), 2.55 - 2.62 (2H, m), 2.94 - 3.02 (1H, m), 3.21 - 3.41 (5H, m), 3.62 - 3.70 (4H, m), 4.04 (3H, s), 4.11 - 4.18 (1H, m), 8.20 (1H, d, J = 1.5 Hz), 8.51 (1H, d, J = 2.2 Hz), 8.80 (1H, d, J = 1.8 Hz), 11.42 (1H, brs), 12.23 (1H, brs) 8 8 ESI-: 624 NMR-DMSO-d6: 0.94 (6H, d, J = 6.2 Hz), 1.27 - 1.37 (2H, m), 1.90 - 2.01 (2H, m), 2.11 - 2.17 (2H, m), 2.41 - 2.55 (6H, m), 3.00 - 3.08 (2H, m), 3.52 - 3.61 (4H, m), 3.69 (1H, d, J = 14.4 Hz), 3.99 (1H, d, J = 14.4 Hz), 7.54 - 7.61 (1H, m), 7.99 - 8.14 (3H, m) 9 9 ESI+: 628, 630 NMR-DMSO-d6: 1.35 - 1.40 (3H, m), 1.59 - 1.72 (1H, m), 1.85 - 1.98 (2H, m), 2.12 - 2.22 (1H, m), 2.88 (2H, t, J = 8.0 Hz), 3.05 - 3.64 (12H, m), 4.38 - 4.48 (3H, m), 4.71 - 4.77 (1H, m), 7.87 (1H, d, J = 8.4 Hz), 8.06 (1H, dd, J = 8.3, 2.0 Hz), 8.17 (1 H, d, J = 2.0 Hz), 8.31 (1H, d, J = 1.6 Hz), 10.67 (1H, brs), 11.47 (1H, brs), 12.03 (1H, brs) 10 10 ESI+: 656 NMR-DMSO-d6: 1.36 (3H, d, J = 6.2 Hz), 1.55 - 1.71 (1H, m), 1.83 - 1.98 (2H, m), 2.08 - 2.26 (1H, m), 2.76 - 2.91 (2H, m), 3.05 - 3.19 (1H, m), 3.20 - 4.03 (16H, m), 4.31 - 4.55 (3H, m), 4.70 - 4.85 (1H, m), 7.74 - 7.88 (1H, m), 7.90 - 7.96 (2H, m), 8.31 (1H, s), 10.45 (1H, brs), 10.73 (1H, brs), 12.01 (1H, brs) [Table 100] Ex Syn DAT 11 11 ESI-:626, 628 NMR-DMSO-d6: 1.41 (3H, d, J = 6.4 Hz), 1.61 - 1.74 (1H, m), 1.88 - 1.98 (2H, m), 2.14 - 2.24 (1H, m), 2.88 (2H, t, J = 7.7 Hz), 3.10 - 3.65 (13H, m), 4.38 - 4.49 (3H, m), 4.71 - 4.78 (1H, m), 7.97 (1H, s), 8.08 (1H, s), 8.19 (1H, s), 8.31 (1H, d, J = 1.6 Hz), 10.84 (1H, brs), 11.51 (1H, brs), 12.02 (1H, brs) 12 12 ESI+: 613 NMR-DMSO-d6: 1.34 (3H, d, J = 6.4 Hz), 1.47 - 1.70 (3H, m), 1.82 - 2.01 (4H, m), 2.13 - 2.23 (1H, m), 3.05 - 3.15 (1H, m), 3.34 - 3.73 (7H, m), 3.97 - 4.07 (2H, m), 4.08 (2H, s), 4.46 (1H, dd, J = 14.8, 7.9 Hz), 4.75 - 4.85 (1H, m), 7.79 - 7.84 (1H, m), 7.86 - 7.93 (2H, m), 8.22 (1H, d, J = 1.5 Hz), 9.97 (1H, brs), 11.83 (1H, brs) 13 13 ESI+: 643, 645 NMR-DMSO-d6: 0.84 (3H, t, J = 7.4 Hz), 1.46 - 1.68 (4H, m), 1.77 - 1.99 (5H, m), 2.11 - 2.23 (1H, m), 3.10 - 3.29 (2H, m), 3.34 - 3.73 (6H, m), 3.98 - 4.07 (2H, m), 4.08 (2H, s), 4.48 (1H, dd, J = 15.0,7.5 Hz), 4.77 (1H, dd, J = 14.7, 1.9 Hz), 7.98 (1H, s), 8.03 (1H, s), 8.12 (1H, s), 8.22 (1H, d, J= 1.5 Hz), 10.17 - 10.28 (1H, m), 11.83 (1H, brs) 14 1 ESI+: 594 NMR-DMSO-d6: 1.38 (3H, d, J = 6.4 Hz), 1.60 - 1.72 (1H, m), 1.85 - 1.97 (2H, m), 2.11 - 2.23 (1H, m), 2.89 (2H, t, J = 7.7 Hz), 3.02 - 3.20 (3H, m), 3.28 - 3.63 (8H, m), 3.85 - 4.49 (5H, m.), 4.73 (1H, dd, J = 14.8, 2.0 Hz), 6.33 (1H, s), 7.76 - 7.82 (1H, m), 7.89 - 7.97 (2H, m), 8.46 - 8.49 (1H, m), 10.62 - 10.72 (1H, m), 11.42 (1H, brs), 11.85 (1 H, brs) 15 1 ESI+: 622 16 1 ESI+: 594 [Table 101] Ex Syn DAT 17 1 ESI+: 612 NMR-DMSO-d6: 1.38 (3H, d, J = 6.4 Hz), 1.60 - 1.74 (1H, m), 1.84 - 1.97 (2H, m), 2.12 - 2.22 (1H, m), 2.88 (2H, t, J = 7.7 Hz), 3.06 - 3.24 (3H, m), 3.27 - 3.36 (2H, m), 3.36 - 3.48 (1H, m), 3.48 - 3.64 (5H, m), 3.90 - 4.38 (2H, m), 4.38 - 4.50 (3H, m), 4.70 - 4.80 (1H, m), 7.77 - 7.83 (1H, m), 7.90 - 8.02 (2H, m), 8.31 (1H, d, J = 1.4 Hz), 10.60 - 10.80 (1H, m), 11.45 (1H, brs), 12.01 (1H, brs) 18 1 ESI+: 626 NMR-DMSO-d6: 1.39 (3H, d, J = 6.4 Hz), 1.62 - 1.74 (1H, m), 1.85 - 1.97 (2H, m), 2.10 - 2.22 (1H, m), 2.48 (3H, s), 2.88 (2H, t, J = 7.7 Hz), 3.05 - 3.22 (3H, m), 3.26 - 3.36 (2H, m), 3.36 - 3.62 (6H, m), 4.00 - 4.55 (5H, m), 4.70 - 4.80 (1H, m), 7.77 - 7.83 (1H, m), 7.89 - 7.99 (2H, m), 10.85 - 10.98 (1H, m), 11.44 (1H, brs), 11.92 (1H, brs) 19 1 ESI+: 593 NMR-DMSO-d6: 1.38 (3H, d, J = 6.4 Hz), 1.60 -1.74 (1H, m), 1.85 - 1.96 (2H, m), 2.10 - 2.23 (1H, m), 2.90 (2H, t, J = 7.7 Hz), 3.04 - 3.25 (3H, m), 3.29 - 3.68 (8H, m), 3.92 - 5.20 (2H, m), 4.41 (1H, dd, J = 14.9, 7.8 Hz), 4.66 - 4.76 (1H, m), 6.53 - 7.00 (2H, m), 7.80 (1H, d, J = 8.6 Hz), 7.94 - 8.02 (2H, m), 8.07 (1H, d, J = 6.8 Hz), 10.89 (1H, brs), 11.59 (1H, brs) 20 1 ESI+: 608 21 1 ESI+: 622 22 1 ESI+: 608 23 3 ESI-: 588 [Table 102] Ex Syn DAT 24 1 ESI+: 607 NMR-DMSO-d6: 0.99 - 1.11 (3H, m), 1.34 (3H, d, J = 6.4 Hz), 1.43 - 1.69 (4H, m), 1.69 - 1.78 (2H, m), 1.83 - 1.97 (2H, m), 2.11 - 2.22 (1H, m), 2.26 (2H, t, J = 7.5 Hz), 2.44 (3H, s), 2.85 (2H, t, J = 11.6 Hz), 3.03 - 3.16 (1H, m), 3.29 - 3.72 (3H, m), 4.15 - 4.32 (2H, m), 4.45 (1H, dd, J = 14.8, 7.7 Hz), 4.79 (1H, dd, J = 14.9, 2.3 Hz), 6.08 (1 H, brs), 7.75 - 7.82 (1H, m), 7.83 - 7.91 (2H, m), 9.97 (1H, brs), 11.57 (1H, brs) 25 1 ESI+: 593 26 1 ESI+: 626 NMR-DMSO-d6: 1.05 (6H, d, J = 6.4 Hz), 2.42 (3H, s), 2.85 (2H, t, J = 7.6 Hz), 3.02 - 3.23 (8H, m), 3.29 - 3.41 (6H, m), 3.48 - 3.64 (2H, m), 3.94 - 4.50 (4H, m), 6.27 (1H, s), 7.54 (1H, d, J = 8.4 Hz), 8.40 (1 H, d, J = 11.3 Hz), 8.54 (1H, s), 10.82 (1H, brs), 11.30 (1H, brs) 27 1 ESI+: 624 28 1 ESI+: 609 NMR-DMSO-d6: 1.37 (3H, d, J = 6.4 Hz), 1.58 - 1.70 (1H, m), 1.84 - 1.97 (2H, m), 1.98 - 2.23 (3H, m), 2.45 (2H, t, J = 6.3 Hz), 3.04 - 3.16 (1H, m), 3.31 - 3.73 (13H, m), 4.22 (1H, brs), 4.44 (1H, dd, J = 14.9, 7.8 Hz), 4.78 (1H, dd, J = 14.8, 2.4 Hz), 5.97 (1H, brs), 7.75 - 7.84 (1H, m), 7.86 - 7.94 (2H, m), 10.37 (1H, brs), 11.79 (1H, brs) 29 1 ESI-: 610 30 1 ESI+: 609 31 1 ESI+: 626 [Table 103] Ex Syn DAT 32 1 ESI+: 644, 646 NMR-DMSO-d6: 1.40 - 1.51 (1H, m), 1.53 - 1.64 (1H, m), 1.80 - 1.94 (2H, m), 2.65 - 2.80 (2H, m), 2.84 - 2.96 (3H, m), 3.08 - 3.21 (3H, m), 3.26 (3H, s), 3.27 - 3.35 (2H, m), 3.37 - 3.44 (1H, m), 3.48 - 3.62 (4H, m), 4.35 - 4.46 (2H, m), 4.70 - 7.19 (2H, m), 7.79 (1H, d, J = 8.6 Hz), 8.25 (1H, d, J = 1.4 Hz), 8.43 (1H, dd, J = 8.5, 2.0 Hz), 8.74 (1H, d, J = 2.0 Hz), 10.90 - 12.03 (2H, m) 33 1 ESI+: 600 34 1 ESI+: 626 NMR-DMSO-d6: 1.32 - 1.40 (3H, m), 1.56 - 1.71 (1H, m), 1.83 - 1.97 (2H, m), 2.11 - 2.23 (1H, m), 2.28 - 2.46 (2H, m), 2.75 - 2.81 (3H, m), 2.83 - 2.91 (2H, m), 3.06 - 3.18 (1H, m), 3.21 - 3.33 (1H, m), 3.36 - 3.55 (3H, m), 3.59 - 3.70 (1H, m), 3.88 - 4.18 (6H, m), 4.40 - 4.49 (1H, m), 4.73 - 4.81 (1H, m), 7.78 - 7.83 (1H, m), 7.90 - 7.95 (2H, m), 8.23 (1H, d, J= 1.8 Hz), 10.34 (1H, brs), 11.23 (1H, brs), 11.88 (1H, brs) 35 1 ESI+: 642, 644 36 1 ESI-: 640, 642 37 1 ESI+: 646 38 1 ESI+: 640 39 1 ESI+: 613 NMR-DMSO-d6: 1.35 (3H, d, J = 6.6 Hz), 1.56 - 1.69 (1H, m), 1.84 - 1.97 (7H, m), 2.13 - 2.22 (1H, m), 3.04 - 3.16 (1H, m), 3.23 (3H, s), 3.34 - 3.55 (5H, m), 4.00 - 4.11 (2H, m), 4.39 - 4.50 (1H, m), 4.75 - 4.83 (1H, m), 7.77 - 7.85 (1H, m), 7.87 - 7.94 (2H, m), 8.24 (1H, d, J = 1.6 Hz), 10.06 (1H, brs), 11.84 (1H, brs) 40 1 ESI-: 640 41 1 ESI+: 640 [Table 104] Ex Syn DAT 42 1 ESI+: 639 NMR-DMSO-d6: 0.77 - 0.88 (2H, m), 1.07 - 1.27 (2H, m), 2.83 (2H, t, J = 7.5 Hz), 2.95 - 3.69 (18H, m), 4.34 - 4.52 (2H, m), 7.61 - 7.67 (1H, m), 8.24 - 8.33 (3H, m), 10.66 (1H, brs), 11.20 (1H, brs), 11.59 (1H, s), 12.74 (1H, brs) 43 1 ESI+: 642 44 1 ESI+: 640 45 1 ESI+: 644 NMR-DMSO-d6: 1.32 - 1.40 (3H, m), 1.59 - 1.71 (1H, m), 1.83 - 1.97 (2H, m), 2.12 - 2.23 (1H, m), 2.81 - 2.93 (2H, m), 3.07 - 3.18 (1H, m), 3.22 - 4.62 (14H, m), 4.72 - 4.80 (1H, m), 4.85 - 5.12 (2H, m), 7.79 - 7.83 (1H, m), 7.91 - 7.98 (2H, m), 8.32 (1H, s), 10.55 (1H, brs), 11.46 (1H, brs), 12.04 (1H, brs) 46 1 ESI+: 640 47 1 ESI+: 641 48 1 ESI+: 628 49 1 ESI+: 656 50 1 ESI-: 632 51 1 ESI-: 642, 644 NMR-DMSO-d6: 1.38 (3H, d, J = 6.4 Hz), 1.60 - 1.73 (1H, m), 1.86 - 1.96 (2H, m), 2.11 - 2.22 (1H, m), 2.88 (2H, t, J = 7.6 Hz), 3.07 - 3.23 (3H, m), 3.28 - 4.20 (10H, m), 4.37 - 4.48 (3H, m), 4.68 - 4.76 (1H, m), 7.67 - 7.72 (2H, m), 7.92 (1H, t, J = 1.7 Hz), 8.31 (1H, d, J = 1.4 Hz), 10.74 (1H, brs), 11.48 (1H, brs), 12.01 (1H, brs) 52 1 ESI+: 656 53 1 ESI+: 642 54 1 ESI+: 627 55 1 ESI+: 672 56 1 ESI+: 642 57 1 ESI-: 654, 656 58 1 ESI+: 644 [Table 105] Ex Syn DAT 59 1 ESI+: 660, 662 NMR-DMSO-d6: 1.29 - 1.43 (3H, m), 1.55 - 1.70 (1H, m), 1.83 - 2.01 (2H, m), 2.11 - 2.23 (1H, m), 2.79 - 2.91 (2H, m), 3.02 - 3.94 (13H, m), 4.18 - 4.68 (3H, m), 4.72 - 4.81 (1H, m), 4.83 - 5.13 (2H, m), 7.87 (1H, d, J = 8.2 Hz), 8.03 (1H, dd, J = 8.4,2.0 Hz), 8.15 (1H, d, J = 2.0 Hz), 8.32 (1H, s), 10.32 (1H, brs), 12.04 (1H, brs) 60 1 ESI+: 640 61 1 ESI+: 640 62 1 ESI+: 644 63 1 ESI-: 640, 642 64 1 ESI-: 654, 656 65 1 ESI-: 654, 656 66 1 ESI-: 640, 642 67 1 ESI-: 627, 629 68 1 ESI-: 641, 643 69 1 ESI+: 656 70 1 ESI+: 670 71 1 ESI-: 684, 686 72 1 ESI+: 686, 688 73 1 ESI+: 686 74 1 ESI+: 672, 674 75 1 ESI+: 686 76 1 ESI+: 642 77 1 ESI-: 612,614 NMR-DMSO-d6: 1.42 (3H, d, J = 6.4 Hz), 1.62 - 1.76 (1H, m), 1.87 - 1.99 (2H, m), 2.13 - 2.24 (1H, m), 3.14 - 3.26 (1H, m), 3.26 - 3.90 (12H, m), 4.19 (2H, s), 4.36 - 4.48 (1H, m), 4.69 - 4.78 (1H, m), 7.95 - 7.99 (1H, m), 8.06 - 8.09 (1H, m), 8.18 - 8.21 (1H, m), 8.31 - 8.33 (1H, m), 10.51 - 11.27 (2H, m), 12.01 (1H, brs) 78 1 ESI-: 654,656 79 1 ESI+: 656 80 1 ESI-: 632 [Table 106] Ex Syn DAT 81 1 ESI+: 642 82 1 ESI-: 684,686 83 1 ESI+: 658 84 2 ESI+: 637 NMR-DMSO-d6: 1.13 (3H, d, J = 6.0 Hz), 1.28 - 1.42 (1H, m), 1.58 - 1.71 (2H, m), 1.88 - 2.02 (1H, m), 2.09 - 2.23 (3H, m), 2.36 - 2.44 (3H, m), 2.96 - 3.04 (1H, m), 3.14 (6H, s), 3.21 - 3.92 (8H, m), 3.34 (1H, d, J = 14.0 Hz), 4.13 (1H, d, J = 14.0 Hz), 5.51 (1H, s), 7.58 - 7.65 (1H, m), 8.01 - 8.06 (1H, m), 8.07 (1H, s), 10.98 (1H, s) 85 2 ESI+: 613 86 2 ESI+: 642 87 2 ESI+: 628 88 2 ESI+: 600 89 2 ESI+: 625 90 2 ESI+: 625 91 3 ESI+: 624 NMR-DMSO-d6: 1.38 (3H, d, J = 6.4 Hz), 1.60 - 1.73 (1H, m), 1.86 - 1.97 (2H, m), 2.10 - 2.23 (1H, m), 2.89 (2H, t, J = 7.7 Hz), 3.07 - 3.23 (3H, m), 3.27 - 3.36 (2H, m), 3.37 - 3.60 (6H, m), 3.66 (3H, s), 3.88 - 4.58 (5H, m), 4.70 - 4.80 (1H, m), 7.77 - 7.83 (1H, m), 7.92 - 8.00 (2H, m), 8.31 (1H, s), 10.60 - 10.75 (1H, m), 11.32 - 11.56 (2H, m) 92 3 ESI-: 608,610 93 3 ESI-: 604 94 3 ESI-: 622 95 3 ESI+: 658, 660 96 4 ESI+: 596 97 4 ESI+: 614 98 4 ESI+: 614 99 4 ESI-: 620 100 5 ESI+: 625 101 7 ESI+: 639 [Table 107] Ex Syn DAT 102 7 ESI+: 639 - The compound of the formula (I) or a salt thereof is a muscarinic M3 receptor-positive allosteric modulator, and can thus be used as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor.
Claims (11)
- A compound of the formula (I) or a salt thereof:X is C-H or N,Y is C-R3e or N,R1 and R2 are the same as each other or are different from each other, and are C1-6 alkyl which may be substituted, or R1 and R2 may be combined with the adjacent nitrogen atom to form cyclic amino which may be substituted,R3a, R3b, R3c, and R3d are the same as each other or are different from each other, and are H, halogen, C1-6 alkyl, halogeno C1-6 alkyl, -O-C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl, or -O-halogeno C1-6 alkyl,in a case where Y is C-R3e, R3e is H, halogen, C1-6 alkyl, halogeno C1-6 alkyl, -O-C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl, or -O-halogeno C1-6 alkyl,R4 is H, halogen, or -O-C1-6 alkyl,R5 is H, C1-6 alkyl, or -NR51R52,Q is heterocyclylene which may be substituted,W is a bond, C1-6 alkylene, -O-C1-6 alkylene, or -N(RN)-C1-6 alkylene,R51 and R52 are the same as each other or are different from each other, and are H or C1-6 alkyl,RN is H or C1-6 alkyl, andn is 0 or 1).
- The compound or a salt thereof according to claim 1, wherein
R1 and R2(i) are the same as each other or are different from each other, and are C1-6 alkyl which may be substituted with -O-C1-6 alkyl or C3-8 cycloalkyl, or(ii) R1 and R2 are combined with the adjacent nitrogen atom to form cyclic amino which may be substituted, and the cyclic amino is azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl,Q is heterocyclylene which may be substituted, and the heterocyclylene is pyrrolidine-1,3-diyl, piperidine-1,4-diyl, or piperazine-1,4-diyl, and the 3-position of pyrrolidine or the 4-position of piperidine is bonded to W, and
W is a bond, C1-6 alkylene, -O-C1-6 alkylene or -N(RN)-C1-6 alkylene, and RN is C1-6 alkyl. - The compound or a salt thereof according to claim 2, wherein
X is N,
Y is C-R3e,
R1 and R2 are combined with the adjacent nitrogen atom to form cyclic amino which may be substituted with C1-6 alkyl, -O-C1-6 alkyl, or C3-8 cycloalkyl, and the cyclic amino is azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl,
R3a, R3c, R3d, and R3e are the same as each other or are different from each other, and are H or halogen, and R36 is halogeno C1-6 alkyl,
R4 is H or halogen,
R5 is H or C1-6 alkyl,
Q is heterocyclylene which may be substituted with -C1-6 alkylene-O-C1-6 alkyl, and the heterocyclylene is piperidine-1,4-diyl or piperazine-1,4-diyl,
W is C1-6 alkylene, or -O-C1-6 alkylene, and
n is 1. - The compound or a salt thereof according to claim 3, wherein
R1 and R2 are combined with the adjacent nitrogen atom to form pyrrolidine which is substituted with one or two C1-6 alkyl,
R3a, R3c, R3a, and R3e are the same as each other or are different from each other, and are H or halogen, and R3b is trifluoromethyl, and
W is -CH2-CH2- or -O-CH2-. - The compound or a salt thereof according to claim 1, wherein the compound is a compound selected from the group consisting of:3-(4-{6-[(5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperazin-1-yl)propanoic acid,3-(4-{6-[(5-{[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]methyl}-4-[3-fluoro-5-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)amino]-5-fluoro-2-methylpyrimidin-4-yl}piperazin-1-yl)propanoic acid,3-(4-{6-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}piperazin-1-yl)propanoic acid,3-[(2S)-4-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}-2-(methoxymethyl)piperazin-1-yl]propanoic acid,[(1-{5-fluoro-6-[(4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]pyrimidin-4-yl}piperidin-4-yl)oxy]acetic acid, and3-[(2S)-4-{6-[(4-[4-chloro-3-(trifluoromethyl)phenyl]-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}-1,3-thiazol-2-yl)amino]-5-fluoropyrimidin-4-yl}-2-(methoxymethyl)piperazin-1-yl]propanoic acid.
- A pharmaceutical composition comprising the compound or a salt thereof according to claim 1, and a pharmaceutically acceptable excipient.
- A pharmaceutical composition for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, comprising the compound or a salt thereof according to claim 1.
- Use of the compound or a salt thereof according to claim 1 for the manufacture of a pharmaceutical composition for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor.
- Use of the compound or a salt thereof according to claim 1 for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor.
- The compound or a salt thereof according to claim 1 for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor.
- A method for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, comprising administering to a subject an effective amount of the compound or a salt thereof according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL15836701T PL3196200T3 (en) | 2014-08-26 | 2015-08-25 | 2-aminothiazole derivatives or salt thereof as muscarinic m3 ligands for the treatment of bladder diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014171092 | 2014-08-26 | ||
PCT/JP2015/073914 WO2016031833A1 (en) | 2014-08-26 | 2015-08-25 | 2-aminothiazole derivative or salt thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3196200A1 true EP3196200A1 (en) | 2017-07-26 |
EP3196200A4 EP3196200A4 (en) | 2018-02-28 |
EP3196200B1 EP3196200B1 (en) | 2019-05-08 |
Family
ID=55399719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15836701.1A Active EP3196200B1 (en) | 2014-08-26 | 2015-08-25 | 2-aminothiazole derivatives or salt thereof as muscarinic m3 ligands for the treatment of bladder diseases |
Country Status (14)
Country | Link |
---|---|
US (1) | US9844549B2 (en) |
EP (1) | EP3196200B1 (en) |
JP (1) | JP6569678B2 (en) |
KR (1) | KR20170042608A (en) |
CN (1) | CN106573928B (en) |
BR (1) | BR112017003901A2 (en) |
CA (1) | CA2959290A1 (en) |
ES (1) | ES2736098T3 (en) |
MX (1) | MX2017002500A (en) |
PL (1) | PL3196200T3 (en) |
PT (1) | PT3196200T (en) |
RU (1) | RU2702106C2 (en) |
TR (1) | TR201908031T4 (en) |
WO (1) | WO2016031833A1 (en) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID30460A (en) | 1999-04-15 | 2001-12-06 | Bristol Myers Squibb Co | INHIBITORS, INHIBITORS, THYROCIN CINASE PROTEIN |
WO2003062233A1 (en) * | 2002-01-18 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | 2-acylaminothiazole derivative or salt thereof |
AU2003222786A1 (en) | 2002-04-18 | 2003-10-27 | Ucb, S.A. | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions |
WO2005007651A1 (en) * | 2003-07-17 | 2005-01-27 | Astellas Pharma Inc. | 2-acylaminothiazole derivative or salt thereof |
GB0516313D0 (en) * | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
AR065344A1 (en) * | 2007-02-15 | 2009-06-03 | Argenta Discovery Ltd | DERIVATIVES OF AZONIA OCTANO BICYCLE AS ACTIVATORS OF THE M3 RECEIVER |
BRPI0818201B8 (en) * | 2007-10-24 | 2021-05-25 | Astellas Pharma Inc | azolecarboxamide compound or salt thereof and use thereof for the treatment of urinary frequency, urinary urgency, urinary incontinence and lower urinary tract pain associated with various lower urinary tract diseases, and various diseases accompanied by pain |
UA112061C2 (en) | 2010-07-29 | 2016-07-25 | Райджел Фармасьютікалз, Інк. | AMPK ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
CN103269692B (en) * | 2010-08-03 | 2018-02-23 | 韦利塞普特治疗有限公司 | For treating the beta 3 adrenoreceptor agonists of overactive bladder and the drug regimen of muscarinic receptor antagonist |
CN104039789B (en) * | 2011-12-22 | 2016-09-07 | 默克专利股份有限公司 | Four azepines-cyclopenta [a] indenyl and the purposes as forward allosteric modulators thereof |
US9403802B2 (en) | 2012-03-02 | 2016-08-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use therefor |
EP2921480B1 (en) * | 2012-11-19 | 2017-10-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
TWI647227B (en) * | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | 2-guanamine thiazole derivative or a salt thereof |
KR102482844B1 (en) | 2014-06-06 | 2022-12-30 | 가부시키가이샤 아사히야쿠교 | 2-acylaminothiazole derivative or salt thereof |
-
2015
- 2015-08-25 US US15/506,561 patent/US9844549B2/en active Active
- 2015-08-25 CA CA2959290A patent/CA2959290A1/en not_active Abandoned
- 2015-08-25 ES ES15836701T patent/ES2736098T3/en active Active
- 2015-08-25 WO PCT/JP2015/073914 patent/WO2016031833A1/en active Application Filing
- 2015-08-25 CN CN201580045374.8A patent/CN106573928B/en active Active
- 2015-08-25 BR BR112017003901A patent/BR112017003901A2/en not_active IP Right Cessation
- 2015-08-25 TR TR2019/08031T patent/TR201908031T4/en unknown
- 2015-08-25 EP EP15836701.1A patent/EP3196200B1/en active Active
- 2015-08-25 MX MX2017002500A patent/MX2017002500A/en unknown
- 2015-08-25 JP JP2016545558A patent/JP6569678B2/en active Active
- 2015-08-25 PL PL15836701T patent/PL3196200T3/en unknown
- 2015-08-25 KR KR1020177004905A patent/KR20170042608A/en not_active Application Discontinuation
- 2015-08-25 RU RU2017105450A patent/RU2702106C2/en active
- 2015-08-25 PT PT15836701T patent/PT3196200T/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2017105450A3 (en) | 2019-03-19 |
ES2736098T3 (en) | 2019-12-26 |
PT3196200T (en) | 2019-06-17 |
RU2702106C2 (en) | 2019-10-04 |
US9844549B2 (en) | 2017-12-19 |
CN106573928A (en) | 2017-04-19 |
US20170290824A1 (en) | 2017-10-12 |
WO2016031833A1 (en) | 2016-03-03 |
RU2017105450A (en) | 2018-09-27 |
KR20170042608A (en) | 2017-04-19 |
MX2017002500A (en) | 2017-05-23 |
EP3196200B1 (en) | 2019-05-08 |
TR201908031T4 (en) | 2019-06-21 |
JPWO2016031833A1 (en) | 2017-06-22 |
EP3196200A4 (en) | 2018-02-28 |
JP6569678B2 (en) | 2019-09-04 |
PL3196200T3 (en) | 2019-09-30 |
CA2959290A1 (en) | 2016-03-03 |
BR112017003901A2 (en) | 2017-12-12 |
CN106573928B (en) | 2020-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6183451B2 (en) | 2-acylaminothiazole derivatives or salts thereof | |
EP3153511B1 (en) | 2-acylaminothiazole derivative for use in the prevention or treatment of bladder/urinary tract diseases | |
JP2010501629A (en) | Pyridine compounds for treating GPR119 related disorders | |
US20100029687A1 (en) | Piperidine derivative or salt thereof | |
KR20140114404A (en) | Pyrazine carboxamide compound | |
EP2325175A1 (en) | 2,4-diaminopyrimidine compound | |
JP2014518281A (en) | Voltage-gated sodium channel blocker | |
EP3489231B1 (en) | Piperazine derivative | |
EP3196200B1 (en) | 2-aminothiazole derivatives or salt thereof as muscarinic m3 ligands for the treatment of bladder diseases | |
EP3333165B1 (en) | Piperazine derivative | |
WO2023177593A1 (en) | Phenyl triazole mll1-wdr5 protein-protein interaction inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20170223 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20180126 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 417/12 20060101ALI20180122BHEP Ipc: A61K 31/506 20060101ALI20180122BHEP Ipc: A61K 31/4439 20060101ALI20180122BHEP Ipc: C07D 417/14 20060101AFI20180122BHEP Ipc: A61P 43/00 20060101ALI20180122BHEP Ipc: A61K 31/496 20060101ALI20180122BHEP Ipc: A61P 13/10 20060101ALI20180122BHEP Ipc: A61P 13/02 20060101ALI20180122BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20181029 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
GRAR | Information related to intention to grant a patent recorded |
Free format text: ORIGINAL CODE: EPIDOSNIGR71 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTC | Intention to grant announced (deleted) | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
INTG | Intention to grant announced |
Effective date: 20190327 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1129970 Country of ref document: AT Kind code of ref document: T Effective date: 20190515 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602015030088 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 3196200 Country of ref document: PT Date of ref document: 20190617 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20190606 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: VALIPAT S.A., CH |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20190401627 Country of ref document: GR Effective date: 20190708 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190808 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190808 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602015030088 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20200211 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190825 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1129970 Country of ref document: AT Kind code of ref document: T Effective date: 20190508 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190908 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20150825 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190508 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20220627 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20220629 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20220715 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20220825 Year of fee payment: 8 Ref country code: PT Payment date: 20220823 Year of fee payment: 8 Ref country code: IT Payment date: 20220712 Year of fee payment: 8 Ref country code: IE Payment date: 20220712 Year of fee payment: 8 Ref country code: GB Payment date: 20220707 Year of fee payment: 8 Ref country code: ES Payment date: 20220901 Year of fee payment: 8 Ref country code: AT Payment date: 20220725 Year of fee payment: 8 Ref country code: DE Payment date: 20220621 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20220720 Year of fee payment: 8 Ref country code: FR Payment date: 20220709 Year of fee payment: 8 Ref country code: BE Payment date: 20220718 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20220803 Year of fee payment: 8 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602015030088 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20230901 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240307 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 1129970 Country of ref document: AT Kind code of ref document: T Effective date: 20230825 |